

US 2003/027894-

REC'D 20 OCT 2003

WIPO

PCT

PI 1079182

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 15, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/410,166

FILING DATE: September 11, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/27894



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

N. Woodson
N. WOODSON
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

09-13-02 60410166 .091/PTO


EXPRESS MAIL NO: EV 016 019 645 US
DATED: 11 September 2002

09/11/02
1030 U.S. PTO

09/11/02
1030 U.S. PTO

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

| | | | | | |
|---|------------------------------|--------------------|---|---|-----|
| DOCKET NUMBER | | PR1981 | | Type a plus sign (+) inside this box | |
| INVENTOR(S)/APPLICANT(S) | | | | | |
| LAST NAME | FIRST NAME | MIDDLE INITIAL | RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY) | | |
| 1) deSavage 2) Wood 3) Zhang | Frederic William Zemin | J. I. | Foster City, CA Hillsborough, CA Foster City, CA | | |
| APPLICATION IDENTIFIER (if no INVENTOR(S)/APPLICANT(S) are named) | | | | | |
| TITLE OF THE INVENTION (280 characters max) | | | | | |
| COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | | | | | |
| CORRESPONDENCE ADDRESS | | | | | |
| David A. Carpenter, Ph.D.  09157 PATENT TRADEMARK OFFICE | | | Telephone Number (650) 225-3733 | | |
| | | | Facsimile Number (650) 952-9881 | | |
| STATE | California | ZIP CODE | 94080-4990 | COUNTRY | USA |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | | |
| <input checked="" type="checkbox"/> Specification Number of Pages (including claims) | | 116 | | <input type="checkbox"/> Small Entity Statement | |
| <input checked="" type="checkbox"/> Drawings | | Number of Pages 46 | | <input checked="" type="checkbox"/> Other (specify): postcard | |
| METHOD OF PAYMENT (check one) | | | | | |
| <input type="checkbox"/> A check or money order is enclosed to cover the Provisional filing fees. | | | | | |
| <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 07-0630. A duplicate of this sheet is enclosed. | | | | | |
| PROVISIONAL FILING FEE AMOUNT (\$) 160.00 | | | | | |

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number(s) is(are):

Respectfully submitted,
GENENTECH, INC.

By:

David A. Carpenter, Ph.D.
Reg. No. 45,945

Date: September 11, 2002

Revised (12/11/97)

PATENT
Genentech Docket No.: PR1981

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

FIELD OF THE INVENTION

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

5

BACKGROUND OF THE INVENTION

Malignant tumors (cancers) are the second leading cause of death in the United States, after heart disease (Boring et al., *CA Cancer J. Clin.* 43:7 (1993)). Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent
10 tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread via the blood or lymphatic system to regional lymph nodes and to distant sites via a process called metastasis. In a cancerous state, a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.

In attempts to discover effective cellular targets for cancer therapy, researchers have sought to identify
15 polypeptides that are specifically overexpressed in a particular type of cancer cell as compared to on one or more normal non-cancerous cell(s). The identification of such tumor-associated cell polypeptides has given rise to the ability to specifically target cancer cells for destruction via antibody-based therapies. In this regard, it is noted that antibody-based therapy has proved very effective in the treatment of certain cancers. For example, HERCEPTIN® and RITUXAN® (both from Genentech Inc., South San Francisco, California) are antibodies that have been used
20 successfully to treat breast cancer and non-Hodgkin's lymphoma, respectively. More specifically, HERCEPTIN® is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) proto-oncogene. HER2 protein overexpression is observed in 25-30% of primary breast cancers. RITUXAN® is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.

25 In other attempts to discover effective cellular targets for cancer therapy, researchers have sought to identify polypeptides that are overexpressed by a particular type of cancer cell relative to normal expression of polypeptides in one or more normal non-cancerous cell(s). Identification of antagonists of such overexpressed polypeptides would be expected to serve as effective therapeutic agents for the treatment of such cancers. Furthermore, identification of the overexpression of such polypeptides would be useful for the diagnosis of particular cancers in mammals.

30 The kinases that control signal transduction pathways, cell cycle and programmed cell death are critical to cell regulation. Overexpression or activating mutations of these critical kinases may disrupt cellular regulation and lead to tumor formation. Twenty percent of all known oncogenes are protein kinases. Identifying the appropriate signal transduction pathway and developing drugs to specifically inhibit these oncogenic kinases has been a major goal of cancer research for some time. High throughput screening has led to identification of small molecules with

different modes of inhibition such as; competition with the catalytic adenosine triphosphate binding site, inhibition of substrate binding, or modification the substrate itself. Certain compounds are highly specific for a single kinase, while others can inhibit several kinases with similar binding structures (Busse et al., Semin Oncol 2001, 28:47-55). For example, the tyrosine kinase Bcr-Abl has been identified as a causative factor in chronic myeloid leukemia (CML). The small molecule imatinib mesylate (Novartis Pharmaceuticals Corp, East Hanover, NJ) was recently approved for the treatment of CML, demonstrating that treatment of the kinase component of a signal transduction pathway is effective in the treatment of cancer (Griffin J. Semin Oncol 2001, 28:3-8).

Despite the above identified advances in mammalian cancer therapy, there is a great need for additional diagnostic and therapeutic agents capable of detecting the presence of a tumor in a mammal and for effectively inhibiting neoplastic cell growth, respectively. Accordingly, it is an objective of the present invention to identify polypeptides that are overexpressed in certain cancer cells as compared to normal cells or other different cancer cells, and to use those polypeptides, and their encoding nucleic acids, to produce compositions of matter useful in the therapeutic treatment and diagnostic detection of cancer in mammals.

SUMMARY OF THE INVENTION

15 A. Embodiments

In the present specification, Applicants describe for the first time the identification of various cellular polypeptides (and their encoding nucleic acids or fragments thereof) which are expressed to a greater degree by one or more types of cancer cell as compared to one or more types of normal non-cancer cells. Such polypeptides are herein referred to as TUMOR-ASSOCIATED KINASE polypeptides ("TASK" polypeptides) and are expected to serve as effective targets for cancer therapy and diagnosis in mammals.

Accordingly, in one embodiment of the present invention, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a tumor-associated antigenic target polypeptide or fragment thereof (a "TASK" polypeptide).

In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TASK polypeptide having an amino acid sequence as disclosed herein, or any other specifically defined fragment of a full-length TASK polypeptide amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid-sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% nucleic acid sequence identity, to (a) a DNA molecule comprising the coding sequence of a full-length TASK polypeptide cDNA as disclosed herein, or the coding sequence of any other specifically defined fragment of the full-length TASK polypeptide amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In further aspects, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%,

85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% nucleic acid sequence identity, to a DNA molecule that encodes the same mature polypeptide encoded by the full-length coding sequence of any of the human protein cDNAs as disclosed herein. In this regard, the term "full-length coding sequence" refers to the TASK polypeptide-encoding nucleotide sequence of the cDNA (which is often shown between start and stop codons, inclusive thereof, in the accompanying figures).

5 Another aspect of the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a TASK polypeptide which is kinase domain-inactivated, or is complementary to such encoding nucleotide sequence. Therefore, catalytically inactive forms of the herein described TASK polypeptides are contemplated.

10 In other aspects, the present invention is directed to isolated nucleic acid molecules which hybridize to (a) a nucleotide sequence encoding a TASK polypeptide having a full-length amino acid sequence as disclosed herein, or any other specifically defined fragment of a full-length TASK polypeptide amino acid sequence as disclosed herein, or (b) the complement of the nucleotide sequence of (a). In this regard, an embodiment of the present invention is directed to fragments of a full-length TASK polypeptide coding sequence, or the complement thereof, as disclosed herein, that may find use as, for example, hybridization probes useful as, for example, diagnostic probes, 15 antisense oligonucleotide probes, or for encoding fragments of a full-length TASK polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-TASK polypeptide antibody, a TASK binding oligopeptide or other small organic molecule that binds to a TASK polypeptide. Such nucleic acid fragments are usually at least about 5 nucleotides in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a TASK polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the TASK polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which TASK polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such novel fragments of TASK polypeptide-encoding nucleotide sequences are 30 contemplated herein. Also contemplated are the TASK polypeptide fragments encoded by these nucleotide molecule fragments, preferably those TASK polypeptide fragments that comprise a binding site for an anti-TASK antibody, a TASK binding oligopeptide or other small organic molecule that binds to a TASK polypeptide.

35 In another embodiment, the invention provides isolated TASK polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.

In a certain aspect, the invention concerns an isolated TASK polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence

identity, to a TASK polypeptide having a full-length amino acid sequence as disclosed herein, or an amino acid sequence encoded by any of the nucleic acid sequences disclosed herein or any other specifically defined fragment of a full-length TASK polypeptide amino acid sequence as disclosed herein.

In a further aspect, the invention concerns an isolated TASK polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity, to an amino acid sequence encoded by any of the human protein cDNAs as disclosed herein.

Another aspect of the invention provides an isolated TASK polypeptid. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the TASK polypeptide and recovering the TASK polypeptide from the cell culture.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides isolated chimeric polypeptides comprising any of the herein described TASK polypeptides fused to a heterologous (non-TASK) polypeptide. Example of such chimeric molecules comprise any of the herein described TASK polypeptides fused to a heterologous polypeptide such as, for example, an epitope tag sequence or a Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, single-chain antibody or antibody that competitively inhibits the binding of an anti-TASK polypeptide antibody to its respective antigenic epitope. Antibodies of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies of the present invention may optionally be produced in CHO cells or bacterial cells and preferably induce death of a cell to which they bind. For diagnostic purposes, the antibodies of the present invention may be detectably labeled, attached to a solid support, or the like.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described antibodies. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described antibodies is further provided and comprises culturing host cells under conditions suitable for expression of the desired antibody and recovering the desired antibody from the cell culture.

In another embodiment, the invention provides oligopeptides ("TASK binding oligopeptides") which bind, preferably specifically, to any of the above or below described TASK polypeptides. Optionally, the TASK binding oligopeptides of the present invention may be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic

enzyme, or the like. The TASK binding oligopeptides of the present invention may optionally be produced in CHO cells or bacterial cells and preferably induce death of a cell to which they bind. For diagnostic purposes, the TASK binding oligopeptides of the present invention may be detectably labeled, attached to a solid support, or the like.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described TASK binding oligopeptides. Host cell comprising any such vector are also provided.

5 By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described TASK binding oligopeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired oligopeptide and recovering the desired oligopeptide from the cell culture.

In another embodiment, the invention provides small organic molecules ("TASK binding organic molecules") which bind, preferably specifically, to any of the above or below described TASK polypeptides. 10 Optionally, the TASK binding organic molecules of the present invention may be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The TASK binding organic molecules of the present invention preferably inactivate, either partially or wholly the kinase activity of the TASK. The TASK binding organic molecules of the present invention most preferably induce death of a cell to which they bind. For diagnostic 15 purposes, the TASK binding organic molecules of the present invention may be detectably labeled, attached to a solid support, or the like.

In a still further embodiment, the invention concerns a composition of matter comprising a TASK polypeptide as described herein, a chimeric TASK polypeptide as described herein, an anti-TASK antibody as described herein, a TASK binding oligopeptide as described herein, or a TASK binding organic molecule as 20 described herein, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

In yet another embodiment, the invention concerns an article of manufacture comprising a container and a composition of matter contained within the container, wherein the composition of matter may comprise a TASK polypeptide as described herein, a chimeric TASK polypeptide as described herein, an anti-TASK antibody as described herein, a TASK binding oligopeptide as described herein, or a TASK binding organic molecule as 25 described herein. The article may further optionally comprise a label affixed to the container, or a package insert included with the container, that refers to the use of the composition of matter for the therapeutic treatment or diagnostic detection of a tumor.

Another embodiment of the present invention is directed to the use of a TASK polypeptide as described herein, a chimeric TASK polypeptide as described herein, an anti-TASK polypeptide antibody as described herein, 30 a TASK binding oligopeptide as described herein, or a TASK binding organic molecule as described herein, for the preparation of a medicament useful in the treatment of a condition which is responsive to the TASK polypeptide, chimeric TASK polypeptide, anti-TASK polypeptide antibody, TASK binding oligopeptide, or TASK binding organic molecule.

B. Additional Embodiments

35 Another embodiment of the present invention is directed to a method for killing a cancer cell that expresses a TASK polypeptide, wherein the method comprises contacting the cancer cell with an antibody, an oligopeptide or a small organic molecule that binds to the TASK polypeptide, thereby resulting in the death of the cancer cell.

Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TASK binding oligopeptides and TASK binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and TASK binding oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

Another embodiment of the present invention is directed to a method for inhibiting the growth of a cancer cell, wherein the growth of said cancer cell is at least in part dependent upon the growth potentiating effect(s) of a TASK polypeptide, wherein the method comprises contacting the TASK polypeptide with an antibody, an oligopeptide or a small organic molecule that binds to the TASK polypeptide, thereby antagonizing the growth-potentiating activity of the TASK polypeptide and, in turn, inhibiting the growth of the cancer cell. Preferably the growth of the cancer cell is completely inhibited. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TASK binding oligopeptides and TASK binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and TASK binding oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

Yet another embodiment of the present invention is directed to a method of therapeutically treating a TASK polypeptide-expressing tumor in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of an antibody, an oligopeptide or a small organic molecule that binds to the TASK polypeptide, thereby resulting in the effective therapeutic treatment of the tumor. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TASK binding oligopeptides and TASK binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

Yet another embodiment of the present invention is directed to a method of therapeutically treating a tumor in a mammal, wherein the growth of said tumor is at least in part dependent upon the growth potentiating effect(s) of a TASK polypeptide, wherein the method comprises administering to the mammal a therapeutically effective amount of an antibody, an oligopeptide or a small organic molecule that binds to the TASK polypeptide, thereby antagonizing the growth potentiating activity of said TASK polypeptide and resulting in the effective therapeutic treatment of the tumor. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TASK binding oligopeptides and TASK binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and oligopeptides employed in the methods

of the present invention may optionally be produced in CHO cells or bacterial cells.

Yet another embodiment of the present invention is directed to a method for treating or preventing a cell proliferative disorder associated with altered, preferably increased, expression or activity of a TASK polypeptide, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a TASK polypeptide. Preferably, the cell proliferative disorder is cancer and the antagonist of the TASK polypeptide is an anti-TASK polypeptide antibody, TASK binding oligopeptide, TASK binding organic molecule or antisense oligonucleotide. Effective treatment or prevention of the cell proliferative disorder may be a result of direct killing or growth inhibition of cells that express a TASK polypeptide or by antagonizing the cell proliferative activity of a TASK polypeptide.

Yet another embodiment of the present invention is directed to a method of determining the presence of a TASK polypeptide in a sample suspected of containing the TASK polypeptide, wherein the method comprises exposing the sample to an antibody, oligopeptide or small organic molecule that binds to the TASK polypeptide and determining binding of the antibody, oligopeptide or organic molecule to the TASK polypeptide in the sample, wherein the presence of such binding is indicative of the presence of the TASK polypeptide in the sample. Optionally, the sample may contain cells (which may be cancer cells) suspected of expressing the TASK polypeptide. The antibody, TASK binding oligopeptide or TASK binding organic molecule employed in the method may optionally be detectably labeled, attached to a solid support, or the like.

A further embodiment of the present invention is directed to a method of diagnosing the presence of a tumor in a mammal, wherein the method comprises detecting the level of expression of a gene encoding a TASK polypeptide (a) in a test sample of tissue cells obtained from said mammal, and (b) in a control sample of known normal cells of the same tissue origin, wherein a higher level of expression of the TASK polypeptide in the test sample, as compared to the control sample, is indicative of the presence of tumor in the mammal from which the test sample was obtained.

Another embodiment of the present invention is directed to a method of diagnosing the presence of a tumor in a mammal, wherein the method comprises (a) contacting a test sample comprising tissue cells obtained from the mammal with an antibody, oligopeptide or small organic molecule that binds to a TASK polypeptide and (b) detecting the formation of a complex between the antibody, oligopeptide or small organic molecule and the TASK polypeptide in the test sample, wherein the formation of a complex is indicative of the presence of a tumor in the mammal. Optionally, the antibody, TASK binding oligopeptide or TASK binding organic molecule employed is detectably labeled, attached to a solid support, or the like, and/or the test sample of tissue cells is obtained from an individual suspected of having a cancerous tumor.

Further embodiments of the present invention will be evident to the skilled artisan upon a reading of the present specification.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a TASK100 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA297189".

Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID

NO:1 shown in Figure 1.

Figure 3A-B shows a nucleotide sequence (SEQ ID NO:3) of a TASK101 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA137028".

Figure 4A-B shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3A-B.

5 Figure 5A-B shows a nucleotide sequence (SEQ ID NO:5) of a TASK102 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA297389".

Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5A-B.

10 Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a TASK103 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA226732".

Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a TASK104 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA270476".

15 Figure 10 shows the amino acid sequence (SEQ ID NO:10) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.

Figure 11 shows a nucleotide sequence (SEQ ID NO:11) of a TASK105 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA227383".

20 Figure 12 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 11.

Figure 13 shows a nucleotide sequence (SEQ ID NO:13) of a TASK106 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA227409".

Figure 14 shows the amino acid sequence (SEQ ID NO:14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.

25 Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a TASK107 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA227090".

Figure 16 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

30 Figure 17 shows a nucleotide sequence (SEQ ID NO:17) of a TASK108 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA210495".

Figure 18 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 17.

Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a TASK109 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA254470".

35 Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:19 shown in Figure 19.

Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a TASK110 cDNA, wherein SEQ ID NO:21

is a clone designated herein as "DNA255289".

Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a TASK111 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA256662".

5 Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a TASK112 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA269860".

10 Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.

Figure 27A-B shows a nucleotide sequence (SEQ ID NO:27) of a TASK113 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA269878".

Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27A-B.

15 Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a TASK114 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA269998".

Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

20 Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a TASK115 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA274277".

Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.

Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a TASK116 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA297188".

25 Figure 34 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a TASK117 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA297190".

30 Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a TASK118 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA297191".

Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.

35 Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a TASK119 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA297288".

Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID

NO:39 shown in Figure 39.

Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a TASK120 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA151475".

Figure 42 shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.

5

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. Definitions

The terms "TASK polypeptide" and "TASK" as used herein and when immediately followed by a numerical designation, refer to various polypeptides, wherein the complete designation (i.e., TASK/number) refers to specific polypeptide sequences as described herein. The terms "TASK/number polypeptide" and "TASK/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides, polypeptide variants and fragments of native sequence polypeptides and polypeptide variants (which are further defined herein). The TASK polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "TASK polypeptide" refers to each individual TASK/number polypeptide disclosed herein. All disclosures in this specification which refer to the "TASK polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, formation of TASK binding oligopeptides to or against, formation of TASK binding organic molecules to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "TASK polypeptide" also includes variants of the TASK/number polypeptides disclosed herein.

A "native sequence TASK polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding TASK polypeptide derived from nature. Such native sequence TASK polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence TASK polypeptide" specifically encompasses naturally-occurring truncated forms of the specific TASK polypeptide, naturally-occurring variant forms (*e.g.*, alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In certain embodiments of the invention, the native sequence TASK polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons (if indicated) are shown in bold font and underlined in the figures. Nucleic acid residues indicated as "N" in the accompanying figures are any nucleic acid residue. However, while the TASK polypeptides disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the TASK polypeptides.

"TASK polypeptide variant" means a TASK polypeptide, preferably an active TASK polypeptide, as defined herein having at least about 80% amino acid sequence identity with a full-length native sequence TASK polypeptide sequence as disclosed herein, or any other fragment of a full-length TASK polypeptide sequence as

disclosed herein (such as those encoded by a nucleic acid that represents only a portion of the complete coding sequence for a full-length TASK polypeptide). Such TASK polypeptide variants include, for instance, TASK polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a TASK polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity, to a full-length native sequence TASK polypeptide sequence as disclosed herein, or any other specifically defined fragment of a full-length TASK polypeptide sequence as disclosed herein. Ordinarily, TASK variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600 amino acids in length, or more. Optionally, TASK variant polypeptides will have no more than one conservative amino acid substitution as compared to the native TASK polypeptide sequence, alternatively no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitution as compared to the native TASK polypeptide sequence.

"Percent (%) amino acid sequence identity" with respect to the TASK polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific TASK polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "TASK", wherein "TASK" represents the amino acid sequence of a hypothetical TASK polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "TASK" polypeptide of interest is being compared, and "X," "Y" and "Z" each represent different hypothetical amino acid residues. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

"TASK variant polynucleotide" or "TASK variant nucleic acid sequence" means a nucleic acid molecule which encodes a TASK polypeptide, preferably an active TASK polypeptide, as defined herein and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence TASK polypeptide sequence as disclosed herein, or any other fragment of a full-length TASK polypeptide sequence as disclosed herein (such as those encoded by a nucleic acid that represents only a portion of the complete coding sequence for a full-length TASK polypeptide). Ordinarily, a TASK variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence TASK polypeptide sequence as disclosed herein, or any other fragment of a full-length TASK polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

Ordinarily, TASK variant polynucleotides are at least about 5 nucleotides in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length.

"Percent (%) nucleic acid sequence identity" with respect to TASK-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the TASK nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1

below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "TASK-DNA", wherein "TASK-DNA" represents a hypothetical TASK-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "TASK-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides. Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

In other embodiments, TASK variant polynucleotides are nucleic acid molecules that encode a TASK polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length TASK polypeptide as disclosed herein. TASK variant polypeptides may be those that are encoded by a TASK variant polynucleotide.

"Isolated," when used to describe the various TASK polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the TASK polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by

at least one purification step.

An "isolated" TASK polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml),

0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a TASK polypeptide or anti-TASK antibody fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

"Active" or "activity" for the purposes herein refers to form(s) of a TASK polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring TASK, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring TASK other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring TASK and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring TASK.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native TASK polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native TASK polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native TASK polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a TASK polypeptide may comprise contacting a TASK polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the TASK polypeptide.

"Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully "treated" for a TASK polypeptide-expressing cancer if, after receiving a therapeutic amount of an anti-TASK antibody, TASK binding oligopeptide or TASK binding organic molecule according to the methods of the present invention, the

patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells or absence of the cancer cells; reduction in the tumor size; inhibition (i.e., slow to some extent and preferably stop) of cancer cell infiltration into peripheral organs including the spread of cancer into soft tissue and bone; inhibition (i.e., slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. To the extent the anti-TASK antibody or TASK binding oligopeptide may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. Reduction of these signs or symptoms may also be felt by the patient.

The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and/or determining the response rate (RR). Metastasis can be determined by staging tests and by bone scan and tests for calcium level and other enzymes to determine spread to the bone. CT scans can also be done to look for spread to the pelvis and lymph nodes in the area. Chest X-rays and measurement of liver enzyme levels by known methods are used to look for metastasis to the lungs and liver, respectively. Other routine methods for monitoring the disease include transrectal ultrasonography (TRUS) and transrectal needle biopsy (TRNB).

For bladder cancer, which is a more localized cancer, methods to determine progress of disease include urinary cytologic evaluation by cystoscopy, monitoring for presence of blood in the urine, visualization of the urothelial tract by sonography or an intravenous pyelogram, computed tomography (CT) and magnetic resonance imaging (MRI). The presence of distant metastases can be assessed by CT of the abdomen, chest x-rays, or radionuclide imaging of the skeleton.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

"Mammal" for purposes of the treatment of, alleviating the symptoms of or diagnosis of a cancer refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®.

By "solid phase" or "solid support" is meant a non-aqueous matrix to which an antibody, TASK binding oligopeptide or TASK binding organic molecule of the present invention can adhere or attach. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a TASK polypeptide, an antibody thereto or a TASK binding oligopeptide) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

A "small" molecule or "small" organic molecule is defined herein to have a molecular weight below about 500 Daltons.

An "effective amount" of a polypeptide, antibody, TASK binding oligopeptide, TASK binding organic molecule or an agonist or antagonist thereof as disclosed herein is an amount sufficient to carry out a specifically stated purpose. An "effective amount" may be determined empirically and in a routine manner, in relation to the stated purpose.

The term "therapeutically effective amount" refers to an amount of an antibody, polypeptide, TASK binding oligopeptide, TASK binding organic molecule or other drug effective to "treat" a disease or disorder in a subject or mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. See the definition herein of "treating". To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.

A "growth inhibitory amount" of an anti-TASK antibody, TASK polypeptide, TASK binding oligopeptide or TASK binding organic molecule is an amount capable of inhibiting the growth of a cell, especially tumor, e.g., cancer cell, either *in vitro* or *in vivo*. A "growth inhibitory amount" of an anti-TASK antibody, TASK polypeptide, TASK binding oligopeptide or TASK binding organic molecule for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner.

A "cytotoxic amount" of an anti-TASK antibody, TASK polypeptide, TASK binding oligopeptide or TASK binding organic molecule is an amount capable of causing the destruction of a cell, especially tumor, e.g., cancer cell, either *in vitro* or *in vivo*. A "cytotoxic amount" of an anti-TASK antibody, TASK polypeptide, TASK binding oligopeptide or TASK binding organic molecule for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner.

The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-TASK monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-TASK antibody compositions with polypepitopic specificity, polyclonal antibodies, single chain anti-TASK antibodies, and fragments of anti-TASK

antibodies (see below) as long as they exhibit the desired biological or immunological activity. The term "immunoglobulin" (Ig) is used interchangeable with antibody herein.

An "isolated antibody" is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains (an IgM antibody consists of 5 of the basic heterotetramer unit along with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages comprising 2-5 of the basic 4-chain units along with J chain). In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to a H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (V_H) followed by three constant domains (C_H) for each of the α and γ chains and four C_H domains for μ and ϵ isotypes. Each L chain has at the N-terminus, a variable domain (V_L) followed by a constant domain (C_L) at its other end. The V_L is aligned with the V_H and the C_L is aligned with the first constant domain of the heavy chain (C_{H1}). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains. The pairing of a V_H and V_L together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th edition, Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.

The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains (C_H), immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated α , δ , ϵ , γ , and μ , respectively. The γ and α classes are further divided into subclasses on the basis of relatively minor differences in C_H sequence and function, e.g., humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

The term "variable" refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of

15-30 amino acids separated by shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino acids long. The variable domains of native heavy and light chains each comprise four FRs, largely adopting a β -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the β -sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g. around about residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the V_L , and around about 1-35 (H1), 50-65 (H2) and 95-102 (H3) in the V_H ; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (e.g. residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the V_L , and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the V_H ; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al., Nature, 256:495 (1975), or may be made using recombinant DNA methods in bacterial, eukaryotic animal or plant cells (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example.

The monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc), and human constant region sequences.

An "intact" antibody is one which comprises an antigen-binding site as well as a C_L and at least heavy chain

constant domains, C_H1, C_H2 and C_H3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. Preferably, the intact antibody has one or more effector functions.

"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies (see U.S. Patent No. 5,641,870, Example 2; Zapata et al., *Protein Eng.* 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire L chain along with the variable region domain of the H chain (V_H), and the first constant domain of one heavy chain (C_H1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')₂ fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the C_H1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')₂ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types of cells.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

"Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that comprise the V_H and V_L antibody domains connected into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypeptide linker between the V_H and V_L domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, *infra*.

The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10 residues) between the V_H and V_L domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the V_H and V_L domains of the two antibodies are present on different polypeptide chains. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993).

"Humanized" forms of non-human (*e.g.*, rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992).

A "species-dependent antibody," *e.g.*, a mammalian anti-human IgE antibody, is an antibody which has a stronger binding affinity for an antigen from a first mammalian species than it has for a homologue of that antigen from a second mammalian species. Normally, the species-dependent antibody "bind specifically" to a human antigen (*i.e.*, has a binding affinity (Kd) value of no more than about 1×10^{-7} M, preferably no more than about 1×10^{-8} and most preferably no more than about 1×10^{-9} M) but has a binding affinity for a homologue of the antigen from a second non-human mammalian species which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen. The species-dependent antibody can be of any of the various types of antibodies as defined above, but preferably is a humanized or human antibody.

A "TASK binding oligopeptide" is an oligopeptide that binds, preferably specifically, to a TASK polypeptide as described herein. TASK binding oligopeptides may be chemically synthesized using known oligopeptide synthesis methodology or may be prepared and purified using recombinant technology. TASK binding oligopeptides are usually at least about 5 amino acids in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids in length or more, wherein such oligopeptides that are capable of binding, preferably specifically, to a TASK polypeptide as described herein. TASK binding oligopeptides may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening oligopeptide libraries for oligopeptides that are capable of specifically binding to a polypeptide target are well known in the art (*see, e.g.*, U.S. Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., *Proc. Natl. Acad. Sci. U.S.A.*, 81:3998-4002 (1984); Geysen et al., *Proc. Natl. Acad. Sci. U.S.A.*, 82:178-182 (1985); Geysen et al., in *Synthetic Peptides as Antigens*, 130-149 (1986); Geysen et al., *J. Immunol. Meth.*, 102:259-274 (1987); Schoofs et al., *J. Immunol.*, 140:611-616 (1988), Cwirla, S. E. et al. (1990) *Proc. Natl. Acad. Sci. USA*, 87:6378; Lowman, H.B. et al. (1991)

Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363, and Smith, G. P. (1991) Current Opin. Biotechnol., 2:668).

A "TASK binding organic molecule" is an organic molecule other than an oligopeptide or antibody as defined herein that binds, preferably specifically, to a TASK polypeptide as described herein. TASK binding organic molecules may be identified and chemically synthesized using known methodology (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). TASK binding organic molecules are usually less than about 2000 daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 daltons in size, wherein such organic molecules that are capable of binding, preferably specifically, to a TASK polypeptide as described herein may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening organic molecule libraries for molecules that are capable of binding to a polypeptide target are well known in the art (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585).

An antibody, oligopeptide or other organic molecule "which binds" an antigen of interest, e.g. a tumor-associated polypeptide antigen target, is one that binds the antigen with sufficient affinity such that the antibody, oligopeptide or other organic molecule is useful as a diagnostic and/or therapeutic agent in targeting a cell or tissue expressing the antigen, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the antibody, oligopeptide or other organic molecule to a "non-target" protein will be less than about 10% of the binding of the antibody, oligopeptide or other organic molecule to its particular target protein as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA). With regard to the binding of an antibody, oligopeptide or other organic molecule to a target molecule, the term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. The term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a K_d for the target of at least about 10^{-4} M, alternatively at least about 10^{-5} M, alternatively at least about 10^{-6} M, alternatively at least about 10^{-7} M, alternatively at least about 10^{-8} M, alternatively at least about 10^{-9} M, alternatively at least about 10^{-10} M, alternatively at least about 10^{-11} M, alternatively at least about 10^{-12} M, or greater. In one embodiment, the term "specific binding" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

An antibody, oligopeptide or other organic molecule that "inhibits the growth of tumor cells expressing a TASK polypeptide" or a "growth inhibitory" antibody, oligopeptide or other organic molecule is one which results in measurable growth inhibition of cancer cells expressing or overexpressing the appropriate TASK polypeptide. Preferred growth inhibitory anti-TASK antibodies, oligopeptides or organic molecules inhibit growth of TASK-

expressing tumor cells by greater than 20%, preferably from about 20% to about 50%, and even more preferably, by greater than 50% (e.g., from about 50% to about 100%) as compared to the appropriate control, the control typically being tumor cells not treated with the antibody, oligopeptide or other organic molecule being tested. In one embodiment, growth inhibition can be measured at an antibody concentration of about 0.1 to 30 µg/ml or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells to the antibody. Growth inhibition of tumor cells *in vivo* can be determined in various ways such as is described in the Experimental Examples section below. The antibody is growth inhibitory *in vivo* if administration of the anti-TASK antibody at about 1 µg/kg to about 100 mg/kg body weight results in reduction in tumor size or tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days.

An antibody, oligopeptide or other organic molecule which "induces apoptosis" is one which induces programmed cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). The cell is usually one which overexpresses a TASK polypeptide. Preferably the cell is a tumor cell, e.g., a prostate, breast, ovarian, stomach, endometrial, lung, kidney, colon, bladder cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl serine (PS) translocation can be measured by annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells. Preferably, the antibody, oligopeptide or other organic molecule which induces apoptosis is one which results in about 2 to 50 fold, preferably about 5 to 50 fold, and most preferably about 10 to 50 fold, induction of annexin binding relative to untreated cell in an annexin binding assay.

Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxic cells (e.g., Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are absolutely required for such killing. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an *in vitro* ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g., in a animal model such as that disclosed in Clynes et al. (USA) 95:652-656 (1998).

"Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The preferred FcR

is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (see review M. in Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).

"Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least FcγRIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source, e.g., from blood.

"Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma and B-cell lymphoma, brain, as well as head and neck cancer, and associated metastases.

The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.

"Tumor", as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

An antibody, oligopeptide or other organic molecule which "induces cell death" is one which causes a

viable cell to become nonviable. The cell is one which expresses a TASK polypeptide, preferably a cell that overexpresses a TASK polypeptide as compared to a normal cell of the same tissue type. Preferably, the cell is a cancer cell, e.g., a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell. Cell death *in vitro* may be determined in the absence of complement and immune effector cells to distinguish cell death induced by antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). Thus, the assay for cell death may be performed using heat inactivated serum (i.e., in the absence of complement) and in the absence of immune effector cells. To determine whether the antibody, oligopeptide or other organic molecule is able to induce cell death, loss of membrane integrity as evaluated by uptake of propidium iodide (PI), trypan blue (see Moore et al. Cytotechnology 17:1-11 (1995)) or 7AAD can be assessed relative to untreated cells. Preferred cell death-inducing antibodies, oligopeptides or other organic molecules are those which induce PI uptake in the PI uptake assay in BT474 cells.

A "TASK-expressing cell" is a cell which expresses an endogenous or transfected TASK polypeptide. A "TASK-expressing cancer" is a cancer comprising cells that overexpress a TASK polypeptide. A "TASK-expressing cancer" optionally produces sufficient levels of TASK polypeptide, such that an anti-TASK antibody, oligopeptide or other organic molecule can bind thereto and have a therapeutic effect with respect to the cancer. In another embodiment, a "TASK-expressing cancer" optionally produces sufficient levels of TASK polypeptide, such that an anti-TASK antibody, oligopeptide or other organic molecule antagonist can bind thereto and have a therapeutic effect with respect to the cancer. With regard to the latter, the antagonist may be an antisense oligonucleotide which reduces, inhibits or prevents production of the TASK polypeptide by tumor cells. A cancer which "overexpresses" a TASK polypeptide is one which has significantly higher levels of TASK polypeptide thereof, compared to a noncancerous cell of the same tissue type. Such overexpression may be caused by gene amplification or by increased transcription or translation. TASK polypeptide overexpression may be determined in a diagnostic or prognostic assay by evaluating increased levels of the TASK protein present in the cell (e.g., via an immunohistochemistry assay using anti-TASK antibodies prepared against an isolated TASK polypeptide which may be prepared using recombinant DNA technology from an isolated nucleic acid encoding the TASK polypeptide; FACS analysis, etc.). Alternatively, or additionally, one may measure levels of TASK polypeptide-encoding nucleic acid or mRNA in the cell, e.g., via fluorescent *in situ* hybridization using a nucleic acid based probe corresponding to a TASK-encoding nucleic acid or the complement thereof; (FISH; see WO98/45479 published October, 1998), Southern blotting, Northern blotting, or polymerase chain reaction (PCR) techniques, such as real time quantitative PCR (RT-PCR). Aside from the above assays, various *in vivo* assays are available to the skilled practitioner. For example, one may expose cells within the body of the patient to an antibody which is optionally labeled with a detectable label, e.g., a radioactive isotope, and binding of the antibody to cells in the patient can be evaluated, e.g., by external scanning for radioactivity or by analyzing a biopsy taken from a patient previously exposed to the antibody.

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a

contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody, oligopeptide or other organic molecule so as to generate a "labeled" antibody, oligopeptide or other organic molecule. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactive isotopes of Lu), chemotherapeutic agents e.g. methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below. A tumoricidal agent causes destruction of tumor cells.

A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially a TASK-expressing cancer cell, either *in vitro* or *in vivo*. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of TASK-expressing cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami et al. (WB Saunders: Philadelphia, 1995), especially p. 13. The taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.

"Doxorubicin" is an anthracycline antibiotic. The full chemical name of doxorubicin is (8S-cis)-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexapyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione.

The term "cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin;

prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- α and - β ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- β ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- α and TGF- β ; insulin-like growth factor-I and -II; 5 erythropoietin (EPO); osteoinductive factors; interferons such as interferon - α , - β , and - γ ; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; a tumor necrosis factor such as TNF- α or TNF- β ; and other polypeptide factors including LIF and kit ligand (KL). As used 10 herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.

Table 1

```

/*
 *
 * C-C increased from 12 to 15
 * Z is average of EQ
5  * B is average of ND
 * match with stop is _M; stop-stop = 0; J (joker) match = 0
 */
#define _M      -8      /* value of a match with a stop */

10 int _day[26][26] = {
/* A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
/* A */ { 2, 0, -2, 0, 0, -4, 1, -1, -1, 0, -1, -2, -1, 0, _M, 1, 0, -2, 1, 1, 0, 0, -6, 0, -3, 0 },
/* B */ { 0, 3, -4, 3, 2, -5, 0, 1, -2, 0, 0, -3, -2, 2, _M, -1, 1, 0, 0, 0, 0, -2, -5, 0, -3, 1 },
/* C */ { -2, -4, 15, -5, -5, -4, -3, -3, -2, 0, -5, -6, -5, -4, _M, -3, -5, -4, 0, -2, 0, -2, -8, 0, 0, -5 },
15 /* D */ { 0, 3, -5, 4, 3, -6, 1, 1, -2, 0, 0, -4, -3, 2, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 2 },
/* E */ { 0, 2, -5, 3, 4, -5, 0, 1, -2, 0, 0, -3, -2, 1, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 3 },
/* F */ { -4, -5, -4, -6, -5, 9, -5, -2, 1, 0, -5, 2, 0, -4, _M, -5, -5, -4, -3, -3, 0, -1, 0, 0, 7, -5 },
/* G */ { 1, 0, -3, 1, 0, -5, 5, -2, -3, 0, -2, -4, -3, 0, _M, -1, -1, -3, 1, 0, 0, -1, -7, 0, -5, 0 },
/* H */ { -1, 1, -3, 1, 1, -2, -2, 6, -2, 0, 0, -2, -2, 2, _M, 0, 3, 2, -1, -1, 0, -2, -3, 0, 0, 2 },
20 /* I */ { -1, -2, -2, -2, -2, 1, -3, -2, 5, 0, -2, 2, 2, -2, _M, -2, -2, -2, -1, 0, 0, 4, -5, 0, -1, -2 },
/* J */ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 },
/* K */ { -1, 0, -5, 0, 0, -5, -2, 0, -2, 0, 5, -3, 0, 1, _M, -1, 1, 3, 0, 0, 0, -2, -3, 0, -4, 0 },
/* L */ { -2, -3, -6, -4, -3, 2, -4, -2, 2, 0, -3, 6, 4, -3, _M, -3, -2, -3, -3, -1, 0, 2, -2, 0, -1, -2 },
/* M */ { -1, -2, -5, -3, -2, 0, -3, -2, 2, 0, 0, 4, 6, -2, _M, -2, -1, 0, -2, -1, 0, 2, -4, 0, -2, -1 },
25 /* N */ { 0, 2, -4, 2, 1, -4, 0, 2, -2, 0, 1, -3, -2, 2, _M, -1, 1, 0, 1, 0, 0, -2, -4, 0, -2, 1 },
/* O */ { _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, 0, _M, _M, _M, _M, _M, _M, _M, _M, _M },
/* P */ { 1, -1, -3, -1, -1, -5, -1, 0, -2, 0, -1, -3, -2, -1, _M, 6, 0, 0, 1, 0, 0, -1, -6, 0, -5, 0 },
/* Q */ { 0, 1, -5, 2, 2, -5, -1, 3, -2, 0, 1, -2, -1, 1, _M, 0, 4, 1, -1, -1, 0, -2, -5, 0, -4, 3 },
/* R */ { -2, 0, -4, -1, -1, -4, -3, 2, -2, 0, 3, -3, 0, 0, _M, 0, 1, 6, 0, -1, 0, -2, 2, 0, -4, 0 },
30 /* S */ { 1, 0, 0, 0, 0, -3, 1, -1, -1, 0, 0, -3, -2, 1, _M, 1, -1, 0, 2, 1, 0, -1, -2, 0, -3, 0 },
/* T */ { 1, 0, -2, 0, 0, -3, 0, -1, 0, 0, 0, -1, -1, 0, _M, 0, -1, -1, 1, 3, 0, 0, -5, 0, -3, 0 },
/* U */ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 },
/* V */ { 0, -2, -2, -2, -2, -1, -1, -2, 4, 0, -2, 2, 2, -2, _M, -1, -2, -2, -1, 0, 0, 4, -6, 0, -2, -2 },
/* W */ { -6, -5, -8, -7, -7, 0, -7, -3, -5, 0, -3, -2, -4, -4, _M, -6, -5, 2, -2, -5, 0, -6, 17, 0, 0, -6 },
35 /* X */ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 },
/* Y */ { -3, -3, 0, -4, -4, 7, -5, 0, -1, 0, -4, -1, -2, -2, _M, -5, -4, -4, -3, -3, 0, -2, 0, 0, 10, -4 },
/* Z */ { 0, 1, -5, 2, 3, -5, 0, 2, -2, 0, 0, -2, -1, 1, _M, 0, 3, 0, 0, 0, 0, -2, -6, 0, -4, 4 }
};

```

Table 1 (cont')

```

/*
*/
#include <stdio.h>
#include <ctype.h>

5
#define MAXJMP 16 /* max jumps in a diag */
#define MAXGAP 24 /* don't continue to penalize gaps larger than this */
#define JMPS 1024 /* max jumps in an path */
10 #define MX 4 /* save if there's at least MX-1 bases since last jmp */

#define DMAT 3 /* value of matching bases */
#define DMIS 0 /* penalty for mismatched bases */
#define DINS0 8 /* penalty for a gap */
15 #define DINS1 1 /* penalty per base */
#define PINS0 8 /* penalty for a gap */
#define PINS1 4 /* penalty per residue */

struct jmp {
20     short n[MAXJMP]; /* size of jmp (neg for del) */
     unsigned short x[MAXJMP]; /* base no. of jmp in seq x */
}; /* limits seq to 2^16 - 1 */

struct diag {
25     int score; /* score at last jmp */
     long offset; /* offset of prev block */
     short jmp; /* current jmp index */
     struct jmp jp; /* list of jmps */
};

30 struct path {
     int spc; /* number of leading spaces */
     short n[JMPS]; /* size of jmp (gap) */
     int x[JMPS]; /* loc of jmp (last elem before gap) */
};

35 char *ofile; /* output file name */
char *namex[2]; /* seq names getseqs() */
char *prog; /* prog name for err msgs */
char *seqx[2]; /* seqs getseqs() */
40 int dmax; /* best diag nw() */
int dmax0; /* final diag */
int dna; /* set if dna: main() */
int endgaps; /* set if penalizing end gaps */
int gapx, gapy; /* total gaps in seqs */
45 int len0, len1; /* seq lens */
int ngapx, ngapy; /* total size of gaps */
int smax; /* max score nw() */
int *xbm; /* bitmap for matching */
long offset; /* current offset in jmp file */
50 struct diag *dx; /* holds diagonals */
struct path pp[2]; /* holds path for seqs */

char *calloc(), *malloc(), *index(), *strcpy();
55 char *getseq(), *g_calloc();

```

Table 1 (cont')

```

/* Needleman-Wunsch alignment program
*
* usage prog file1 file2
* where file1 and file2 are two dna or two protein sequences.
5 * The sequences can be in upper- or lower-case and may contain ambiguity
* Any lines beginning with ',', '>' or '<' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
10 * Output is in the file "align.out"
*
* The program may create a tmp file in /tmp to hold info about traceback
* Original version developed under BSD 4.3 on a vax 8650
*/
#include "nw.h"
15 #include "day.h"

static _dbval[26] = {
    1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};

20 static _pbval[26] = {
    1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
    1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
25 1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)                                main
30     int      ac,
     char      *av[],
{
    prog = av[0];
    if (ac != 3) {
35         fprintf(stderr, "usage: %s file1 file2\n", prog),
        fprintf(stderr, "where file1 and file2 are two dna or two protein sequences\n"),
        fprintf(stderr, "The sequences can be in upper- or lower-case\n"),
        fprintf(stderr, "Any lines beginning with ',', '>' or '<' are ignored\n"),
        fprintf(stderr, "Output is in the file \"align.out\"\n"),
        exit(1),
40     }
    namex[0] = av[1];
    namex[1] = av[2];
    seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
45     xbm = (dna)? _dbval : _pbval;

    endgaps = 0;                                /* 1 to penalize endgaps */
    ofile = "align.out";                        /* output file */

50     nw();                                    /* fill in the matrix, get the possible jmps */
    readjmps();                                /* get the actual jmps */
    print();                                    /* print stats, alignment */

55     cleanup(0);                             /* unlink any tmp files */
}

```

Table 1 (cont')

```

/* do the alignment, return best score: main()
 * dna. values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
 * pro: PAM 250 values
 * When scores are equal, we prefer mismatches to any gap, prefer
5  * a new gap to extending an ongoing gap, and prefer a gap in seqx
   * to a gap in seq y.
   */
nw()
{
10  char      *px, *py,      /* seqs and ptrs */
   int       *ndely, *dely; /* keep track of dely */
   int       ndelx, delx,   /* keep track of delx */
   int       *tmp,         /* for swapping row0, row1 */
   int       mis;          /* score for each type */
15  int       ins0, ins1, /* insertion penalties */
   register  id,          /* diagonal index */
   register  ij;          /* jmp index */
   register  *col0, *col1; /* score for curr, last row */
   register  xx, yy,      /* index into seqs */

20  dx = (struct diag *)g_calloc("to get diags", len0+len1+1, sizeof(struct diag)),

   ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
   dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
25  col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
   col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
   ins0 = (dna)? DINS0 * PINS0;
   ins1 = (dna)? DINS1 * PINS1;

30  smax = -10000,
   if (endgaps) {
       for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
           col0[yy] = dely[yy] = col0[yy-1] - ins1,
           ndely[yy] = yy;
35       }
       col0[0] = 0;      /* Waterman Bull Math Biol 84 */
   }
   else
       for (yy = 1; yy <= len1; yy++)
40       dely[yy] = -ins0;

   /* fill in match matrix
   */
45  for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
       /* initialize first entry in col
       */
       if (endgaps) {
           if (xx == 1)
           col1[0] = delx = -(ins0+ins1);
50       else
           col1[0] = delx = col0[0] - ins1,
           ndelx = xx;
       }
       else {
55       col1[0] = 0,
           delx = -ins0;
           ndelx = 0;
       }
   }

```

Table 1 (cont')

...nw

```

5      for (py = seqx[1], yy = 1, yy <= len1; py++, yy++) {
        ins = col0[yy-1];
        if (dna)
            mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
        else
            mis += _day[*px-'A'][*py-'A'];

10      /* update penalty for del in x seq;
        * favor new del over ongong del
        * ignore MAXGAP if weighting endgaps
        */
        if (endgaps || ndely[yy] < MAXGAP) {
15            if (col0[yy] - ins0 >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
            } else {
                dely[yy] -= ins1;
                ndely[yy]++;
20            }
        } else {
            if (col0[yy] - (ins0+ins1) >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
25            } else
                ndely[yy]++;
        }

        /* update penalty for del in y seq;
        * favor new del over ongong del
        */
        if (endgaps || ndelx < MAXGAP) {
30            if (col1[yy-1] - ins0 >= delx) {
                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
            } else {
                delx -= ins1;
                ndelx++;
35            }
        } else {
            if (col1[yy-1] - (ins0+ins1) >= delx) {
                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
40            } else
                ndelx++;
        }

45      /* pick the maximum score, we're favoring
        * mis over any del and delx over dely
        */
50

```

Table 1 (cont')

...nw

```

id = xx - yy + len1 - 1;
if (mis >= delx && mis >= dely[yy])
    col1[yy] = mis,
5   else if (delx >= dely[yy]) {
        col1[yy] = delx,
        ij = dx[id].ijmp,
        if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
10      && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++,
            if (++ij >= MAXJMP) {
                writejumps(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
            dx[id].jp.n[ij] = ndelx;
            dx[id].jp.x[ij] = xx;
            dx[id].score = delx;
20      }
        else {
            col1[yy] = dely[yy],
            ij = dx[id].ijmp,
25      if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
            && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
                dx[id].ijmp++,
                if (++ij >= MAXJMP) {
                    writejumps(id);
                    ij = dx[id].ijmp = 0;
                    dx[id].offset = offset;
                    offset += sizeof(struct jmp) + sizeof(offset);
                }
            }
            dx[id].jp.n[ij] = -ndely[yy];
            dx[id].jp.x[ij] = xx;
            dx[id].score = dely[yy];
35      }
        if (xx == lcn0 && yy < len1) {
            /* last col
            */
            if (endgaps)
                col1[yy] = ins0+ins1*(len1-yy),
40          if (col1[yy] > smax) {
                smax = col1[yy];
                dmax = id,
            }
        }
    }
50   if (endgaps && xx < len0)
        col1[yy-1] = ins0+ins1*(len0-xx),
        if (col1[yy-1] > smax) {
            smax = col1[yy-1],
            dmax = id,
55   }
    tmp = col0; col0 = col1; col1 = tmp;
}
(void) free((char *)ndely);
(void) free((char *)dely);
60  (void) free((char *)col0);
    (void) free((char *)col1);
    }

```

Table 1 (cont')

```

/*
 *
 * print() -- only routine visible outside this module
 *
5  * static.
 * getmat() -- trace back best path, count matches print()
 * pr_align() -- print alignment of described in array p[]. print()
 * dumpblock() -- dump a block of lines with numbers, stars. pr_align()
10 * nums() -- put out a number line: dumpblock()
 * putline() -- put out a line (name, [num], seq, [num]). dumpblock()
 * stars() -- put a line of stars: dumpblock()
 * stripname() -- strip any path and prefix from a seqname
 */

15 #include "nw.h"

#define SPC      3
#define P_LINE   256 /* maximum output line */
20 #define P_SPC   3 /* space between name or num and seq */

extern _day[26][26],
int olen, /* set output line length */
FILE *fx; /* output file */

25 print()
{
    int lx, ly, firstgap, lastgap, /* overlap */

30     if ((fx = fopen(ofile, "w")) == 0) {
        fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1),
    }
    fprintf(fx, "<first sequence %s (length = %d)\n", namecx[0], len0);
35     fprintf(fx, "<second sequence: %s (length = %d)\n", namecx[1], len1);
    olen = 60;
    lx = len0;
    ly = len1;
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) { /* leading gap in x */
40         pp[0].spc = firstgap = len1 - dmax - 1;
        ly -= pp[0].spc;
    }
    else if (dmax > len1 - 1) { /* leading gap in y */
45         pp[1].spc = firstgap = dmax - (len1 - 1),
        lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) { /* trailing gap in x */
50         lastgap = len0 - dmax0 - 1;
        lx -= lastgap;
    }
    else if (dmax0 > len0 - 1) { /* trailing gap in y */
55         lastgap = dmax0 - (len0 - 1);
        ly -= lastgap;
    }
    getmat(lx, ly, firstgap, lastgap);
    pr_align();
}

```


Table 1 (cont')

```

/*
 * trace back the best path, count matches
 */
static
5  getmat(lx, ly, firstgap, lastgap)                                getmat
    int      lx, ly;
    int      firstgap, lastgap;
/* "core" (minus endgaps) */
/* leading trailing overlap */
{
    int      nm, i0, i1, siz0, siz1;
10    char      outx[32];
    double    pct;
    register  n0, n1;
    register char *p0, *p1;

15    /* get total matches, score
    */
    i0 = i1 = siz0 = siz1 = 0;
    p0 = seqx[0] + pp[1] spc;
    p1 = seqx[1] + pp[0] spc;
20    n0 = pp[1].spc + 1;
    n1 = pp[0].spc + 1;

    nm = 0;
    while ( *p0 && *p1 ) {
25        if (siz0) {
            p1++;
            n1++;
            siz0--;
        }
        else if (siz1) {
30            p0++;
            n0++;
            siz1--;
        }
        else {
35            if (xbm[*p0-'A'] & xbm[*p1-'A'])
                nm++;
            if (n0++ == pp[0].x[i0])
                siz0 = pp[0].n[i0++];
40            if (n1++ == pp[1].x[i1])
                siz1 = pp[1].n[i1++];
            p0++;
            p1++;
        }
45    }

    /* pct homology
    * if penalizing endgaps, base is the shorter seq
    * else, knock off overhangs and take shorter core
    */
50    if (endgaps)
        lx = (len0 < len1)? len0 : len1;
    else
        lx = (lx < ly)? lx : ly;
55    pct = 100.*((double)nm)/((double)lx);
    fprintf(fx, "\n");
    fprintf(fx, "< %d match%s in an overlap of %d: %.2f percent similarity\n",
        nm, (nm == 1)? "" : "es", lx, pct);

```

Table 1 (cont')

```

fprintf(fx, "<gaps in first sequence: %d", gapx);
if (gapx) {
    (void) sprintf(outx, " (%d %s%s)",
        gapx, (dna)? "base"."residue", (ngapx == 1)? "" : "s");
    fprintf(fx, "%s", outx),

    fprintf(fx, ", gaps in second sequence %d", gapy);
    if (gapy) {
        (void) sprintf(outx, " (%d %s%s)",
            gapy, (dna)? "base"."residue", (ngapy == 1)? "" : "s");
        fprintf(fx, "%s", outx);
    }
    if (dna)
        fprintf(fx,
            "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
            smax, DMAT, DMIS, DINS0, DINS1),
    else
        fprintf(fx,
            "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
            smax, PINSO, PINS1),
    if (endgaps)
        fprintf(fx,
            "<endgaps penalized. left endgap: %d %s%s, right endgap %d %s%s\n",
            firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s",
            lastgap, (dna)? "base" : "residue", (lastgap == 1)? "" : "s"),
    else
        fprintf(fx, "<endgaps not penalized\n"),
}

static      nm,          /* matches in core -- for checking */
static      lmax,        /* lengths of stripped file names */
static      ij[2];       /* jmp index for a path */
static      nc[2];       /* number at start of current line */
static      ni[2],       /* current elem number -- for gapping */
static      siz[2],
static char  *ps[2];      /* ptr to current element */
static char  *po[2];      /* ptr to next output char slot */
static char  out[2][P_LINE]; /* output line */
static char  star[P_LINE], /* set by stars() */

/*
 * print alignment of described in struct path pp[]
 */
static
pr_align()
{
    int      nn;          /* char count */
    int      more;
    register i;
    for (i = 0, lmax = 0; i < 2, i++) {
        nn = stripname(namex[i]);
        if (nn > lmax)
            lmax = nn;
        nc[i] = 1;
        ni[i] = 1,
        siz[i] = ij[i] = 0,
        ps[i] = seqx[i],
        po[i] = out[i];
    }
}

```

--getmat

pr_align

Table 1 (cont')

```

for (nn = nm = 0, more = 1, more, ) {
    for (i = more = 0, i < 2; i++) {
        /*
5         * do we have more of this sequence?
        */
        if (!*ps[i])
            continue;

10         more++;

        if (pp[i] spc) { /* leading space */
            *po[i]++ = ' ';
            pp[i].spc--;
15         }
        else if (siz[i]) { /* in a gap */
            *po[i]++ = '-';
            siz[i]--;
20         }
        else { /* we're putting a seq element
            */
            *po[i] = *ps[i];
            if (islower(*ps[i]))
                *ps[i] = toupper(*ps[i]);
25             po[i]++;
            ps[i]++;

            /*
            * are we at next gap for this seq?
            */
30             if (ni[i] == pp[i].x[ij[i]]) {
                /*
                * we need to merge all gaps
                * at this location
                */
                siz[i] = pp[i].n[ij[i]]++;
                while (ni[i] == pp[i].x[ij[i]])
                    siz[i] += pp[i].n[ij[i]]++;
35             }
            ni[i]++;
40         }
    }
    if (++nn == olen || !more && nn) {
        dumpblock();
        for (i = 0; i < 2; i++)
            po[i] = out[i];
        nn = 0;
45     }
}

50 )

/*
 * dump a block of lines, including numbers, stars: pr_align()
 */
55 static
dumpblock()
{
    register i;

60     for (i = 0, i < 2, i++)
        *po[i]-- = '\0';

```

...pr_align

dumpblock

Table 1 (cont')

```

5      (void) putc('\n', fx);
      for (i = 0, i < 2; i++) {
          if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' '))
              if (i == 0)
                  nums(i);
              if (i == 0 && *out[i])
                  stars(),
10      putline(i),
              if (i == 0 && *out[i])
                  fprintf(fx, star);
              if (i == 1)
                  nums(i),
15      }
    }
}

/*
20  * put out a number line: dumpblock()
  */
static
nums(ix)                                nums
{
    int      ix;      /* index in out[] holding seq line */
    char      nline[P_LINE],
    register  i, j;
    register char *pn, *px, *py;

30  for (pn = nline, i = 0; i < lmax+P_SPC; i++, pn++)
        *pn = ' ';
    for (i = nc[ix], py = out[ix], *py; py++, pn++) {
        if (*py == ' ' || *py == '-')
            *pn = ' ';
35  else {
            if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                j = (i < 0)? -i : i;
                for (px = pn; j; j /= 10, px--)
                    *px = j%10 + '0';
40  if (i < 0)
                    *px = '-';
            }
            else
                *pn = ' ';
45  i++;
        }
    }
    *pn = '\0';
    nc[ix] = i;
    for (pn = nline, *pn; pn++)
        (void) putc(*pn, fx);
    (void) putc('\n', fx);
55  }

/*
  * put out a line (name, [num], seq, [num]): dumpblock()
  */
static
putline(ix)                                putline
60  int      ix;

```

Table 1 (cont')

```

5      int          i,
      register char *px;

      for (px = namex[ix], i = 0, *px && *px != '.', px++, i++)
          (void) putc(*px, fx);
      for (; i < lmax+P_SPC, i++)
          (void) putc(' ', fx),

10     /* these count from 1:
      * nl[] is current element (from 1)
      * nc[] is number at start of current line
      */
15     for (px = out[ix]; *px; px++)
          (void) putc(*px&0x7F, fx);
      (void) putc('\n', fx);
    }

20     /*
      * put a line of stars (seqs always in out[0], out[1]): dumpblock()
      */
25     static
    stars()
    {
        int          i;
        register char *p0, *p1, cx, *px,

30         if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
            !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
            return,
        px = star;
35         for (i = lmax+P_SPC, i, i--)
            *px++ = ' ';

        for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
            if (isalpha(*p0) && isalpha(*p1)) {
40                 if (xbm[*p0-'A']&xbm[*p1-'A']){
                    cx = '*',
                    nm++,
                }
                else if (!dna && _day[*p0-'A'][*p1-'A'] > 0)
45                     cx = '.',
                else
                    cx = ' ',
            }
            else
50                 cx = ' ',
            *px++ = cx;
        }
        *px++ = '\n';
55         *px = '\0',
    }

```

...putline

stars

Table 1 (cont')

```

/*
 * strip path or prefix from pn, return len: pr_align()
 */
static
5 stripname(pn)                                stripname
    char      *pn;      /* file name (may be path) */
{
    register char      *px, *py;
10     py = 0;
    for (px = pn; *px; px++)
        if (*px == '/')
            py = px + 1;
15     if (py)
        (void) strcpy(pn, py);
    return(strlen(pn));
}
20
25
30
35
40
45
50
55
60

```

Table 1 (cont')

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
 * g_alloc() -- calloc() with error checkin
5  * readjumps() -- get the good jumps, from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file. nw()
 */
#include "nw.h"
#include <sys/file.h>

10 char      *jname = "/tmp/bomgXXXXXX",          /* tmp file for jumps */
FILE      *fj,

int        cleanup(),                          /* cleanup tmp file */
15 long      lseek();

/*
 * remove any tmp file if we blow
 */
20 cleanup(i)                                     cleanup
{
    int      i;

    if (fj)
        (void) unlink(jname);
25     exit(i);
}

/*
 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ',', '<', or '>'
 * seq in upper or lower case
 */
30 char      *
getseq(file, lcn)                                     getseq
35 {
    char      *file;      /* file name */
    int      *lcn,        /* seq lcn */

    char      line[1024], *pseq;
    register char *px, *py;
    int      natgc, tlen;
    FILE      *fp,

    if ((fp = fopen(file, "r")) == 0) {
        fprintf(stderr, "%s: can't read %s\n", prog, file),
        exit(1),
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
        if (*line == ',' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n', px++)
            if (isupper(*px) || islower(*px))
                tlen++;
    }
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
        exit(1),
    }
    pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0',
60

```

Table 1 (cont')

```

5      py = pseq + 4,
      *len = tlen,
      rewind(fp);

10     while (fgets(line, 1024, fp)) {
        if (*line == ';' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n'; px++){
            if (isupper(*px))
                *py++ = *px,
            else if (islower(*px))
                *py++ = toupper(*px);
            if (index("ATGCU",*(py-1)))
                natgc++;
        }
        *py++ = '\0',
        *py = '\0',
        (void) fclose(fp),
        dna = natgc > (tlen/3);
        return(pseq+4);
    }

25 char *
g_alloc(msg, nx, sz)
    char *msg, /* program, calling routine */
    int nx, sz, /* number and size of elements */

30     char *px, *calloc();

    if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
        if (*msg) {
            fprintf(stderr, "%s: g_alloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz),
            exit(1),
        }
        return(px);
    }

40 /*
 * get final jmps from dx[] or tmp file, set pp[], reset dmax: main()
 */
readjmps()
45 {
    int fd = -1;
    int siz, i0, i1,
    register i, j, xx;

50     if (fj) {
        (void) fclose(fj),
        if ((fd = open(jname, O_RDONLY, 0)) < 0) {
            fprintf(stderr, "%s: can't open() %s\n", prog, jname);
            cleanup(1),
        }
    }
    for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; i++) {
        while (1) {
            for (j = dx[dmax] ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)

```


Table 1 (cont')

...readjumps

```

5      if (j < 0 && dx[dmax].offset && fj) {
        (void) lseek(fd, dx[dmax].offset, 0),
        (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp)),
        (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset)),
        dx[dmax].ijmp = MAXJMP-1,
      }
      else
10         break;
    }
    if (i >= JMPS) {
        fprintf(stderr, "%s: too many gaps in alignment\n", prog);
        cleanup(1),
    }
15    if (j >= 0) {
        siz = dx[dmax].jp.n[j];
        xx = dx[dmax].jp.x[j];
        dmax += siz,
        if (siz < 0) {
20             /* gap in second seq */
            pp[1].n[i1] = -siz;
            xx += siz;
            /* id = xx - yy + len1 - 1
            */
            pp[1].x[i1] = xx - dmax + len1 - 1;
            gapy++;
            ngapy += siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
            i1++;
30         }
        else if (siz > 0) {
            /* gap in first seq */
            pp[0].n[i0] = siz;
            pp[0].x[i0] = xx;
            gapx++;
            ngapx += siz,
            /* ignore MAXGAP when doing endgaps */
            siz = (siz < MAXGAP || endgaps)? siz : MAXGAP,
            i0++;
35         }
    }
    else
40         break;
}

45 /* reverse the order of jumps
*/
for (j = 0, i0--; j < i0; j++, i0--) {
    i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0], pp[0].n[i0] = i;
    i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0], pp[0].x[i0] = i,
50 }
for (j = 0, i1--; j < i1; j++, i1--) {
    i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1], pp[1].n[i1] = i;
    i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1], pp[1].x[i1] = i,
55 }
if (fd >= 0)
    (void) close(fd);
if (fj) {
    (void) unlink(jname);
    fj = 0,
    offset = 0,
60 }
    }

```

Table 1 (cont')

```

/*
 * write a filled jmp struct offset of the prev one (if any): nw0
 */
5  writejumps(ix)                                     writejumps
    int      ix;
    {
        char      *mktemp(),
10         if (!fj) {
            if (mktemp(jname) < 0) {
                fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname),
                    cleanup(1),
            }
            if ((fj = fopen(jname, "w")) == 0) {
                fprintf(stderr, "%s: can't write %s\n", prog, jname);
                exit(1),
            }
20         }
        (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj),
        (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj),
    }

25

30

35

40

45

50

55

60

```

Table 2

| | | |
|--------------------|--------------------|---------------------------|
| TASK | XXXXXXXXXXXXXXXXXX | (Length = 15 amino acids) |
| Comparison Protein | XXXXXXXXYYYYYY | (Length = 12 amino acids) |

5 % amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the TASK polypeptide) =

10 5 divided by 15 = 33.3%

Table 3

| | | | |
|----|--------------------|------------------|---------------------------|
| 15 | TASK | XXXXXXXXXXXX | (Length = 10 amino acids) |
| | Comparison Protein | XXXXXXXXYYYYZZYZ | (Length = 15 amino acids) |

% amino acid sequence identity =

20 (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the TASK polypeptide) =

5 divided by 10 = 50%

Table 4

| | | | |
|----|----------------|------------------|---------------------------|
| 25 | TASK-DNA | NNNNNNNNNNNNNN | (Length = 14 nucleotides) |
| | Comparison DNA | NNNNNNLLLLLLLLLL | (Length = 16 nucleotides) |

% nucleic acid sequence identity =

30 (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the TASK-DNA nucleic acid sequence) =

6 divided by 14 = 42.9%

Table 5

| | | |
|----------------|--------------|---------------------------|
| TASK-DNA | NNNNNNNNNNNN | (Length = 12 nucleotides) |
| Comparison DNA | NNNNLLLVV | (Length = 9 nucleotides) |

5 % nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2)
divided by (the total number of nucleotides of the TASK-DNA nucleic acid sequence) =

10 4 divided by 12 = 33.3%

II. Compositions and Methods of the Invention

A. Anti-TASK Antibodies

15 In one embodiment, the present invention provides anti-TASK antibodies which may find use herein as therapeutic and/or diagnostic agents. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

1. Polyclonal Antibodies

20 Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen (especially when synthetic peptides are used) to a protein that is immunogenic in the species to be immunized. For example, the antigen can be conjugated to keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N}=\text{C}=\text{NR}$, where R and R^1 are different alkyl groups.

25 Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 μg or 5 μg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and the serum is assayed for antibody titer. Animals are
30 boosted until the titer plateaus. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

2. Monoclonal Antibodies

35 Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind

to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. After immunization, lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium which medium preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells (also referred to as fusion partner). For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the selective culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred fusion partner myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a selective medium that selects against the unfused parental cells. Preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 and derivatives e.g., X63-Ag8-653 cells available from the American Type Culture Collection, Manassas, Virginia, USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); and Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis described in Munson et al., Anal. Biochem., 107:220 (1980).

Once hybridoma cells that produce antibodies of the desired specificity, affinity, and/or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal e.g., by i.p. injection of the cells into mice.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (e.g., using protein A or protein G-Sepharose) or ion-exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, etc.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody protein,

to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., Curr. Opinion in Immunol., 5:256-262 (1993) and Plückthun, Immunol. Revs. 130:151-188 (1992).

In a further embodiment, monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., Bio/Technology, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nuc. Acids. Res. 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA that encodes the antibody may be modified to produce chimeric or fusion antibody polypeptides, for example, by substituting human heavy chain and light chain constant domain (C_H and C_L) sequences for the homologous murine sequences (U.S. Patent No. 4,816,567; and Morrison, et al., Proc. Natl Acad. Sci. USA, 81:6851 (1984)), or by fusing the immunoglobulin coding sequence with all or part of the coding sequence for a non-immunoglobulin polypeptide (heterologous polypeptide). The non-immunoglobulin polypeptide sequences can substitute for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

3. Human and Humanized Antibodies

The anti-TASK antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain.

Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity and HAMA response (human anti-mouse antibody) when the antibody is intended for human therapeutic use. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human V domain sequence which is closest to that of the rodent is identified and the human framework region (FR) within it accepted for the humanized antibody (Sims et al., J. Immunol. 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987)). Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993)).

It is further important that antibodies be humanized with retention of high binding affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

Various forms of a humanized anti-TASK antibody are contemplated. For example, the humanized antibody may be an antibody fragment, such as a Fab, which is optionally conjugated with one or more cytotoxic agent(s) in order to generate an immunoconjugate. Alternatively, the humanized antibody may be an intact antibody, such as an intact IgG1 antibody.

As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin

gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno. 7:33 (1993); U.S. Patent Nos. 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); 5,545,807; and WO 97/17852.

Alternatively, phage display technology (McCafferty et al., Nature 348:552-553 [1990]) can be used to produce human antibodies and antibody fragments *in vitro*, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats, reviewed in, e.g., Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol. 222:581-597 (1991), or Griffith et al., EMBO J. 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905.

As discussed above, human antibodies may also be generated by *in vitro* activated B cells (see U.S. Patents 5,567,610 and 5,229,275).

4. Antibody fragments

In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors.

Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from *E. coli*, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form F(ab')₂ fragments (Carter et al., Bio/Technology 10:163-167 (1992)). According to another approach, F(ab')₂ fragments can be isolated directly from recombinant host cell culture. Fab and F(ab')₂ fragment with increased *in vivo* half-life comprising a salvage receptor binding epitope residues are described in U.S. Patent No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced nonspecific binding during *in vivo* use. sFv fusion proteins may be constructed to yield fusion of an

effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineering, ed. Borrebaeck, supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

5. Bispecific Antibodies

Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of a TASK protein as described herein. Other such antibodies may combine a TASK binding site with a binding site for another protein. Alternatively, an anti-TASK arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD3), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16), so as to focus and localize cellular defense mechanisms to the TASK-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express TASK. These antibodies possess a TASK-binding arm and an arm which binds the cytotoxic agent (e.g., saporin, anti-interferon-α, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')₂ bispecific antibodies).

WO 96/16673 describes a bispecific anti-ErbB2/anti-FcγRIII antibody and U.S. Patent No. 5,837,234 discloses a bispecific anti-ErbB2/anti-FcγRI antibody. A bispecific anti-ErbB2/Fcα antibody is shown in WO98/02463. U.S. Patent No. 5,821,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody.

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al., EMBO J. 10:3655-3659 (1991).

According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least part of the hinge, C_H2, and C_H3 regions. It is preferred to have the first heavy-chain constant region (C_H1) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios have no significant affect on the yield of the desired chain combination.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-

light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology 121:210 (1986).

5 According to another approach described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the C_H3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s)
10 are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example,
15 been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the
20 literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by
25 reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175: 217-225 (1992) describe the
30 production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell
35 culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced

at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a V_H connected to a V_L by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol., 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared Tutt et al., J. Immunol. 147:60 (1991).

6. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

7. Multivalent Antibodies

A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. The antibodies of the present invention can be multivalent antibodies (which are other than of the IgM class) with three or more antigen binding sites (e.g. tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. The preferred multivalent antibody herein comprises (or consists of) three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide chain(s) may comprise $VD1-(X1)_n-VD2-(X2)_n-Fc$, wherein VD1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, X1 and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fc region chain. The multivalent antibody herein preferably further comprises at least two (and preferably four) light chain variable domain polypeptides. The multivalent antibody herein may, for instance, comprise from about two to about eight light chain variable domain polypeptides. The light chain variable domain polypeptides contemplated here comprise a light chain variable domain and, optionally, further comprise a CL domain.

8. Effector Function Engineering

It may be desirable to modify the antibody of the invention with respect to effector function, e.g., so as to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al., Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design 3:219-230 (1989). To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, or IgG₄) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

9. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, croton, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, and ¹⁸⁶Re. Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

Conjugates of an antibody and one or more small molecule toxins, such as a calicheamicin, maytansinoids, a tricothene, and CC1065, and the derivatives of these toxins that have toxin activity, are also contemplated herein.

Maytansine and maytansinoids

In one preferred embodiment, an anti-TASK antibody (full length or fragments) of the invention is conjugated to one or more maytansinoid molecules.

Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub *Maytenus serrata* (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, the disclosures of which are hereby expressly incorporated by reference.

Maytansinoid-antibody conjugates

In an attempt to improve their therapeutic index, maytansine and maytansinoids have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference. Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) described immunoconjugates comprising a maytansinoid designated DM1 linked to the monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an *in vivo* tumor growth assay. Chari et al., Cancer Research 52:127-131 (1992) describe immunoconjugates in which a maytansinoid was conjugated via a disulfide linker to the murine antibody A7 binding to an antigen on human colon cancer cell lines, or to another murine monoclonal antibody TA.1 that binds the HER-2/*neu* oncogene. The cytotoxicity of the TA.1-maytansinoid conjugate was tested *in vitro* on the human breast cancer cell line SK-BR-3, which expresses 3×10^5 HER-2 surface antigens per cell. The drug conjugate achieved a degree of cytotoxicity similar to the free maytansinoid drug, which could be increased by increasing the number of maytansinoid molecules per antibody molecule. The A7-maytansinoid conjugate showed low systemic cytotoxicity in mice.

Anti-TASK polypeptide antibody-maytansinoid conjugates (immunoconjugates)

Anti-TASK antibody-maytansinoid conjugates are prepared by chemically linking an anti-TASK antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. An average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody, although even one molecule of toxin/antibody would be expected to enhance cytotoxicity over the use of naked antibody. Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural sources. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020 and in the other patents and nonpatent publications referred to hereinabove. Preferred maytansinoids are maytansinol and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.

There are many linking groups known in the art for making antibody-maytansinoid conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 or EP Patent 0 425 235 B1, and Chari et al., Cancer

Research 52:127-131 (1992). The linking groups include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred.

Conjugates of the antibody and maytansinoid may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Carlsson et al., Biochem. J. 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP) to provide for a disulfide linkage.

The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In a preferred embodiment, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.

Calicheamicin

Another immunoconjugate of interest comprises an anti-TASK antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. patents 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296 (all to American Cyanamid Company). Structural analogues of calicheamicin which may be used include, but are not limited to, γ_1^I , α_2^I , α_3^I , N-acetyl- γ_1^I , PSAG and θ_1^I (Hinman et al., Cancer Research 53:3336-3342 (1993), Lode et al., Cancer Research 58:2925-2928 (1998) and the aforementioned U.S. patents to American Cyanamid). Another anti-tumor drug that the antibody can be conjugated is QFA which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody mediated internalization greatly enhances their cytotoxic effects.

Other cytotoxic agents

Other antitumor agents that can be conjugated to the anti-TASK antibodies of the invention include BCNU, streptozocin, vincristine and 5-fluorouracil, the family of agents known collectively LL-E33288 complex described in U.S. patents 5,053,394, 5,770,710, as well as esperamicins (U.S. patent 5,877,296).

Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, croton, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, for example, WO 93/21232 published October 28, 1993.

The present invention further contemplates an immunoconjugate formed between an antibody and a compound with nucleolytic activity (e.g., a ribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

For selective destruction of the tumor, the antibody may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated anti-TASK antibodies. Examples include
 5 At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu. When the conjugate is used for diagnosis, it may comprise a radioactive atom for scintigraphic studies, for example tc^{99m} or I¹²³, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

10 The radio- or other labels may be incorporated in the conjugate in known ways. For example, the peptide may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen. Labels such as tc^{99m} or I¹²³, Re¹⁸⁶, Re¹⁸⁸ and In¹¹¹ can be attached via a cysteine residue in the peptide. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine-123.
 15 "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes other methods in detail.

Conjugates of the antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridylidithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds
 20 (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.
 25 The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Research 52:127-131 (1992); U.S. Patent No. 5,208,020) may be used.

Alternatively, a fusion protein comprising the anti-TASK antibody and cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. The length of DNA may comprise respective regions encoding the
 30 two portions of the conjugate either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.

In yet another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand"
 35 (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a radionucleotide).

10. Immunoliposomes

The anti-TASK antibodies disclosed herein may also be formulated as immunoliposomes. A "liposome"

is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and WO97/38731 published October 23,

5 1997. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al.,
10 J. Biol. Chem. 257:286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst. 81(19):1484 (1989).

B. TASK Binding Oligopeptides

TASK binding oligopeptides of the present invention are oligopeptides that bind, preferably specifically, to a TASK polypeptide as described herein. TASK binding oligopeptides may be chemically synthesized using
15 known oligopeptide synthesis methodology or may be prepared and purified using recombinant technology. TASK binding oligopeptides are usually at least about 5 amino acids in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids
20 in length or more, wherein such oligopeptides that are capable of binding, preferably specifically, to a TASK polypeptide as described herein. TASK binding oligopeptides may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening oligopeptide libraries for oligopeptides that are capable of specifically binding to a polypeptide target are well known in the art (see, e.g., U.S. Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT
25 Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 81:3998-4002 (1984); Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 82:178-182 (1985); Geysen et al., in Synthetic Peptides as Antigens, 130-149 (1986); Geysen et al., J. Immunol. Meth., 102:259-274 (1987); Schoofs et al., J. Immunol., 140:611-616 (1988), Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378; Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363, and Smith, G. P. (1991) Current Opin. Biotechnol., 2:668).

In this regard, bacteriophage (phage) display is one well known technique which allows one to screen large oligopeptide libraries to identify member(s) of those libraries which are capable of specifically binding to a polypeptide target. Phage display is a technique by which variant polypeptides are displayed as fusion proteins to
35 the coat protein on the surface of bacteriophage particles (Scott, J.K. and Smith, G. P. (1990) Science 249: 386). The utility of phage display lies in the fact that large libraries of selectively randomized protein variants (or randomly cloned cDNAs) can be rapidly and efficiently sorted for those sequences that bind to a target molecule with high

affinity. Display of peptide (Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378) or protein (Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363) libraries on phage have been used for screening millions of polypeptides or oligopeptides for ones with specific binding properties (Smith, G. P. (1991) Current Opin. Biotechnol., 2:668). Sorting phage libraries of random mutants requires a strategy for constructing and propagating a large number of variants, a procedure for affinity purification using the target receptor, and a means of evaluating the results of binding enrichments. U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,689, and 5,663,143.

Although most phage display methods have used filamentous phage, lambdoid phage display systems (WO 95/34683; U.S. 5,627,024), T4 phage display systems (Ren, Z-J. et al. (1998) Gene 215:439; Zhu, Z. (1997) CAN 33:534; Jiang, J. et al. (1997) can 128:44380; Ren, Z-J. et al. (1997) CAN 127:215644; Ren, Z-J. (1996) Protein Sci. 5:1833; Efimov, V. P. et al. (1995) Virus Genes 10:173) and T7 phage display systems (Smith, G. P. and Scott, J.K. (1993) Methods in Enzymology, 217, 228-257; U.S. 5,766,905) are also known.

Many other improvements and variations of the basic phage display concept have now been developed. These improvements enhance the ability of display systems to screen peptide libraries for binding to selected target molecules and to display functional proteins with the potential of screening these proteins for desired properties. Combinatorial reaction devices for phage display reactions have been developed (WO 98/14277) and phage display libraries have been used to analyze and control bimolecular interactions (WO 98/20169; WO 98/20159) and properties of constrained helical peptides (WO 98/20036). WO 97/35196 describes a method of isolating an affinity ligand in which a phage display library is contacted with one solution in which the ligand will bind to a target molecule and a second solution in which the affinity ligand will not bind to the target molecule, to selectively isolate binding ligands. WO 97/46251 describes a method of biopanning a random phage display library with an affinity purified antibody and then isolating binding phage, followed by a micropanning process using microplate wells to isolate high affinity binding phage. The use of *Staphylococcus aureus* protein A as an affinity tag has also been reported (Li et al. (1998) Mol Biotech., 9:187). WO 97/47314 describes the use of substrate subtraction libraries to distinguish enzyme specificities using a combinatorial library which may be a phage display library. A method for selecting enzymes suitable for use in detergents using phage display is described in WO 97/09446. Additional methods of selecting specific binding proteins are described in U.S. Patent Nos. 5,498,538, 5,432,018, and WO 98/15833.

Methods of generating peptide libraries and screening these libraries are also disclosed in U.S. Patent Nos. 5,723,286, 5,432,018, 5,580,717, 5,427,908, 5,498,530, 5,770,434, 5,734,018, 5,698,426, 5,763,192, and 5,723,323.

C. TASK Binding Organic Molecules

TASK binding organic molecules are organic molecules other than oligopeptides or antibodies as defined herein that bind, preferably specifically, to a TASK polypeptide as described herein. TASK binding organic molecules may be identified and chemically synthesized using known methodology (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). TASK binding organic molecules are usually less than about 2000 daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 daltons in size, wherein such organic molecules that are capable of binding, preferably specifically, to a TASK polypeptide as described herein may be identified without

undue experimentation using well known techniques. In this regard, it is noted that techniques for screening organic molecule libraries for molecules that are capable of binding to a polypeptide target are well known in the art (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). TASK binding organic molecules may be, for example, aldehydes, ketones, oximes, hydrazones, semicarbazones, carbazides, primary amines, secondary amines, tertiary amines, N-substituted hydrazines, hydrazides, alcohols, ethers, thiols, thioethers, disulfides, carboxylic acids, esters, amides, ureas, carbamates, carbonates, ketals, thioketals, acetals, thioacetals, aryl halides, aryl sulfonates, alkyl halides, alkyl sulfonates, aromatic compounds, heterocyclic compounds, anilines, alkenes, alkynes, diols, amino alcohols, oxazolidines, oxazolines, thiazolidines, thiazolines, enamines, sulfonamides, epoxides, aziridines, isocyanates, sulfonyl chlorides, diazo compounds, acid chlorides, or the like.

D. Screening for Anti-TASK Antibodies, TASK Binding Oligopeptides and TASK Binding Organic Molecules With the Desired Properties

Techniques for generating antibodies, oligopeptides and organic molecules that bind to TASK polypeptides have been described above. One may further select antibodies, oligopeptides or other organic molecules with certain biological characteristics, as desired.

The growth inhibitory effects of an anti-TASK antibody, oligopeptide or other organic molecule of the invention may be assessed by methods known in the art, e.g., using cells which express a TASK polypeptide either endogenously or following transfection with the TASK gene. For example, appropriate tumor cell lines and TASK-transfected cells may be treated with an anti-TASK monoclonal antibody, oligopeptide or other organic molecule of the invention at various concentrations for a few days (e.g., 2-7) days and stained with crystal violet or MTT or analyzed by some other colorimetric assay. Another method of measuring proliferation would be by comparing ³H-thymidine uptake by the cells treated in the presence or absence an anti-TASK antibody, TASK binding oligopeptide or TASK binding organic molecule of the invention. After treatment, the cells are harvested and the amount of radioactivity incorporated into the DNA quantitated in a scintillation counter. Appropriate positive controls include treatment of a selected cell line with a growth inhibitory antibody known to inhibit growth of that cell line. Growth inhibition of tumor cells *in vivo* can be determined in various ways known in the art. Preferably, the tumor cell is one that overexpresses a TASK polypeptide. Preferably, the anti-TASK antibody, TASK binding oligopeptide or TASK binding organic molecule will inhibit cell proliferation of a TASK-expressing tumor cell *in vitro* or *in vivo* by about 25-100% compared to the untreated tumor cell, more preferably, by about 30-100%, and even more preferably by about 50-100% or 70-100%, in one embodiment, at an antibody concentration of about 0.5 to 30 µg/ml. Growth inhibition can be measured at an antibody concentration of about 0.5 to 30 µg/ml or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells to the antibody. The antibody is growth inhibitory *in vivo* if administration of the anti-TASK antibody at about 1 µg/kg to about 100 mg/kg body weight results in reduction in tumor size or reduction of tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days.

To select for an anti-TASK antibody, TASK binding oligopeptide or TASK binding organic molecule which induces cell death, loss of membrane integrity as indicated by, e.g., propidium iodide (PI), trypan blue or 7AAD uptake may be assessed relative to control. A PI uptake assay can be performed in the absence of complement and immune effector cells. TASK polypeptide-expressing tumor cells are incubated with medium alone or medium

containing the appropriate anti-TASK antibody (e.g., at about 10 μ g/ml), TASK binding oligopeptide or TASK binding organic molecule. The cells are incubated for a 3 day time period. Following each treatment, cells are washed and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell clumps. Tubes then receive PI (10 μ g/ml). Samples may be analyzed using a FACSCAN \textregistered flow cytometer and FACSCONVERT \textregistered CellQuest software (Becton Dickinson). Those anti-TASK antibodies, TASK binding oligopeptides or TASK binding organic molecules that induce statistically significant levels of cell death as determined by PI uptake may be selected as cell death-inducing anti-TASK antibodies, TASK binding oligopeptides or TASK binding organic molecules.

To screen for antibodies, oligopeptides or other organic molecules which bind to an epitope on a TASK polypeptide bound by an antibody of interest, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. This assay can be used to determine if a test antibody, oligopeptide or other organic molecule binds the same site or epitope as a known anti-TASK antibody. Alternatively, or additionally, epitope mapping can be performed by methods known in the art. For example, the antibody sequence can be mutagenized such as by alanine scanning, to identify contact residues. The mutant antibody is initially tested for binding with polyclonal antibody to ensure proper folding. In a different method, peptides corresponding to different regions of a TASK polypeptide can be used in competition assays with the test antibodies or with a test antibody and an antibody with a characterized or known epitope.

E. Antibody Dependent Enzyme Mediated Prodrug Therapy (ADEPT)

The antibodies of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Patent No. 4,975,278.

The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to convert it into its more active, cytotoxic form.

Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β -galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; β -lactamase useful for converting drugs derivatized with β -lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328:457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.

The enzymes of this invention can be covalently bound to the anti-TASK antibodies by techniques well

known in the art such as the use of the heterobifunctional crosslinking reagents discussed above. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature 312:604-608 (1984)).

F. Full-Length TASK Polypeptides

The present invention also provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as TASK polypeptides. In particular, cDNAs (partial and full-length) encoding various TASK polypeptides have been identified and isolated, as disclosed in further detail in the Examples below.

As disclosed in the Examples below, various cDNA clones have been described. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the TASK polypeptides and encoding nucleic acids described herein, in some cases, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.

G. Anti-TASK Antibody and TASK Polypeptide Variants

In addition to the anti-TASK antibodies and full-length native sequence TASK polypeptides described herein, it is contemplated that anti-TASK antibody and TASK polypeptide variants can be prepared. Anti-TASK antibody and TASK polypeptide variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA, and/or by synthesis of the desired antibody or polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the anti-TASK antibody or TASK polypeptide, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the anti-TASK antibodies and TASK polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the antibody or polypeptide that results in a change in the amino acid sequence as compared with the native sequence antibody or polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the anti-TASK antibody or TASK polypeptide. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the anti-TASK antibody or TASK polypeptide with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

Anti-TASK antibody and TASK polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native antibody or protein. Certain fragments lack amino acid residues that are not essential for a desired

biological activity of the anti-TASK antibody or TASK polypeptide.

Anti-TASK antibody and TASK polypeptide fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating antibody or polypeptide fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired antibody or polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, anti-TASK antibody and TASK polypeptide fragments share at least one biological and/or immunological activity with the native anti-TASK antibody or TASK polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

| | Original Residue | Exemplary Substitutions | Preferred Substitutions |
|----|------------------|-------------------------------------|-------------------------|
| 15 | Ala (A) | val; leu; ile | val |
| | Arg (R) | lys; gln; asn | lys |
| 20 | Asn (N) | gln; his; lys; arg | gln |
| | Asp (D) | glu | glu |
| | Cys (C) | ser | ser |
| | Gln (Q) | asn | asn |
| | Glu (E) | asp | asp |
| 25 | Gly (G) | pro; ala | ala |
| | His (H) | asn; gln; lys; arg | arg |
| | Ile (I) | leu; val; met; ala; phe; norleucine | leu |
| | Leu (L) | norleucine; ile; val; met; ala; phe | ile |
| 30 | Lys (K) | arg; gln; asn | arg |
| | Met (M) | leu; phe; ile | leu |
| | Phe (F) | leu; val; ile; ala; tyr | leu |
| | Pro (P) | ala | ala |
| 35 | Ser (S) | thr | thr |
| | Thr (T) | ser | ser |
| | Trp (W) | tyr; phe | tyr |
| | Tyr (Y) | trp; phe; thr; ser | phe |
| 40 | Val (V) | ile; leu; met; phe; ala; norleucine | leu |

Substantial modifications in function or immunological identity of the anti-TASK antibody or TASK polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- 5 (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

- 10 The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the anti-TASK antibody or TASK polypeptide variant DNA.

- 15 Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244:1081-1085 (1989)]. Alanine is also typically preferred because
- 20 it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Choithia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

- Any cysteine residue not involved in maintaining the proper conformation of the anti-TASK antibody or TASK polypeptide also may be substituted, generally with serine, to improve the oxidative stability of the molecule
- 25 and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the anti-TASK antibody or TASK polypeptide to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

- A particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed. In order
- 30 to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between
- 35

the antibody and human TASK polypeptide. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

Nucleic acid molecules encoding amino acid sequence variants of the anti-TASK antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the anti-TASK antibody.

H. Modifications of Anti-TASK Antibodies and TASK Polypeptides

Covalent modifications of anti-TASK antibodies and TASK polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of an anti-TASK antibody or TASK polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the anti-TASK antibody or TASK polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking anti-TASK antibody or TASK polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-TASK antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the anti-TASK antibody or TASK polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the antibody or polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence anti-TASK antibody or TASK polypeptide (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence anti-TASK antibody or TASK polypeptide. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Glycosylation of antibodies and other polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation

refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Addition of glycosylation sites to the anti-TASK antibody or TASK polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original anti-TASK antibody or TASK polypeptide (for O-linked glycosylation sites). The anti-TASK antibody or TASK polypeptide amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the anti-TASK antibody or TASK polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the anti-TASK antibody or TASK polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the anti-TASK antibody or TASK polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of anti-TASK antibody or TASK polypeptide comprises linking the antibody or polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. The antibody or polypeptide also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980).

The anti-TASK antibody or TASK polypeptide of the present invention may also be modified in a way to form chimeric molecules comprising an anti-TASK antibody or TASK polypeptide fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the anti-TASK antibody or TASK polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the anti-TASK antibody or TASK polypeptide. The presence of such epitope-tagged forms of the anti-TASK antibody or TASK polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the anti-TASK antibody or TASK polypeptide to be readily purified by affinity purification using an anti-tag antibody or another

type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an α -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In an alternative embodiment, the chimeric molecule may comprise a fusion of the anti-TASK antibody or TASK polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH₂ and CH₃, or the hinge, CH₁, CH₂ and CH₃ regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

I. Preparation of Anti-TASK Antibodies and TASK Polypeptides

The description below relates primarily to production of anti-TASK antibodies and TASK polypeptides by culturing cells transformed or transfected with a vector containing anti-TASK antibody- and TASK polypeptide-encoding nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare anti-TASK antibodies and TASK polypeptides. For instance, the appropriate amino acid sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the anti-TASK antibody or TASK polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the desired anti-TASK antibody or TASK polypeptide.

1. Isolation of DNA Encoding Anti-TASK Antibody or TASK Polypeptide

DNA encoding anti-TASK antibody or TASK polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the anti-TASK antibody or TASK polypeptide mRNA and to express it at a detectable level. Accordingly, human anti-TASK antibody or TASK polypeptide DNA can be conveniently obtained from a cDNA library prepared from human tissue. The anti-TASK antibody- or TASK polypeptide-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding anti-TASK antibody or TASK polypeptide is to use PCR methodology [Sambrook et al., *supra*;

Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

Techniques for screening a cDNA library are well known in the art. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like ^{32}P -labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for anti-TASK antibody or TASK polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaCl_2 , CaPO_4 , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or

higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan'*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan'*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

Full length antibody, antibody fragments, and antibody fusion proteins can be produced in bacteria, in particular when glycosylation and Fc effector function are not needed, such as when the therapeutic antibody is conjugated to a cytotoxic agent (e.g., a toxin) and the immunoconjugate by itself shows effectiveness in tumor cell destruction. Full length antibodies have greater half life in circulation. Production in *E. coli* is faster and more cost efficient. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. 5,648,237 (Carter et al.), U.S. 5,789,199 (Joly et al.), and U.S. 5,840,523 (Simmons et al.) which describes translation initiation region (TIR) and signal sequences for optimizing expression and secretion, these patents incorporated herein by reference. After expression, the antibody is isolated from the *E. coli* cell paste in a soluble fraction and can be purified through, e.g., a protein A or G column depending on the isotype. Final purification can be carried out similar to the process for purifying antibody expressed e.g., in CHO cells.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-TASK antibody- or TASK polypeptide-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, *Nature*, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., *Bio/Technology*, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., *J. Bacteriol.*, 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., *Bio/Technology*, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., *J. Basic Microbiol.*, 28:265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., *Proc. Natl. Acad. Sci. USA*, 76:5259-5263 [1979]); *Schwanniomyces* such as

Schwanniomyces occidentalis (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 (1982).

Suitable host cells for the expression of glycosylated anti-TASK antibody or TASK polypeptide are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells, such as cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression or cloning vectors for anti-TASK antibody or TASK polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding anti-TASK antibody or TASK polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more

marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

5 The TASK may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the anti-TASK antibody. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* α -factor leaders, the latter described in U.S. Patent No. 5,010,182),
10 or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in
15 one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker.
20 Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the anti-TASK antibody- or TASK polypeptide-encoding nucleic acid, such as DHFR or
25 thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC
30 No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the anti-TASK antibody- or TASK polypeptide-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the β -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline
35 phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding

anti-TASK antibody or TASK polypeptide.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., *J. Biol. Chem.*, 255:2073 (1980)] or other glycolytic enzymes [Hess et al., *J. Adv. Enzyme Reg.*, 7:149(1968); Holland, *Biochemistry*, 17:4900(1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

Anti-TASK antibody or TASK polypeptide transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the anti-TASK antibody or TASK polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the anti-TASK antibody or TASK polypeptide coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding anti-TASK antibody or TASK polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of anti-TASK antibody or TASK polypeptide in recombinant vertebrate cell culture are described in Gething et al., *Nature*, 293:620-625 (1981); Mantei et al., *Nature*, 281:40-46 (1979); EP 117,060; and EP 117,058.

4. Culturing the Host Cells

The host cells used to produce the anti-TASK antibody or TASK polypeptide of this invention may be

cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be used as culture media for the host cells.

5 Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

5. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence TASK polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to TASK DNA and encoding a specific antibody epitope.

6. Purification of Anti-TASK Antibody and TASK Polypeptide

Forms of anti-TASK antibody and TASK polypeptide may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of anti-TASK antibody and TASK polypeptide can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify anti-TASK antibody and TASK polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating

columns to bind epitope-tagged forms of the anti-TASK antibody and TASK polypeptide. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular anti-TASK antibody or TASK polypeptide produced.

5 When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, are removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of *E. coli*. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and
10 phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.

15 The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human $\gamma 1$, $\gamma 2$ or $\gamma 4$ heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is
20 recommended for all mouse isotypes and for human $\gamma 3$ (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a C_H3 domain, the Bakerbond ABXTM resin (J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such
25 as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSETM chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.

30 Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).

J. Pharmaceutical Formulations

35 Therapeutic formulations of the anti-TASK antibodies, TASK binding oligopeptides, TASK binding organic molecules and/or TASK polypeptides used in accordance with the present invention are prepared for storage by mixing the antibody, polypeptide, oligopeptide or organic molecule having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients,

or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as acetate, Tris, phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; tonicifiers such as trehalose and sodium chloride; sugars such as sucrose, mannitol, trehalose or sorbitol; surfactant such as polysorbate; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN®, PLURONICS® or polyethylene glycol (PEG). The antibody preferably comprises the antibody at a concentration of between 5-200 mg/ml, preferably between 10-100 mg/ml.

The formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, in addition to an anti-TASK antibody, TASK binding oligopeptide, or TASK binding organic molecule, it may be desirable to include in the one formulation, an additional antibody, e.g., a second anti-TASK antibody which binds a different epitope on the TASK polypeptide, or an antibody to some other target such as a growth factor that affects the growth of the particular cancer. Alternatively, or additionally, the composition may further comprise a chemotherapeutic agent, cytotoxic agent, cytokine, growth inhibitory agent, anti-hormonal agent, and/or cardioprotectant. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

K. Diagnosis and Treatment with Anti-TASK Antibodies, TASK Binding Oligopeptides and TASK Binding Organic Molecules

To determine TASK expression in the cancer, various diagnostic assays are available. In one embodiment, TASK polypeptide overexpression may be analyzed by immunohistochemistry (IHC). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a TASK protein staining intensity criteria as follows:

Score 0 - no staining is observed or membrane staining is observed in less than 10% of tumor cells.

5 Score 1+ - a faint/barely perceptible membrane staining is detected in more than 10% of the tumor cells. The cells are only stained in part of their membrane.

Score 2+ - a weak to moderate complete membrane staining is observed in more than 10% of the tumor cells.

10 Score 3+ - a moderate to strong complete membrane staining is observed in more than 10% of the tumor cells.

Those tumors with 0 or 1+ scores for TASK polypeptide expression may be characterized as not overexpressing TASK, whereas those tumors with 2+ or 3+ scores may be characterized as overexpressing TASK.

Alternatively, or additionally, FISH assays such as the INFORM® (sold by Ventana, Arizona) or PATHVISION® (Vysis, Illinois) may be carried out on formalin-fixed, paraffin-embedded tumor tissue to determine
15 the extent (if any) of TASK overexpression in the tumor.

TASK overexpression or amplification may be evaluated using an *in vivo* diagnostic assay, e.g., by administering a molecule (such as an antibody, oligopeptide or organic molecule) which binds the molecule to be detected and is tagged with a detectable label (e.g., a radioactive isotope or a fluorescent label) and externally scanning the patient for localization of the label.

20 As described above, the anti-TASK antibodies, oligopeptides and organic molecules of the invention have various non-therapeutic applications. The anti-TASK antibodies, oligopeptides and organic molecules of the present invention can be useful for diagnosis and staging of TASK polypeptide-expressing cancers (e.g., in radioimaging). The antibodies, oligopeptides and organic molecules are also useful for purification or immunoprecipitation of TASK polypeptide from cells, for detection and quantitation of TASK polypeptide *in vitro*, e.g., in an ELISA or a Western
25 blot, to kill and eliminate TASK-expressing cells from a population of mixed cells as a step in the purification of other cells.

Currently, depending on the stage of the cancer, cancer treatment involves one or a combination of the following therapies: surgery to remove the cancerous tissue, radiation therapy, and chemotherapy. Anti-TASK antibody, oligopeptide or organic molecule therapy may be especially desirable in elderly patients who do not tolerate the toxicity and side effects of chemotherapy well and in metastatic disease where radiation therapy has limited usefulness. The tumor targeting anti-TASK antibodies, oligopeptides and organic molecules of the invention are
30 useful to alleviate TASK-expressing cancers upon initial diagnosis of the disease or during relapse. For therapeutic applications, the anti-TASK antibody, oligopeptide or organic molecule can be used alone, or in combination therapy with, e.g., hormones, antiangiogens, or radiolabelled compounds, or with surgery, cryotherapy, and/or radiotherapy.

35 Anti-TASK antibody, oligopeptide or organic molecule treatment can be administered in conjunction with other forms of conventional therapy, either consecutively with, pre- or post-conventional therapy. Chemotherapeutic drugs such as TAXOTERE® (docetaxel), TAXOL® (paclitaxel), estramustine and mitoxantrone are used in treating

cancer, in particular, in good risk patients. In the present method of the invention for treating or alleviating cancer, the cancer patient can be administered anti-TASK antibody, oligopeptide or organic molecule in conjunction with treatment with the one or more of the preceding chemotherapeutic agents. In particular, combination therapy with paclitaxel and modified derivatives (see, e.g., EP0600517) is contemplated. The anti-TASK antibody, oligopeptide or organic molecule will be administered with a therapeutically effective dose of the chemotherapeutic agent. In another embodiment, the anti-TASK antibody, oligopeptide or organic molecule is administered in conjunction with chemotherapy to enhance the activity and efficacy of the chemotherapeutic agent, e.g., paclitaxel. The Physicians' Desk Reference (PDR) discloses dosages of these agents that have been used in treatment of various cancers. The dosing regimen and dosages of these aforementioned chemotherapeutic drugs that are therapeutically effective will depend on the particular cancer being treated, the extent of the disease and other factors familiar to the physician of skill in the art and can be determined by the physician.

In one particular embodiment, a conjugate comprising an anti-TASK antibody, oligopeptide or organic molecule conjugated with a cytotoxic agent is administered to the patient. Preferably, the immunoconjugate bound to the TASK protein is internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the cancer cell to which it binds. In a preferred embodiment, the cytotoxic agent targets or interferes with the nucleic acid in the cancer cell. Examples of such cytotoxic agents are described above and include maytansinoids, calicheamicins, ribonucleases and DNA endonucleases.

The anti-TASK antibodies, oligopeptides, organic molecules or toxin conjugates thereof are administered to a human patient, in accord with known methods, such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous or subcutaneous administration of the antibody, oligopeptide or organic molecule is preferred.

Other therapeutic regimens may be combined with the administration of the anti-TASK antibody, oligopeptide or organic molecule. The combined administration includes co-administration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities. Preferably such combined therapy results in a synergistic therapeutic effect.

It may also be desirable to combine administration of the anti-TASK antibody or antibodies, oligopeptides or organic molecules, with administration of an antibody directed against another tumor antigen associated with the particular cancer.

In another embodiment, the therapeutic treatment methods of the present invention involves the combined administration of an anti-TASK antibody (or antibodies), oligopeptides or organic molecules and one or more chemotherapeutic agents or growth inhibitory agents, including co-administration of cocktails of different chemotherapeutic agents. Chemotherapeutic agents include estramustine phosphate, prednimustine, cisplatin, 5-fluorouracil, melphalan, cyclophosphamide, hydroxyurea and hydroxyureataxanes (such as paclitaxel and doxorubicin) and/or anthracycline antibiotics. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service Ed., M.C. Perry, Williams &

Wilkins, Baltimore, MD (1992).

The antibody, oligopeptide or organic molecule may be combined with an anti-hormonal compound; e.g., an anti-estrogen compound such as tamoxifen; an anti-progesterone such as onapristone (see, EP 616 812); or an anti-androgen such as flutamide, in dosages known for such molecules. Where the cancer to be treated is androgen independent cancer, the patient may previously have been subjected to anti-androgen therapy and, after the cancer becomes androgen independent, the anti-TASK antibody, oligopeptide or organic molecule (and optionally other agents as described herein) may be administered to the patient.

Sometimes, it may be beneficial to also co-administer a cardioprotectant (to prevent or reduce myocardial dysfunction associated with the therapy) or one or more cytokines to the patient. In addition to the above therapeutic regimes, the patient may be subjected to surgical removal of cancer cells and/or radiation therapy, before, simultaneously with, or post antibody, oligopeptide or organic molecule therapy. Suitable dosages for any of the above co-administered agents are those presently used and may be lowered due to the combined action (synergy) of the agent and anti-TASK antibody, oligopeptide or organic molecule.

For the prevention or treatment of disease, the dosage and mode of administration will be chosen by the physician according to known criteria. The appropriate dosage of antibody, oligopeptide or organic molecule will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody, oligopeptide or organic molecule is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, oligopeptide or organic molecule, and the discretion of the attending physician. The antibody, oligopeptide or organic molecule is suitably administered to the patient at one time or over a series of treatments. Preferably, the antibody, oligopeptide or organic molecule is administered by intravenous infusion or by subcutaneous injections. Depending on the type and severity of the disease, about 1 µg/kg to about 50 mg/kg body weight (e.g., about 0.1-15mg/kg/dose) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A dosing regimen can comprise administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the anti-TASK antibody. However, other dosage regimens may be useful. A typical daily dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. The progress of this therapy can be readily monitored by conventional methods and assays and based on criteria known to the physician or other persons of skill in the art.

Aside from administration of the antibody protein to the patient, the present application contemplates administration of the antibody by gene therapy. Such administration of nucleic acid encoding the antibody is encompassed by the expression "administering a therapeutically effective amount of an antibody". See, for example, WO96/07321 published March 14, 1996 concerning the use of gene therapy to generate intracellular antibodies.

There are two major approaches to getting the nucleic acid (optionally contained in a vector) into the patient's cells; *in vivo* and *ex vivo*. For *in vivo* delivery the nucleic acid is injected directly into the patient, usually at the site where the antibody is required. For *ex vivo* treatment, the patient's cells are removed, the nucleic acid is introduced into these isolated cells and the modified cells are administered to the patient either directly or, for

example, encapsulated within porous membranes which are implanted into the patient (see, e.g., U.S. Patent Nos. 4,892,538 and 5,283,187). There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. A commonly used vector for *ex vivo* delivery of the gene is a retroviral vector.

The currently preferred *in vivo* nucleic acid transfer techniques include transfection with viral vectors (such as adenovirus, Herpes simplex I virus, or adeno-associated virus) and lipid-based systems (useful lipids for lipid-mediated transfer of the gene are DOTMA, DOPE and DC-Chol, for example). For review of the currently known gene marking and gene therapy protocols see Anderson et al., Science 256:808-813 (1992). See also WO 93/25673 and the references cited therein.

The anti-TASK antibodies of the invention can be in the different forms encompassed by the definition of "antibody" herein. Thus, the antibodies include full length or intact antibody, antibody fragments, native sequence antibody or amino acid variants, humanized, chimeric or fusion antibodies, immunoconjugates, and functional fragments thereof. In fusion antibodies an antibody sequence is fused to a heterologous polypeptide sequence. The antibodies can be modified in the Fc region to provide desired effector functions. As discussed in more detail in the sections herein, with the appropriate Fc regions, the naked antibody bound on the cell surface can induce cytotoxicity, e.g., via antibody-dependent cellular cytotoxicity (ADCC) or by recruiting complement in complement dependent cytotoxicity, or some other mechanism. Alternatively, where it is desirable to eliminate or reduce effector function, so as to minimize side effects or therapeutic complications, certain other Fc regions may be used.

In one embodiment, the antibody competes for binding or bind substantially to, the same epitope as the antibodies of the invention. Antibodies having the biological characteristics of the present anti-TASK antibodies of the invention are also contemplated, specifically including the *in vivo* tumor targeting and any cell proliferation inhibition or cytotoxic characteristics.

Methods of producing the above antibodies are described in detail herein.

The present anti-TASK antibodies, oligopeptides and organic molecules are useful for treating a TASK-expressing cancer or alleviating one or more symptoms of the cancer in a mammal. Such a cancer includes prostate cancer, cancer of the urinary tract, lung cancer, breast cancer, colon cancer and ovarian cancer, more specifically, prostate adenocarcinoma, renal cell carcinomas, colorectal adenocarcinomas, lung adenocarcinomas, lung squamous cell carcinomas, and pleural mesothelioma. The cancers encompass metastatic cancers of any of the preceding. The antibody, oligopeptide or organic molecule is able to bind to at least a portion of the cancer cells that express TASK polypeptide in the mammal. In a preferred embodiment, the antibody, oligopeptide or organic molecule is effective to destroy or kill TASK-expressing tumor cells or inhibit the growth of such tumor cells, *in vitro* or *in vivo*, upon binding to TASK polypeptide on the cell. Such an antibody includes a naked anti-TASK antibody (not conjugated to any agent). Naked antibodies that have cytotoxic or cell growth inhibition properties can be further harnessed with a cytotoxic agent to render them even more potent in tumor cell destruction. Cytotoxic properties can be conferred to an anti-TASK antibody by, e.g., conjugating the antibody with a cytotoxic agent, to form an immunoconjugate as described herein. The cytotoxic agent or a growth inhibitory agent is preferably a small molecule. Toxins such

as calicheamicin or a maytansinoid and analogs or derivatives thereof, are preferable.

The invention provides a composition comprising an anti-TASK antibody, oligopeptide or organic molecule of the invention, and a carrier. For the purposes of treating cancer, compositions can be administered to the patient in need of such treatment, wherein the composition can comprise one or more anti-TASK antibodies present as an immunoconjugate or as the naked antibody. In a further embodiment, the compositions can comprise these
 5 antibodies, oligopeptides or organic molecules in combination with other therapeutic agents such as cytotoxic or growth inhibitory agents, including chemotherapeutic agents. The invention also provides formulations comprising an anti-TASK antibody, oligopeptide or organic molecule of the invention, and a carrier. In one embodiment, the formulation is a therapeutic formulation comprising a pharmaceutically acceptable carrier.

Another aspect of the invention is isolated nucleic acids encoding the anti-TASK antibodies. Nucleic acids
 10 encoding both the H and L chains and especially the hypervariable region residues, chains which encode the native sequence antibody as well as variants, modifications and humanized versions of the antibody, are encompassed.

The invention also provides methods useful for treating a TASK polypeptide-expressing cancer or alleviating one or more symptoms of the cancer in a mammal, comprising administering a therapeutically effective amount of an anti-TASK antibody, oligopeptide or organic molecule to the mammal. The antibody, oligopeptide
 15 or organic molecule therapeutic compositions can be administered short term (acute) or chronic, or intermittent as directed by physician. Also provided are methods of inhibiting the growth of, and killing a TASK polypeptide-expressing cell.

The invention also provides kits and articles of manufacture comprising at least one anti-TASK antibody, oligopeptide or organic molecule. Kits containing anti-TASK antibodies, oligopeptides or organic molecules find
 20 use, e.g., for TASK cell killing assays, for purification or immunoprecipitation of TASK polypeptide from cells. For example, for isolation and purification of TASK, the kit can contain an anti-TASK antibody, oligopeptide or organic molecule coupled to beads (e.g., sepharose beads). Kits can be provided which contain the antibodies, oligopeptides or organic molecules for detection and quantitation of TASK *in vitro*, e.g., in an ELISA or a Western blot. Such antibody, oligopeptide or organic molecule useful for detection may be provided with a label such as a
 25 fluorescent or radiolabel.

L. Articles of Manufacture and Kits

Another embodiment of the invention is an article of manufacture containing materials useful for the treatment of anti-TASK expressing cancer. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The
 30 containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the cancer condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an anti-TASK antibody, oligopeptide or organic molecule of the invention. The label or package insert indicates that the composition is used for treating cancer. The label or package insert will
 35 further comprise instructions for administering the antibody, oligopeptide or organic molecule composition to the cancer patient. Additionally, the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline,

Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Kits are also provided that are useful for various purposes, e.g., for TASK-expressing cell killing assays, for purification or immunoprecipitation of TASK polypeptide from cells. For isolation and purification of TASK polypeptide, the kit can contain an anti-TASK antibody, oligopeptide or organic molecule coupled to beads (e.g., sepharose beads). Kits can be provided which contain the antibodies, oligopeptides or organic molecules for detection and quantitation of TASK polypeptide *in vitro*, e.g., in an ELISA or a Western blot. As with the article of manufacture, the kit comprises a container and a label or package insert on or associated with the container. The container holds a composition comprising at least one anti-TASK antibody, oligopeptide or organic molecule of the invention. Additional containers may be included that contain, e.g., diluents and buffers, control antibodies. The label or package insert may provide a description of the composition as well as instructions for the intended *in vitro* or diagnostic use.

M. Uses for TASK Polypeptides and TASK-Polypeptide Encoding Nucleic Acids

Nucleotide sequences (or their complement) encoding TASK polypeptides have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA probes. TASK-encoding nucleic acid will also be useful for the preparation of TASK polypeptides by the recombinant techniques described herein, wherein those TASK polypeptides may find use, for example, in the preparation of anti-TASK antibodies as described herein.

The full-length native sequence TASK gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length TASK cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of TASK or TASK from other species) which have a desired sequence identity to the native TASK sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence TASK. By way of example, a screening method will comprise isolating the coding region of the TASK gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as ^{32}P or ^{35}S , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the TASK gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below. Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.

Other useful fragments of the TASK-encoding nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target TASK mRNA (sense) or TASK DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of TASK DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense

oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechniques 6:958, 1988).

5 Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. Such methods are encompassed by the present invention. The antisense oligonucleotides thus may be used to block expression of TASK proteins, wherein those TASK proteins may play a role in the induction of cancer in mammals. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

10 Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

15 Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaPO₄-mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either *in vivo* or *ex vivo*. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see WO 90/13641).

20 Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

25 Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

30 Antisense or sense RNA or DNA molecules are generally at least about 5 nucleotides in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840,

850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related TASK coding sequences.

5 Nucleotide sequences encoding a TASK can also be used to construct hybridization probes for mapping the gene which encodes that TASK and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

10 When the coding sequences for TASK encode a protein which binds to another protein (example, where the TASK is a receptor), the TASK can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor TASK can be used to isolate correlative ligand(s). Screening assays
15 can be designed to find lead compounds that mimic the biological activity of a native TASK or a receptor for TASK. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized
20 in the art.

Nucleic acids which encode TASK or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A
25 transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding TASK can be used to clone genomic DNA encoding TASK in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding TASK. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009.
30 Typically, particular cells would be targeted for TASK transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding TASK introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding TASK. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated
35 with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of TASK can be used to construct a TASK "knock out" animal which

has a defective or altered gene encoding TASK as a result of homologous recombination between the endogenous gene encoding TASK and altered genomic DNA encoding TASK introduced into an embryonic stem cell of the animal. For example, cDNA encoding TASK can be used to clone genomic DNA encoding TASK in accordance with established techniques. A portion of the genomic DNA encoding TASK can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several
5 kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley,
10 in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability
15 to defend against certain pathological conditions and for their development of pathological conditions due to absence of the TASK polypeptide.

Nucleic acid encoding the TASK polypeptides may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy
20 where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik *et al.*, Proc. Natl.
25 Acad. Sci. USA 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of
30 liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnology 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target
35 cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target

intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson et al., Science 256, 808-813 (1992).

5 The nucleic acid molecules encoding the TASK polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each TASK nucleic acid molecule of the present invention can be used as a chromosome marker.

10 The TASK polypeptides and nucleic acid molecules of the present invention may also be used diagnostically for tissue typing, wherein the TASK polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type. TASK nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.

15 This invention encompasses methods of screening compounds to identify those that mimic the TASK polypeptide (agonists) or prevent the effect of the TASK polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the TASK polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins, including e.g., inhibiting the expression of TASK polypeptide from cells. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

20 The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

All assays for antagonists are common in that they call for contacting the drug candidate with a TASK polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

25 In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the TASK polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the TASK polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the TASK polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

If the candidate-compound interacts with but does not bind to a particular TASK polypeptide encoded by

a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for β -galactosidase. A complete kit (MATCHMAKER™) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a TASK polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

To assay for antagonists, the TASK polypeptide may be added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the TASK polypeptide indicates that the compound is an antagonist to the TASK polypeptide. Alternatively, antagonists may be detected by combining the TASK polypeptide and a potential antagonist with membrane-bound TASK polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The TASK polypeptide can be labeled, such as by radioactivity, such that the number of TASK polypeptide molecules bound can be used to determine the effectiveness of the potential antagonist. Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the TASK polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the TASK polypeptide. Transfected cells that are grown on glass slides are exposed to labeled TASK polypeptide. The TASK polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected

to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

5 As an alternative approach for binding identification, labeled TASK polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the bound proteins can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-

10 sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative binding partner.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled TASK polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

15 More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with TASK polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the TASK polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the TASK polypeptide.

20 Another potential TASK polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature TASK polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the TASK polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the TASK polypeptide (antisense - Okano, Neurochem., 56:560 (1991);

30 Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the TASK polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

35 Potential antagonists include small molecules that bind to the active site, or other relevant binding site of the TASK polypeptide, thereby blocking the normal biological activity of the TASK polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and

synthetic non-peptidyl organic or inorganic compounds.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Biology, 4:469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/33551, *supra*.

These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

Isolated TASK polypeptide-encoding nucleic acid can be used herein for recombinantly producing TASK polypeptide using techniques well known in the art and as described herein. In turn, the produced TASK polypeptides can be employed for generating anti-TASK antibodies using techniques well known in the art and as described herein.

Antibodies specifically binding a TASK polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders, including cancer, in the form of pharmaceutical compositions.

If the TASK polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco *et al.*, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's

instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

EXAMPLE 1: Tissue Expression Profiling Using GeneExpress®

A proprietary database containing gene expression information (GeneExpress®, Gene Logic Inc., Gaithersburg, MD) was analyzed in an attempt to identify polypeptides (and their encoding nucleic acids) whose expression is significantly upregulated in a particular tumor tissue(s) of interest as compared to other tumor(s) and/or normal tissues. Specifically, analysis of the GeneExpress® database was conducted using either software available through Gene Logic Inc., Gaithersburg, MD, for use with the GeneExpress® database or with proprietary software written and developed at Genentech, Inc. for use with the GeneExpress® database. The rating of positive hits in the analysis is based upon several criteria including, for example, tissue specificity, tumor specificity and expression level in normal essential and/or normal proliferating tissues. The following is a list of molecules whose tissue expression profile as determined from an analysis of the GeneExpress® database evidences high tissue expression and significant upregulation of expression in a specific tumor or tumors as compared to other tumor(s) and/or normal tissues and optionally relatively low expression in normal essential and/or normal proliferating tissues. As such, the molecules listed below are excellent polypeptide targets for the diagnosis and therapy of cancer in mammals.

| <u>Molecule</u> | <u>upregulation of expression in:</u> | <u>as compared to:</u> |
|---------------------|---------------------------------------|---------------------------|
| DNA297189 (TASK100) | ovary tumor | normal ovary tissue |
| DNA297189 (TASK100) | breast tumor | normal breast tissue |
| DNA297189 (TASK100) | lung tumor | normal lung tissue |
| DNA297189 (TASK100) | lymphoid tumor | normal lymphoid tissue |
| DNA137028 (TASK101) | uterine tumor | normal uterine tissue |
| DNA297389 (TASK102) | glioma tumor | normal glial tissue |
| DNA297389 (TASK102) | kidney tumor | normal kidney tissue |
| DNA297389 (TASK102) | lung tumor | normal lung tissue |
| DNA297389 (TASK102) | stomach tumor | normal stomach tissue |
| DNA226732 (TASK103) | breast tumor | normal breast tissue |
| DNA226732 (TASK103) | colon tumor | normal colon tissue |
| DNA226732 (TASK103) | uterus tumor | normal uterus tissue |
| DNA226732 (TASK103) | ovary tumor | normal ovary tissue |
| DNA226732 (TASK103) | lung tumor | normal lung tissue |
| DNA226732 (TASK103) | lymphoid tumor | normal lymphoid tissue |
| DNA270476 (TASK104) | breast tumor | normal breast tissue |
| DNA270476 (TASK104) | colon tumor | normal colon tissue |
| DNA270476 (TASK104) | endometrium tumor | normal endometrial tissue |
| DNA270476 (TASK104) | lymphoid tumor | normal lymphoid tissue |
| DNA227383 (TASK105) | breast tumor | normal breast tissue |
| DNA227383 (TASK105) | colon tumor | normal colon tissue |
| DNA227383 (TASK105) | lymphoid tumor | normal lymphoid tissue |
| DNA227409 (TASK106) | breast tumor | normal breast tissue |
| DNA227409 (TASK106) | ovarian tumor | normal ovarian tissue |

| | | | |
|----|---------------------|---------------------|-----------------------------|
| | DNA227090 (TASK107) | colon tumor | normal colon tissue |
| | DNA227090 (TASK107) | lung tumor | normal lung tissue |
| | DNA227090 (TASK107) | breast tumor | normal breast tissue |
| | DNA227090 (TASK107) | ovarian tumor | normal ovarian tissue |
| 5 | DNA210495 (TASK108) | breast tumor | normal breast tissue |
| | DNA254470 (TASK109) | colon tumor | normal colon tissue |
| | DNA254470 (TASK109) | breast tumor | normal breast tissue |
| | DNA254470 (TASK109) | ovarian tumor | normal ovarian tissue |
| 10 | DNA255289 (TASK110) | breast tumor | normal breast tissue |
| | DNA255289 (TASK110) | colon tumor | normal colon tissue |
| | DNA255289 (TASK110) | lung tumor | normal lung tissue |
| | DNA255289 (TASK110) | lymphoid tumor | normal lymphoid tissue |
| 15 | DNA255289 (TASK110) | ovarian tumor | normal ovarian tissue |
| | DNA256662 (TASK111) | breast tumor | normal breast tissue |
| | DNA256662 (TASK111) | lymphoid tumor | normal lymphoid tissue |
| 20 | DNA269860 (TASK112) | lymphoid tumor | normal lymphoid tissue |
| | DNA269860 (TASK112) | testis tumor | normal testis tissue |
| | DNA269860 (TASK112) | uterine tumor | normal uterine tissue |
| | DNA269860 (TASK112) | bladder tumor | normal bladder tissue |
| 25 | DNA269878 (TASK113) | breast tumor | normal breast tissue |
| | DNA269878 (TASK113) | colon tumor | normal colon tissue |
| | DNA269878 (TASK113) | uterus tumor | normal uterus tissue |
| | DNA269878 (TASK113) | lung tumor | normal lung tissue |
| | DNA269878 (TASK113) | lymphoid tumor | normal lymphoid tissue |
| 30 | DNA269878 (TASK113) | ovarian tumor | normal ovarian tissue |
| | DNA269878 (TASK113) | skin tumor | normal skin tissue |
| | DNA269998 (TASK114) | breast tumor | normal breast tissue |
| | DNA269998 (TASK114) | ovarian tumor | normal ovarian tissue |
| 35 | DNA274277 (TASK115) | lymphoid tumor | normal lymphoid tissue |
| | DNA297188 (TASK116) | breast tumor | normal breast tissue |
| | DNA297188 (TASK116) | uterine tumor | normal uterine tissue |
| 40 | DNA297188 (TASK116) | lymphoid tumor | normal lymphoid tissue |
| | DNA297190 (TASK117) | hematopoietic tumor | normal hematopoietic tissue |
| | DNA297190 (TASK117) | colon tumor | normal colon tissue |
| | DNA297190 (TASK117) | breast tumor | normal breast tissue |
| 45 | DNA297191 (TASK118) | breast tumor | normal breast tissue |
| | DNA297191 (TASK118) | lung tumor | normal lung tissue |
| | DNA297191 (TASK118) | ovarian tumor | normal ovarian tissue |
| 50 | DNA297288 (TASK119) | breast tumor | normal breast tissue |
| | DNA297288 (TASK119) | kidney tumor | normal kidney tissue |
| | DNA297288 (TASK119) | colon tumor | normal colon tissue |
| 55 | DNA151475 (TASK120) | kidney tumor | normal kidney tissue |

DNA151475 (TASK120)
DNA151475 (TASK120)

breast tumor
lung tumor

normal breast tissue
normal lung tissue

EXAMPLE 2: Verification of Differential TASK Polypeptide Expression by GEPIS

TASK polypeptides which may have been identified as a tumor antigen as described in one or more of the above Examples were analyzed and verified as follows. An expressed sequence tag (EST) DNA database (LIFESEQ®, Incyte Pharmaceuticals, Palo Alto, CA) was searched and interesting EST sequences were identified by GEPIS. Gene expression profiling *in silico* (GEPIS) is a bioinformatics tool developed at Genentech, Inc. that characterizes genes of interest for new cancer therapeutic targets. GEPIS takes advantage of large amounts of EST sequence and library information to determine gene expression profiles. GEPIS is capable of determining the expression profile of a gene based upon its proportional correlation with the number of its occurrences in EST databases, and it works by integrating the LIFESEQ® EST relational database and Genentech proprietary information in a stringent and statistically meaningful way. In this example, GEPIS is used to identify and cross-validate novel tumor antigens, although GEPIS can be configured to perform either very specific analyses or broad screening tasks. For the initial screen, GEPIS is used to identify EST sequences from the LIFESEQ® database that correlate to expression in a particular tissue or tissues of interest (often a tumor tissue of interest). The EST sequences identified in this initial screen (or consensus sequences obtained from aligning multiple related and overlapping EST sequences obtained from the initial screen) were then subjected to a screen intended to identify the open reading frame in the encoded protein. Finally, GEPIS was employed to generate a complete tissue expression profile for the various sequences of interest. Using this type of screening bioinformatics, various TASK polypeptides (and their encoding nucleic acid molecules) were identified as being significantly overexpressed in a particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. The rating of GEPIS hits is based upon several criteria including, for example, tissue specificity, tumor specificity and expression level in normal essential and/or normal proliferating tissues. The following is a list of molecules whose tissue expression profile as determined by GEPIS evidences high tissue expression and significant upregulation of expression in a specific tumor or tumors as compared to other tumor(s) and/or normal tissues and optionally relatively low expression in normal essential and/or normal proliferating tissues. As such, the molecules listed below are excellent polypeptide targets for the diagnosis and therapy of cancer in mammals.

| <u>Molecule</u> | <u>upregulation of expression in:</u> | <u>as compared to:</u> |
|---------------------|---------------------------------------|------------------------|
| DNA274277 (TASK115) | myeloid tumor | normal myeloid tissue |

EXAMPLE 3: Use of TASK as a hybridization probe

The following method describes use of a nucleotide sequence encoding TASK as a hybridization probe for, i.e., diagnosis of the presence of a tumor in a mammal.

DNA comprising the coding sequence of full-length or mature TASK as disclosed herein can also be employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of TASK) in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled TASK-derived probe to the filters is performed in a solution

of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence TASK can then be identified using standard techniques known in the art.

5

EXAMPLE 4: Expression of TASK in *E. coli*

This example illustrates preparation of an unglycosylated form of TASK by recombinant expression in *E. coli*.

The DNA sequence encoding TASK is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the TASK coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized TASK protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

TASK may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding TASK is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq)). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.₆₀₀ of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH₄)₂SO₄, 0.71 g sodium citrate·2H₂O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO₄) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded TASK polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Certain of the TASK polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

EXAMPLE 5: Expression of TASK in mammalian cells

This example illustrates preparation of a potentially glycosylated form of TASK by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the TASK DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the TASK DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-TASK.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 μ g pRK5-TASK DNA is mixed with about 1 μ g DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500 μ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl_2 . To this mixture is added, dropwise, 500 μ l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO_4 , and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 $\mu\text{Ci/ml}$ ^{35}S -cysteine and 200 $\mu\text{Ci/ml}$ ^{35}S -methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of TASK polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, TASK may be introduced into 293 cells transiently using the dextran sulfate method described by Sompanyrac et al., *Proc. Natl. Acad. Sci.*, 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 μ g pRK5-TASK DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 $\mu\text{g/ml}$ bovine insulin and 0.1 $\mu\text{g/ml}$ bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed TASK can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, TASK can be expressed in CHO cells. The pRK5-TASK can be transfected into CHO cells using known reagents such as CaPO_4 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as ^{35}S -methionine. After determining the presence of TASK polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed TASK can then be concentrated and purified by any selected method.

Epitope-tagged TASK may also be expressed in host CHO cells. The TASK may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged TASK insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged TASK can then be concentrated and purified by any selected method, such as by Ni^{2+} -chelate affinity chromatography.

TASK may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells

by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

- 5 Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

- 10 Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect® (Quiagen), Dosper® or Fugene® (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately 3×10^7 cells are frozen in an ampule for further growth and production as described below.

- 15 The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 µm filtered PS20 with 5% 0.2 µm diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 20 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with 3×10^5 cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at 1.2×10^6 25 cells/mL. On day 0, the cell number pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22 µm filter. 30 The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

- For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration 35 buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 μ L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS

polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Certain of the TASK polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

10 EXAMPLE 6: Expression of TASK in Yeast

The following method describes recombinant expression of TASK in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of TASK from the ADH2/GAPDH promoter. DNA encoding TASK and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of TASK. For secretion, DNA encoding TASK can be

15 cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of TASK.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by

20 precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant TASK can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing TASK may further be purified using selected column chromatography resins.

25 Certain of the TASK polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

EXAMPLE 7: Expression of TASK in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of TASK in Baculovirus-infected insect cells.

30 The sequence coding for TASK is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding TASK, the desired portion of the coding sequence of TASK, or the sequence encoding the mature protein is amplified by PCR with primers complementary to the 5' and 3'

35 regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA

(Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged TASK can then be purified, for example, by Ni²⁺-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl₂; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 µm filter. A Ni²⁺-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A₂₈₀ with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A₂₈₀ baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni²⁺-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His₁₀-tagged TASK are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) TASK can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Certain of the TASK polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

EXAMPLE 8: Preparation of Antibodies that Bind TASK

This example illustrates preparation of monoclonal antibodies which can specifically bind TASK.

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, supra. Immunogens that may be employed include purified TASK, fusion proteins containing TASK, and cells expressing recombinant TASK on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the TASK immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-TASK antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of TASK. Three to four days later, the mice are sacrificed and the spleen cells are

harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

5 The hybridoma cells will be screened in an ELISA for reactivity against TASK. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against TASK is within the skill in the art.

10 The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-TASK monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

Antibodies directed against certain of the TASK polypeptides disclosed herein have been successfully produced using this technique(s).

EXAMPLE 9: Purification of TASK Polypeptides Using Specific Antibodies

15 Native or recombinant TASK polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-TASK polypeptide, mature TASK polypeptide, or pre-TASK polypeptide is purified by immunoaffinity chromatography using antibodies specific for the TASK polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-TASK polypeptide antibody to an activated chromatographic resin.

20 Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

25 Such an immunoaffinity column is utilized in the purification of TASK polypeptide by preparing a fraction from cells containing TASK polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble TASK polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

30 A soluble TASK polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of TASK polypeptide (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/TASK polypeptide binding (e.g., a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and TASK polypeptide is collected.

EXAMPLE 10: Drug Screening

This invention is particularly useful for screening compounds by using TASK polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The TASK polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the TASK polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between TASK polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the TASK polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a TASK polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an TASK polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the TASK polypeptide or fragment, or (ii) for the presence of a complex between the TASK polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the TASK polypeptide or fragment is typically labeled. After suitable incubation, free TASK polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to TASK polypeptide or to interfere with the TASK polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a TASK polypeptide, the peptide test compounds are reacted with TASK polypeptide and washed. Bound TASK polypeptide is detected by methods well known in the art. Purified TASK polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding TASK polypeptide specifically compete with a test compound for binding to TASK polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with TASK polypeptide.

EXAMPLE 11: Tumor Screening

Antagonists to TASK polypeptides may be determined in vivo by a nude mouse model. Mammalian cells can be transfected with sufficient amounts of TASK polypeptide expressing plasmid to generate high levels of TASK polypeptide in the cell line. A known number of overexpressing cells can be injected sub-cutaneously into the flank of nude mice. After allowing sufficient time for a tumor to grow and become visible and measurable (typically 2-3 mm in diameter), the mice can be treated with the potential TASK antagonist. To determine if a beneficial effect has occurred, the tumor is measured in millimeters with Vernier calipers, and the tumor burden is calculated; Tumor weight = $(\text{length} \times \text{width}^2)/2$ (Geran, et al., (1972) Cancer Chemotherapy

Rep., 3 1-104). The nude mouse tumor model is a reproducible assay for assessing tumor growth rates and reduction of tumor growth rate by a possible anti-tumor agent in a dose dependant manner. As an example, the compound 317615-HCL, a candidate Protein Kinase C β inhibitor, was found to have an anti-tumor effect using this model (Teicher et al.,(2002) Can Chemo Pharm 49: 69-77)

- 5 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any
- 10 aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence that encodes the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

(c) the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41) or

(d) the complement of (a), (b), (c).

2. Isolated nucleic acid comprising:

(a) a nucleotide sequence that encodes the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

(c) the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41); or

(d) the complement of (a), (b), (c).

3. Isolated nucleic acid that hybridizes to:

(a) a nucleotide sequence that encodes the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

(c) the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);or

(d) the complement of (a), (b), (c), (d).

4. The nucleic acid of Claim 3, wherein the hybridization occurs under stringent conditions.

5. The nucleic acid of Claim 3 which is at least about 5 nucleotides in length.

6. An expression vector comprising the nucleic acid of Claim 1.

7. The expression vector of Claim 6, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.
8. A host cell comprising the expression vector of Claim 7.
9. The host cell of Claim 8 which is a CHO cell, an *E. coli* cell or a yeast cell.
10. A process for producing a polypeptide comprising culturing the host cell of Claim 8 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.
11. An isolated polypeptide having at least 80% amino acid sequence identity to:
 - (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);
 - (b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);
 - (c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).
12. An isolated polypeptide comprising:
 - (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

(c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

15

13. A chimeric polypeptide comprising the polypeptide of Claim 11 fused to a heterologous polypeptide.

14. The chimeric polypeptide of Claim 13, wherein said heterologous polypeptide is an epitope tag sequence or an Fc region of an immunoglobulin.

20

15. An isolated antibody which binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

35

(c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence

shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

16. The antibody of Claim 15 which binds to a polypeptide comprising:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

(c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

17. The antibody of Claim 15 which is a monoclonal antibody.

18. The antibody of Claim 15 which is an antibody fragment.

19. The antibody of Claim 15 which is a chimeric or a humanized antibody.

20. The antibody of Claim 15 which is conjugated to a growth inhibitory agent.

21. The antibody of Claim 15 which is conjugated to a cytotoxic agent.

22. The antibody of Claim 21, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
23. The antibody of Claim 21, wherein the cytotoxic agent is a toxin.
- 5 24. The antibody of Claim 23, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.
25. The antibody of Claim 23, wherein the toxin is a maytansinoid.
- 10 26. The antibody of Claim 15 which is produced in bacteria.
27. The antibody of Claim 15 which is produced in CHO cells.
28. The antibody of Claim 15 which induces death of a cell to which it binds.
- 15 29. The antibody of Claim 15 which is detectably labeled.
30. An isolated nucleic acid comprising a nucleotide sequence that encodes the antibody of Claim 15.
- 20 31. An expression vector comprising the nucleic acid of Claim 30 operably linked to control sequences recognized by a host cell transformed with the vector.
32. A host cell comprising the expression vector of Claim 31.
- 25 33. The host cell of Claim 32 which is a CHO cell, an *E. coli* cell or a yeast cell.
34. A process for producing an antibody comprising culturing the host cell of Claim 32 under conditions suitable for expression of said antibody and recovering said antibody from the cell culture.
- 30 35. An isolated oligopeptide which binds to a polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID
- 35

NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

(c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

36. The oligopeptide of Claim 35 which binds to a polypeptide comprising:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

(b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

(c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

37. The oligopeptide of Claim 35 which is conjugated to a growth inhibitory agent.
38. The oligopeptide of Claim 35 which is conjugated to a cytotoxic agent.
- 5 39. The oligopeptide of Claim 38, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
40. The oligopeptide of Claim 38, wherein the cytotoxic agent is a toxin.
- 10 41. The oligopeptide of Claim 40, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.
42. The oligopeptide of Claim 40, wherein the toxin is a maytansinoid.
- 15 43. The oligopeptide of Claim 35 which induces death of a cell to which it binds.
44. The oligopeptide of Claim 35 which is detectably labeled.
- 20 45. A TASK binding organic molecule which binds to a polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28),
- 25 Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);
- (b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17),
- 30 Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);
- (c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence
- 35 shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23),

ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

46. The organic molecule of Claim 45 which binds to a polypeptide comprising:

5 (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42);

10 (b) an amino acid sequence encoded by the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41);

15 (c) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41).

25

47. The organic molecule of Claim 45 which is conjugated to a growth inhibitory agent.

48. The organic molecule of Claim 45 which is conjugated to a cytotoxic agent.

30

49. The organic molecule of Claim 48, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

50. The organic molecule of Claim 48, wherein the cytotoxic agent is a toxin.

35

51. The organic molecule of Claim 50, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

52. The organic molecule of Claim 50, wherein the toxin is a maytansinoid.
53. The organic molecule of Claim 45 which induces death of a cell to which it binds.
54. The organic molecule of Claim 45 which is detectably labeled.
55. A composition of matter comprising:
- (a) the polypeptide of Claim 11;
 - (b) the chimeric polypeptide of Claim 13;
 - (c) the antibody of Claim 15,
 - (d) the oligopeptide of Claim 35; or
 - (e) the TASK binding organic molecule of Claim 45, in combination with a carrier.
56. The composition of matter of Claim 55, wherein said carrier is a pharmaceutically acceptable carrier.
57. An article of manufacture:
- (a) a container; and
 - (b) the composition of matter of Claim 55 contained within said container.
58. The article of manufacture of Claim 57 further comprising a label affixed to said container, or a package insert included with said container, referring to the use of said composition of matter for the therapeutic treatment of or the diagnostic detection of a cancer.
59. A method of killing a cancer cell that expresses a polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42); or
 - (b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure

39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41); said method comprising contacting said cancer cell with an antibody, oligopeptide or organic molecule that binds to said polypeptide on said cancer cell, thereby killing said cancer cell.

5

60. The method of Claim 59, wherein said antibody is a monoclonal antibody.

61. The method of Claim 59, wherein said antibody is an antibody fragment.

62. The method of Claim 59, wherein said antibody is a chimeric or a humanized antibody.

10

63. The method of Claim 59, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

64. The method of Claim 59, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

15

65. The method of Claim 64, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

20

66. The method of Claim 64, wherein the cytotoxic agent is a toxin.

67. The method of Claim 66, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

25

68. The method of Claim 66, wherein the toxin is a maytansinoid.

69. The method of Claim 59, wherein said antibody is produced in bacteria.

70. The method of Claim 59, wherein said antibody is produced in CHO cells.

30

71. The method of Claim 59, wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent.

35

72. The method of Claim 59, wherein said cancer cell is selected from the group consisting of a breast cancer cell, a colorectal cancer cell, a lung cancer cell, an ovarian cancer cell, a central nervous system cancer cell, a liver cancer cell, a bladder cancer cell, a pancreatic cancer cell, a cervical cancer cell, a melanoma cell and a leukemia cell.

73. The method of Claim 59, wherein said cancer cell overexpresses said polypeptide as compared to a normal cell of the same tissue origin.

74. A method of therapeutically treating a mammal having a tumor comprising cells that express a polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42); or

(b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41), said method comprising administering to said mammal a therapeutically effective amount of an antibody, oligopeptide or organic molecule that binds to said polypeptide, thereby effectively treating said mammal.

75. The method of Claim 74, wherein said antibody is a monoclonal antibody.

76. The method of Claim 74, wherein said antibody is an antibody fragment.

77. The method of Claim 74, wherein said antibody is a chimeric or a humanized antibody.

78. The method of Claim 74, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

79. The method of Claim 74, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

80. The method of Claim 79, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

81. The method of Claim 79, wherein the cytotoxic agent is a toxin.

82. The method of Claim 81, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.
83. The method of Claim 81, wherein the toxin is a maytansinoid.
- 5 84. The method of Claim 74, wherein said antibody is produced in bacteria.
85. The method of Claim 74, wherein said antibody is produced in CHO cells.
- 10 86. The method of Claim 74, wherein said tumor is further exposed to radiation treatment or a chemotherapeutic agent.
87. The method of Claim 74, wherein said tumor is a breast tumor, a colorectal tumor, a lung tumor, an ovarian tumor, a central nervous system tumor, a liver tumor, a bladder tumor, a pancreatic tumor, or a cervical tumor.
- 15 88. A method of determining the presence of a polypeptide in a sample suspected of containing said polypeptide, wherein said polypeptide has at least 80% amino acid sequence identity to:
- (a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42); or
- 20 (b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41), said method comprising exposing said sample to an antibody, oligopeptide or organic molecule that binds to said polypeptide and determining binding of said antibody, oligopeptide or organic molecule to said polypeptide in said sample.
- 25 89. The method of Claim 88, wherein said sample comprises a cell suspected of expressing said polypeptide.
- 30 90. The method of Claim 89, wherein said cell is a cancer cell.
- 35

91. The method of Claim 88, wherein said antibody, oligopeptide or organic molecule is detectably labeled.

92. A method of diagnosing the presence of a tumor in a mammal, said method comprising detecting the level of expression of a gene encoding a polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42); or

(b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41), in a test sample of tissue cells obtained from said mammal and in a control sample of known normal cells of the same tissue origin, wherein a higher level of expression of said polypeptide in the test sample, as compared to the control sample, is indicative of the presence of tumor in the mammal from which the test sample was obtained.

93. The method of Claim 92, wherein the step detecting the level of expression of a gene encoding said polypeptide comprises employing an oligonucleotide in an *in situ* hybridization or RT-PCR analysis.

94. The method of Claim 92, wherein the step detecting the level of expression of a gene encoding said polypeptide comprises employing an antibody in an immunohistochemistry analysis.

95. A method of diagnosing the presence of a tumor in a mammal, said method comprising contacting a test sample of tissue cells obtained from said mammal with an antibody, oligopeptide or organic molecule that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42); or

(b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41), and detecting the formation of a complex between said antibody, oligopeptide or organic molecule and said polypeptide in the test sample, wherein the formation of a complex is indicative of the presence of a tumor in said mammal.

96. The method of Claim 95, wherein said antibody, oligopeptide or organic molecule is detectably labeled.

97. The method of Claim 95, wherein said test sample of tissue cells is obtained from an individual suspected of having a cancerous tumor.

98. A method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40) or Figure 42 (SEQ ID NO:42); or

(b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39) or Figure 41 (SEQ ID NO:41), said method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a TASK polypeptide. Preferably, the cell proliferative disorder is cancer and the antagonist of said polypeptide.

99. The method of Claim 98, wherein said antagonist is an anti-TASK polypeptide antibody, TASK binding oligopeptide, TASK binding organic molecule or antisense oligonucleotide.

Abstract of the Disclosure

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

1/46

FIGURE 1

CGCCCGCGCGGGCTCAACTTTGTAGAGCGAGGGGCCAACTTGGCAGAGCGCGCGGCCA
GCTTTGCAGAGAGCGCCCTCCAGGGACTATGCGTGCGGGGACACGGGATCTACCCATACC
ATTGACTAACTATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAG
TTGTGTATAAGGGTAGACACAAAACCTACAGGTCAAGTGGTAGCCATGAAAAAATCAGAC
TAGAAAAGTGAAGAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGG
AACTTCGTCATCCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCAGGTTAT
ATCTCATCTTTGAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTG
GTCAGTACATGGATTCTTCACCTGTTAAGGTAGTAACACTCTGGTACAGATCTCCAGAAG
TATTGCTGGGGTCAGCTCGTTACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATAT
TTGCTGAACTAGCAACTAAGAAACCCTTTCCATGGGGATTGAGAAATTGATCAACTCT
TCAGGATTTTCAGAGCTTTGGGCCTCCCAATAATGAAGTGTGGCCAGAAGTGGAACTT
TACAGGACTATAAGAATACATTTCCCAATGGAAACCAGGAAGCCTAGCATCCCATGTCA
AAAACCTGGATGAAAATGGCTTGGATTGCTCTCGAAAATGTTAATCTATGATCCAGCCA
AACGAATTTCTGGCAAAATGGCACTGAATCATCCATATTTAATGATTTGGACAATCAGA
TTAAGAAGATGTAGCTTTCTGACAAAAAGTTTCCATATGTTATGTCAACAGATAGTTGTG
TTTTTATGTTAACTCTTGTCTATTTTGTCTTATATATATTTCTTTGTTATCAAACCTC
AGCTGTACTTCGTCTTCTAATTTCAAAAATATAACTTAAAAATGTAAATATTCTATATGA
ATTTAAATATAATTCTGTAAATGTGAAAAAAAAAAAAAAAAAAAAA

2/46

FIGURE 2

MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIRESLLKELRH
 PNIVSLQDVLMDSRLYLIFEPLSMDLKKYLDSPPGQYMDSSLVKVVTWYRSPEVLLG
 SARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDY
 KNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM

cAMP- and cGMP-dependent protein kinase phosphorylation site.

217-220

Tyrosine kinase phosphorylation site.

9-15

N-myristoylation site.

27-32

43-48

134-139

164-169

190-195

Protein kinase domain

4-230

FIGURE 3A

CCTCGGTTCTATCGATTGAATTCCCCGGGGATCCTCTAGAAATGAAAAAGTACCACGTGTT
GGAGATGATTGGAGAAGGCTCTTTTGGGAGGGTGTACAAGGGTCGAAGAAAATACAGTGC
TCAGGTCGTGGCCCTGAAGTTCATCCCAAATTTGGGGCGCTCAGAGAAGGAGCTGAGGAA
TTTGCAACGAGAGATTGAAATAATGCGGGGTCTGCGGCATCCCAACATTGTGCATATGCT
TGACAGCTTTGAAACTGATAAAGAGGTGGTGGTGGTGACAGACTATGCTGAGGGAGAGCT
CTTTCAGATCCTAGAAGATGACGGAATACTTCTGAAGACCAGGTTTCAAGCCATTGCTGC
CCAGTTGGTGTGACCCCTGTACTATCTGCATTCCACCGCATCTTACACCGAGATATGAA
GCCTCAGAACATCCTCCTCGCCAAGGGTGGTGGCATCAAGCTCTGTGACTTTGGATTTGC
CCGGGCTATGAGCACCATAACAATGGTGTGACATCCATCAAAGGCACACCACTCTATAT
CTCTCCAGAGCTGGTGGAGGAGCGACCATACGACCACACAGCGGACCTCTGGTCTGTTGG
CTGCATACTATATGAACTGGCAGTAGGCACCCCTCCCTTCTATGCTACAAGCATCTTTCA
GCTGGTCAGCCTCATTCTCAAGGACCCTGTGCGCTGGCCCTCAACCATCAGTCCCTGCTT
TAAGAACTTCTGCGAGGACTGCTCACCAGACCCACGGCAGCGACTGTCTGGCCAGA
CTCTTATATACCCCTTTATTTGCTGGTCTGTCATGTACCATAATACTGAGCCAGGAGCC
AGATTTGGGGACCCCATTCACCAGCCGCTACCCCAAGAACTTCAGGTCTTAAAGGACGA
ACAGGCCCATCGGTTGGCCCCCAAGGGTAATCAGTCTCGCATCTTGACTCAGGCCTATAA
ACGCATGGCTGAGGAGGCCATGCAGAAGAAACATCAGAACACAGGACCTGCCCTTGAGCA
AGAGGACAAGACCAGCAAGGTGGCTCCTGGCACAGCCCTCTGCCAGACTCGGGGCCAC
TCTCAGGAATCAAGCCTCCTGGCCGGGATCTTAGCCTCAGAATTGAAGAGCAGCTGGGC
TAAATCAGGGACTGGAGAGGTGCCCTCTGCACCTCGGGAACCCGAGACCCCAAGATTG
TGAACGAGCAATCCCAGAGGAGAGGCCAGAGGTGCTGGGCCAGCGGAGCACTGATGTAGT
GGACCTGGAATAATGAGGAGCCAGACAGTGACAATGAGTGGCAGCACCTGCTAGAGACCAC
TGAGCCTGTGCCATTCAACTGAAGGCTCCTCTCACCTTGCTGTGTAATCCTGACTTCTG
CCAGCGCATCCAGAGTCAGTGCATGAAGCTGGAGGGCAGATCCTGAAAGGCATCTTGGA
GGGTGCTTCCACATCCTGCCTGCATTCCGGGTCTGAGCAGTCTTCTCTCAGCTGCAG
TGATTCTGTTGCCCTTGATTCTCTTCTGCGGGAGGAGGCTTCTGGGGCTGCTGCTGAG
TCTACTCAGGCACAGTCAGGAGAGCAACAGCCTCCAGCAGCAATCTTGGTATGGGACCTT
CTTACAGGACCTGATGGCTGTGATTGAGGCCTACTTTGCCTGTACCTTCAATCTGGAGAG
GAGCCAGACAAGTGACAGCCTGCAGGTGTTTCAAGGAGGTGCCAACCTTTTTCTGGACCT
GTTGGGGAACACTGCTGGCCCAACCAGATGACTCTGAGCAGACTTTGCGGAGGGACAGCCT
TATGTGCTTTACTGTCTGTGCGAAGCCATGGATGGGAACAGCCGGGCCATCTCCAAGC
CTTTTACTCCAGCTTGCTGACGACACAGCAGGTTGTCTTGGATGGGCTCCTTCATGGCTT
GACAGTTCCACAGCTCCCTGTCCACACTCCCAAGGAGCCCGCAAGTGAGCCAGCCACT
GCGAGAGCAGAGTGAGGATATACCTGGAGCCATTTCTCTGCCCTGGCAGCCATATGCAC
TGCTCCTGTGGGACTGCCCGACTGCTGGGATGCCAAGGAGCAGGTCTGTTGGCATTTGGC
AAATCAGCTAACTGAAGACAGCAGCCAGCTCAGGCCATCCCTCATCTCTGGCCTGCAGCA
TCCCATCCTGTGCCCTGCACCTTCTCAAGGTTCTATACTCCTGTGCTTGTGAGTGAGGG
CCTGTGCGCTTCTTGGGGCAGGAGCCCTGGCCTTGGAATCCCTGTTTATGTTGATTCA
GGGCAAGGTAAAGTAGTAGATTGGGAAGAGTCTACTGAAGTGACACTCTACTTCTCTC
CCTTCTGTCTTTTGGGCTCCAAACCTGCCTTGTGGAATGGAGAAGCTAGGCAGTGACGT
TGCTACTCTCTTTACCCATTGCGATGTCTCTCTCTTGTGAGTGACAGCAGCCTGTCTATT
GGGACAGCTTGGTCAGCAAGGGGTGACCTTTGACCTCCAGCCCATGGAATGGATGGCTGC
AGCCACACATGCCTTGTCTGCCCTGCAGAGGTTGCGTTGACTCCACCAGGTAGTTGTGG
ATTCTATGATGGCCTCCTTATCCTTCTGTTGCAGCTCCTCACTGAGCAGGGGAAGGCTAG
CCTAATCAGGGATATGTCCAGTTCAGAAATGTGGACCGTTTTGTGGACCGCTTCTCCAT
GGTCTTGAGGCTCCCCGAGGAGGCATCTGCACAGGAAGGGGAGCTTTCGCTATCCAGTCC
ACCAAGCCCTGAGCCAGACTGGACACTGATTCTCTCCAGGCACTGGCAGCCCTGCTGAG
CCTGGCCATGGCCACCTTTACCCAGGAGCCCCAGTTATGCCTGAGCTGCCTGTCCAGCA
TGGAAGTATCCTCATGTCCATCCTGAAGCATCTGCTTTGCCCCAGCTTCTGAATCAACT
GCGCCAGGCGCCTCATGGGTCTGAGTTTCTCCCTGTCTGCTGCTCTCTGTCTGCCAGT
CCTTTGCTTCCCTTTGCGCTGGACATGGATGCTGACCTCCTTATAGTTGTCTTGGCCGA
CCTGAGGACTCAGAAGTTGCAGCCCATCTGCTGCAGGTCTGCTGCTACCATCTTCCGTT
GATGCAAGTGGAGCTGCCCATCAGCCTTCTCACACGCTGGCCCTCATGGATCCACCTC
TCTCAACCAGTTTGTGAACACAGTGTCTGCCTCCCTAGAACCATCGTCTCGTTTCTCTC
AGTTGCCCTCCTGAGTGACAGCCACTGTTGACCTCCGACCTTCTCTCTGCTGGCCCA
TACTGCGAGGCTCCTGTCTCCAGGCCACTTGTCTTTATCCAAGAGCTTCTGGCTGGCTC
TGATGAATCCTATCGGCCCTTGCAGCCTCCTGGGCCACCCAGAGAATTCTGTGCGGGC
ACACACTTATAGGCTCCTGGGACACTTGCTCCAACACAGCATGGCCCTGCGTGGGGCACT
GCAGAGCCAGTCTGGACTGCTCAGCCTTCTGCTGCTTGGGCTTGAGACAAGGATCCTGT
TGTGCGGTGCGAGTGCCAGCTTGTCTGTGGGCAATGCAGCCTACCAAGGCTGGTCTCTGGG
ACCTGCCCTGGCAGTGCAGTGCCAGTATGACCCAGCTGCTTGGAGATCCTCAGGCTGG
TATCCGGCGCAATGTTGCATCAGCTCTGGGCAACTTGGGACCTGAAGGTTTGGGAGAGGA

4/46

FIGURE 3B

GCTGTTACAGTGCGAAGTACCCAGCGGCTCCTAGAAATGGCATGTGGAGACCCCCAGCC
AAATGTGAAGGAGGCTGCCCTCATTGCCCTCCGGAGCCTGCAACAGGAGCCTGGCATCCA
TCAGGTACTGGTGTCCCTGGGTGCCAGTGAGAACTATCCTTGCTCTCTCTGGGGAATCA
GTCAGTCCACACAGCAGTCCTAGGCCTGCCTCTGCCAAACACTGCAGGAACTCATTCA
CCTCCTGAGGCCAGCCCATAGCATGTGAAGCTTGGCCGCCATGGCCC

5/46

FIGURE 4A

MEKYHVLEMIGEGSFGRVYKGRRKYSAQVVALKFIPKLGSRSEKELRNLOREIETMRGLRH
 PNIVHMLDSFETDKEVVVVTDYAEGELFQILEDDGKLPEDQVQAIAAQLVSALYYLHSHR
 ILHRDMKPQNILLAKGGGIKLCDFGFARAMSTNTMVLTSIKGTPLYMSPELVEERPYPDHT
 ADLWSVGCILYELAVGTPPFYATSIFQLVSLILKDPVRWPSTISPCFKNFLQGLLTKDPR
 QRLSWPDLLYHPFIAGHVTTIITEPAGPDLGTPFTSRLPPELQVLKDEQAHLAPKGNQSR
 ILTQAYKRMAEEAMQKKHONTGPALEQEDKTSKVAPGTAPLPRLGATPQESSILLAGILAS
 ELKSSWAKSGTGEVPSAPRENRTTPDCERAFPEERPEVLGQRSTDVVDLENEEPDSNEW
 QHLETTEPVPIQLKAPLTLLCNPDFCQRIQSOLHEAGGQILKGILEGASHILPAFRVLS
 SLLSSCSDSVALYSFCREAGLPGLLLSLRHSQESNSLQQSWYGTFLQDLMAVIQAYFA
 CTFNLSRQTSDSLQVFQEAANLFLDLLGKLLAQPDSEQTLRRDSLMLCFTVLCRAMDGN
 SRAISKAFYSSLLTTQQVVDGLLHGLTVPQLPVHTPQGAPQVSQPLREQSEDIPGAISS
 ALAAICTAPVGLPDCWDAKEQVCWHLANQLTEDSSQLRPSLISGLQHPILCLHLLKVLYS
 CCLVSEGLCRLLGQEPLALESFLMLIQGKVKVVDWEESTEVTLTYFLSLLVFRLLQNLPCGM
 EKLGSVDVATLFTTHSHVSVLSAAACLLGQLGQGVTFDLQPMEWMAAATHALSAPAEVRL
 TPPGSCGFYDGLLLILLQLLTEQGKASLIRDMSSSEMWTVLWHRFSMVLRLPEEASAEQEG
 ELSLSSPPSPPEPDWTLSIPQGMALLSLAMATFTQEPQLCLSCLSQHGSILMSILKHLIC
 PSFLNQLRQAPHGSEFLPVVLSVCQLLCFFALDMDADLLIVVLADLRDSEVAHLLQV
 CCYHLPLMQVELPISLLTRLALMDPTSLNQFVNTVSASPRTIVSFLSVALLSDQPLLTSD
 LLSLLAHTARVLSPSHLSFIQELLAGSDESYRPLRSLLGHPENSVRATYRLLGHLLQHS
 MALRGALQSQSGLLSLLLLGLGDKDPVVRCSASFAVGNAAYQAGPLGPALAAVPSMTQL
 LGDPQAGIRRNVASALGNLGPGLGELLQCEVPQRLLMACGDPQPNVKEAALIALRSL
 QQEPGIHQVLVSLGASEKLSLLSLGNQSLPHSSPRPASAKHCRKLIHLLRPAHSM

N-glycosylation site.

297-300
 381-384
 1286-1289

Glycosaminoglycan attachment site.

369-372

cAMP- and cGMP-dependent protein kinase phosphorylation site.

23-26
 583-586

N-myristoylation site.

138-143
 270-275
 356-361
 400-405
 464-469
 503-508
 599-604
 622-627
 656-661
 671-676
 784-789
 1106-1111
 1145-1150
 1207-1212

Amidation site.

20-23

6/46

FIGURE 4B

Leucine zipper pattern.

769-790

987-1008

Serine/Threonine protein kinases active-site signature.

121-133

Protein kinase domain

1-294

FIGURE 5A

CAGAGCAGGGCGAGAGCCGATCAGCGGATCACCAGTCTCGCCAGGTGGTGGAGCTGGCA
 GTGAAGGAGCACAAGGCTGAGATTCTCGCTCTGCAGCAGGCTCTCAAAGAGCAGAAGCTG
 AAGGCCGAGAGCCTCTCTGACAAGCTCAATGACCTGGAGAAGAAGCATGCTATGCTTGAA
 ATGAATGCCCCAAGCTTACAGCAGAAGCTGGAGACTGAACGAGAGCTCAAACAGAGGCTT
 CTGGAAGAGCAAGCCAAATTACAGCAGCAGATGGACCTGCAGAAAAATCACATTTTCCGT
 CTGACTCAAGGACTGCAAGAAGCTCTAGATCGGGCTGATCTACTGAAGACAGAAAGAAGT
 GACTTGGAGTATCAGCTGGAAAACATTCAGGTTCTCTATTCTCATGAAAAGGTGAAAATG
 GAAGGCACTATTTCTCAACAAACCAAACCTCATTGATTTTCTGCAAGCCAAAATGGACCAA
 CTTGCTAAAAAGAAAAGGTTCTCTGCAGTACAATGAGCTGAAGCTGGCCCTGGAGAAG
 GAGAAAGCTCGCTGTGCAGAGCTAGAGGAAGCCCTTCAGAAGACCCGCATCGAGCTCCGG
 TCCGCCCCGGGAGGAAGCTGCCACCGCAAAGCAACGGACCACCCACACCCATCCACGCCA
 GCCACCGCGAGGAGCAGATCGCCATGTCTGCCATCGTGGCGTCCGAGAGCACCAGCCC
 AGTGCCATGAGCCTGCTGGCCCCGCCATCCAGCCGAGAAAGGAGTCTTCAACTCCAGAG
 GAATTTAGTCCGCGTCTTAAGGAACGCATGCACCACAATATTCTCACCGATTCAACGTA
 GGAATGAACATGCGAGGCCACAAAGTGTGCTGTGTGTCTGGATACCGTGCACCTTTGGACGC
 CAGGCATCCAAATGTCTCGAATGTGAGGTGATGTGTACCCCAAGTGTCCACGTGCTTG
 CCAGCCACCTGCGGCTTGCCCTGCTGAATATGCCACACACTTCACCGAGGCTTCTGCCGT
 GTTGGTGCTTCCGAACTCGCAATACAGCCAAAGCAGATGTCCATACATACTGAAGATG
 GAATCTCACCCGCACACCCTGTGTCGCCCCGGGAGAACCTCTACTTGCTAGCTCCAGC
 TTCCCTGACAAACAGCGCTGGGTACCGCCTTAGAATCAGTTGTGCGAGGTGGGAGAGTT
 TCTAGGGAAAAAGCAGAAGCTGATGCTAAACTGCTTGGAAACTCCCTGCTGAAACTGGAA
 GGTGATGACCTTACAGATGAACGTGACGCTGCCCTTCAGTGACCAGGTGGTGTGGTG
 GGCACCGAGGAAGGGCTCTACGCCCTGAATGTCTTGAAAAACTCCCTAACCCATGTCCCA
 GGAATTGGAGCAGTCTTCCAAATTTATATTATCAAGGACCTGGAGAAGCTACTCATGATA
 GCAGGAGAAGAGCGGGCACTGTGTCTTGTGGACGTGAAGAAAGTGAACAGTCCCTGGCC
 CAGTCCCACCTGCTGCCAGCCCCGACATCTACCCAAACATTTTGAAGCTGTCAAGGGC
 TGCCAAATTTTGGGGCAGGCAAGATTGAGAACGGGCTCTGCATCTGTGCAGCCATGCCC
 AGCAAAGTCGTCAATCTCCGCTACAACGAAAACCTCAGCAAATACTGCATCCGGAAGAG
 ATAGAGACCTCAGAGCCCTGCAGCTGTATCCACTTCACCAATTACAGTATCCTCATTGGA
 ACCAATAAATTTCTACGAAATCGACATGAAGCAGTACACGCTCGAGGAATTCCTGGATAAG
 AATGACCAATTCCTTGGCACCTGCTGTGTTTGGCCGCTCTTCCAACAGCTTCCCTGTCTCA
 ATCGTGCAGGTGAACAGCGCAGGGCAGCGAGAGGAGTACTTGCTGTGTTTCCACGAATTT
 GGAGTGTTCGTGGATTCTTACGGAAGACGTAGCCGCACAGACGATCTCAAGTGGAGTCGC
 TTACCTTTGGCCCTTTGCCCTACAGAGAACCCTATCTGTTTGTGACCCACTTCAACTCACT
 TAAGTACTTGAATCCAGGCACGCTCCTCAGCAGGGACCCCTGCCCGAGCGTACCTGGAC
 ATCCCGAACC CGCGCTACCTGGGCCCTGCCATTTCTCAGGAGCGATTTACTTGGCGTCC
 TCATACCAGGATAAATTAAGGGTCATTTGCTGCAAGGGAAACCTCGTGAAGGAGTCCGGC
 ACTGAACACCACCGGGGCCGCTCCACCTCCCGCAGCAGCCCCAACAAGCGAGGCCACCC
 ACGTACAACGAGCACATCACAAGCGCTGGCCCTCAGCCCGAGCGCCGCCGAAGGCCCC
 AGCCACCCGCGAGAGCCAAGCACACCCACCGCTACCGCGAGGGGCGGACCGAGCTGCGC
 AGGGACAAGTCTCTGGCCGCCCTTGGAGCGAGAGAAGTCCCCCGGCCGGATGCTCAGC
 ACGCGGAGAGAGCGGTCCCCCGGGAGGCTGTTTGAAGACAGCAGCAGGGGCCGGCTGCCCT
 GCGGGAGCGTGAGGACCCCGCTGTCCAGGTGAACAAGGTCTGGGACCAGTCTTCAGTA
 TAAATCTCAGCCAGAAAAACCAACTCTCATCTTGATCTGCAGGAAAAACACAAACACAC
 TATGGAATCTGCTGATGGGGACCAAGCGCCACGCTGCTCAGCCACCTCTGGCTCAGC
 GGGGCCCAGACCACCTCGGCACGGACACCCCTGTCTCAGGAGGGGCGAGGTGGCTGAGG
 CTCTTCGGAGCTGTGACGCGCCGGTGCCTGCCCTGGGCACCTCCCTGCAGTCATCTCTTT
 GCACTTTGTACTCTTTCAAAGCATTCAAAACTTTTGTACCTAGCTCTAGCCTGTACCA
 GTTAGTTTCATCAAAGGAAACCAACCGGGATGCTAACAAACATGGTTAGAATCCTAATT
 AGCTACTTTAAGATCCTAGGATTGGTTGGTTTTTCTTTTCTCTTTGTTTCTTTTCT
 CTTTTTTTTTTTTTTTTTAAGACAACAGAATTCTTAATAGATTTGAATAGCGACGTATT
 TCCTGTTGTAGTCTTTTAGCTCGACCACATCATCAGGTCTTTGCCACCGAGGCATAGT
 GTAGAACAGTCCCGGTGAGTTGGCCAACTCCCGCAGCCAAGTAGGTTTCATCCTTGTTC
 TGTTTCATCTCATAGATGGCCCTGCTTTCCCGAGGGTGACATCGTAGCCAAATGTTTACT
 GTTTTCATTGCTTTTATGGCCTTGACGACTTCCCTCCACAGCTGAGAATGTATGGA
 GGTCACTCGGGGCTCAGCTCGGAGGAGTGACTTGGGGCCAAGGGACCTCGAGACGCTTT
 CCTTCCCAACCCCGAGCGTCATCTCCCGAGCTGCTGTTCCCGCTTTCCATATAGCTTT
 GCCCAGGAAAGCATGCAATAGACTTGCTCGGAGCCAGCACTCCTGGGTCTCGGGGTCG

8/46

FIGURE 5B

GGAGGGGACGGGGGCACCCACTTCCTTGCTGTGACGGCGTGTGTTCCCCACTCTGGGA
TGGGGAAGAGGCCCGTCGGGAGTTCTGCATGGCAGTTCACTGCATGTGCTGCCCCCTTGG
GTTGCTCTGCCAATGTATTAATACCATCCCATAGCTCCTGCCAAATCGAGACCCCTCTGAC
GACTTGCCGACTAACTGGCCACCACAAGCTGCAGTCTGTAGCACTGAACAAACAAAAAAC
AAAACGCTCAAGCCTTACGACCAGAGAAGGATTTAGCAAACCACCACCTCCCACTCAGT
GTCCCCCTCAAACCTTCACTTCCCTGCCTGCAGAGGATGACTCTGTTTACACCCCAATCC
AGCGCGGTTCTACCCACGAAACTGTGACTTTCCAAATGAGCCCTTCCCTAGGGCTAGAC
CTAAGACCAGGAAGTTTGAGAAAGCAGCCGAGCTCAACTCTTCCAGCTCCGCCAGGGTT
GGGAAGTCCTTAGGTGCAGTGCAGCTCCCACTGGGTCTGCGGACCCCTCTATTAGAGTAC
GAAATTCCTGGCAACTGGTATAGAACCAACCTAGAGGCTTTGCAGTTGGCAAGCTAACTC
GCGGCCTTATTTCTGCCTTTAATCTCCCAAGGCATCTGTTGCTTTGGGTCTTCCACGA
CTCTTAGGCCCCGCTCAACAACCCAGGCACCTCCTAGGTAGGCTCAAAGGTAGACCCGTT
TCCACCGCAGCAGGTGAACATGACCGTGTTTCAACTGTGTCCACAGTTCAGATCCCTTT
CCAGATTGCAACCTGGCCTGCATCCAGCTCCTTCCCTGCTCGTGTCTTAACCTAAGTGCT
TTCTTGTTTGAAACGCCCTACAAACCTCCATGTGGTAGCTCCTTTGGCAAATGTCTGCTG
TGGCGTTTTATGTGTGCTTGGAGTCTGTGGGGTCTGACTCCCTCCCTCCCGTCCCCAG
GGCAGATTTGATTGAATGTTTGTCTGAAGTTTGTCTCTTGGTCCACAGTATTTGGAAAGG
TCACTGAAATGGGTCTTTCAGTCTTGGCATTTCATTTAGGATCTCCATGAGAAATGGGC
TTCTTGAGCCCTGAAATGTATATTGTGTGTCTCATCTGTGAACTGCTTTCTGCTATATA
GAACTAGCTCAAAAGACTGTACATATTTACAAGAACTTTATATTCGTAAAAAAG
AGGAAATTGAATTGGTTTCTACTTTTTTATTGTAAAAGGTGCATTTTCAACACTTACTT
TTGGTTTCAATGGTGGTAGTTGTGGACAGCCATCTTCACTGGAGGGTGGGGAGCTCCGTG
TGACCACCAAGATGCCAGCAGGATATACCGTAACACGAAATTGCTGTCAAAGCTTATTA
GCATCAATCAAGATTCTAGGTCTCCAAAGTACAGGCTTTTCTTCATTACCTTTTTTAT
TCAGAACGAGGAAGAGAACACAAGGAATGATTCAAGATCCACCTTGAGAGGAATGAACTT
TGTTGTTGAACAATTAGTGAAATAAAGCAATGATCTAAACT

9/46

FIGURE 6

MLEMNARSLQOKLETERELKQRLLEEQAQLQQQMDLQKNHIFRLTQGLQEALDRADLLKT
 ERSDLEYQLENIQVLYSHEKVKMEGTISQQTKLIDFLQAKMDQPAKKKKVPLQYNELKLA
 LEKEKARCAELEALQKTRIELRSAREEAAHRKATDHPHPSTPATARQQIAMSIVRSPE
 HQPSAMSLAPSSRRKESSTPEEFSRRLKERMHHNIPHRFNVGLNMRATKCAVCLDTVH
 FGRQASKCLECQVMCHPKCSTCLPATCGLPAEYATHFTEAFCDKMNSPGLQTKEPSSSL
 HLEGWMKVPRNNKRGQQGWRKYIVLEGSKVLIYDNEAREAGQRPVEEFELCLPDGDVSI
 HGAVGASELANTAKADVPIILKMESHPTTCWPGRTLYLLAPSFDPKQRWVTALESVVAG
 GRVSREKAEADAKLLGNSLLKLEGDDRLDMNCTLPFSDQVVLVGTEEGLYALNVLKNLSLT
 HVPGIGAVFQIYIIKDLEKLLMIAGEERALCLVDVKVKQSLAQSHLPAQPDISPNI FEA
 VKGCHLFGAGKIENGLCICAAMPSKVILRYNENLSKYCIRKEIETSEPCSCIHFTNYSI
 LIGTNKFYEIDMKQYTTLEEFLDKNDHSLAPAVFAASSNSFPVSIQVNSAGQREEYLLCF
 HEFGVFVDSYGRRSRTDDLKWSRLPLAFAYREPYLFVTHFNSLEVI EI QARSSAGTPARA
 YLDIPNPRYLGPASSGAIYLASSYQDKLRVICCKGNLVKESGTEHHRGPSTSRSSPNKR
 GPPTYNEHITKRVASSPAPPEGPSHPREPSTPHRYREGRTELRRDKSPGRPLEREKSPGR
 MLSTRRERSPGRLFEDSSRGRLPAGAVRTPLSQVNKVDQSSV

N-glycosylation site.

451-454
 574-577
 597-600

cAMP- and cGMP-dependent protein kinase phosphorylation site.

152-155
 196-199

N-myristoylation site.

47-52
 362-367
 420-425
 464-469
 555-560

Amidation site.

670-673

Carbamoyl-phosphate synthase subdomain signature 2.

1-8

CNH domain
 448-745

PH domain
 300-419

Phorbol esters/diacylglycerol binding domain
 219-267

10/46

FIGURE 7

AAAGGCCTGCAGCAGGACGAGGACCTGAGCCAGGAATGCAGGATGCGGGCGGTGAAGAAG
GAAGGGGGTGCTCTGAGTGAAGCCATGTCCCTGGAGGGAGATGAATGGGAACTGAGTAAA
GAAAATGTACAACCTTTAAGGCAAGGGCGGATCATGTCCACGCTTCAGGGAGCACTGGCA
CAAGAATCTGCCTGTAAACAATACCTCTTCAGCAGCAGAAACGGGCATTTGAATATGAAATT
CGATTTTACACTGGAAATGACCTCTGGATGTTTGGGATAGGTATATCAGCTGGACAGAG
CAGAACTATCCTCAAGGTGGGAAAGAGAGTAATATGTCAACGTTATTAGAAAGAGCTGTA
GAAGCACTACAAGGAGAAAAACGATATTATAGTGATCCTCGATTTCTCAATCTCTGGCTT
AAATTAGGGCGTTTATGCAATGAGCCTTTGGATATGTACAGTTACTTGCACAACCAAGGG
ATTGGTGTCTTCACTTGCTCAGTTCTATATCTCATGGGCAGAAGAATATGAAGCTAGAGAA
AAGCTTTAGGAAAGCAGATGCGATATTTTCAGGAAGGGATTCAACAGAAAGCTGAACCACTA
GAAAGACTACAGTCCCAGCACCGACAATTCCAAGCTCGAGTGTCTCGGCAAACTCTGTTG
GCACTTGAGAAAGAAGAAGAGGAGGAAGTTTGTGAGTCTTCTGTACCACAACGAAGCACA
CTAGCTGAAGTAAAGAGCAAAGGGGAAAAAGACAGCAAGAGCTCCAATCATCCGTGTAGGA
GGTGCTCTCAAGGCTCCAAGCCAGAAGCAGAGGACTCCAAAATCCATTTCTCAACAGATG
CAAAATAATAGTAGAATTACTGTCTTTTGTATGAAAATGCTGATGAGGCTTCTACAGCAGAG
TTGTCTAAGCCTACAGTCCAGCCATGGATAGCACCCCATGCCAGGGCCAAAGAGAAT
GAGCTGCAAGCAGGCCCCTTGGAACACAGGCAGGTCTTGGAAACACAGGCTCGTGGCAAT
ACAGCTTCACTGATAGCTGTACCCGCTGTGCTTCCAGTTTCACTCCATATGTGGAAGAG
ACTGCACAACAGCCAGTTATGACACCATGTAAAATTGAACCTAGTATAAACACATCCTA
AGCACCAGAAAGCCTGGAAAGGAAGAAGGAGATCCTCTACAAAGGGTTCAGAGCCATCAG
CAAGCGTCTGAGGAGAAGAAAGAGAAGATGATGTATTGTAAGGAGAAGATTTATGCAGGA
GTAGGGGAATTCCTTTGAAGAAATTCGGGCTGAAGTTTTCGGAAGAAATTAAGAGAG
CAAAGGGAAGCCGAGCTATTGACCAAGTGCAGAGAAGAGAGCAGAAATGCAGAAACAGATT
GAAGAGATGGAGAAGAAGCTAAAAGAAATCCAACTACTCAGCAAGAAAGAACAGGTGAT
CAGCAAGAAGAGACGATGCTTACAAAGGAGACAATAAAGTGCATAATGTCTTCCGAGTCT
CAGAAATACCGCAATGACTCTATCCAGTTCTGTTTGTCAAGTAACTGTTGTGCCAGA
GAAACTTCACTTGCAGGAACATTTGGCAGGAACAACTCAATTTCAAAGGTCCAGTGTA
CCTTTCTCCATTTTGTATGAGTTTCTTCTTTCAGAAAAGAAGATAAAAGTCTCTCTGCA
GATCCCCCAGAGTTTATGCTCAACGAAGACCCCTTGCAGTTCTCAAAACCTCAGAAAGC
ATCACCCTCAATGAAGATGTGTCTCCAGATGTTTGTGATGAATTTACAGGAATTGAACCC
TTGAGCGAGGATCTCCCTTCTGATCCTGAGAGACTGTTACCGGAAGAAGATCTAGATGTA
GACACTTGTGACTTTGCCAGAGCAGCTCGTTTGTATCCACTCCTTTTCATGAGATAATG
TCCTTGAAGGATCTCCCTTCTGATCCTGAGAGACTGTTACCGGAAGAAGATCTAGATGTA
AAGACCTCTGAGGACCAGCAGACAGCTTGTGGCACTATCTACAGTCAGACTCTCAGCATC
AAGAAGCTGAGCCCAATTTATTGAAGACAGTCTGTGAAGCCACACACTCCTCTGGCTTCTCT
GGTCTTCTGCGCTCGGTGCAAGCACCTCCTCCATCAAATGTCTTCAAATTCCTGAGAAA
CTAGAACTTACTAATGAGACTTCAGAAAACCTACTCAGTCAACATGGTGTTCACAGTAT
CGCAGACAGCTACTGAAGTCCCTACCAGAGTTAAGTGCCTCTGCAGAGTTGTGTATAGAA
GACAGACCAATGAGCCCAATTTAGTTGGAATTTGAAGAGAAATGAATTAGGTAAATGAGGATTAC
TGCATTAAACGAGAATACCTAATATGTGAAGATTACAAGTTATTCTGGGTGGCGCAAGA
AACTCTGCAGAAATTAACAGTAATAAAGGTATCTTCTCAACCTGTCCCATGGGACTTTTAT
ATCAACCTCAAGTTAAAGGAACGTTTAAATGAAGATTTTGATCAATTTTGAGCTGTTAT
CAATATCAAGATGGCTGTATTGTTTGGCACCAATATATAAACTGCTTCAACCTTCAGGAT
CTTCTCCAACACAGTGAATATATTACCCATGAATAACAGTGTGATTATTATAACCTT
TTGACAATAGTGGAGATGCTACACAAAGCAGAAATAGTCCATGGTGAAGTTGAGTCCAAGG
TGTCTGATTTCTCAGAAAAGAAATCCACGATCCCTATGATTGTAACAAGAAACAAATCAAGCT
TTGAAGATAGTGGACTTTTCTACAGTGTGACCTTAGGGTGCAGCTGGATGTTTTTACC
CTCAGCGGCTTTCGGACTGTACAGATCCTGGAAGGACAAAAGATCCTGGCTAACTGTTCT
TCTCCCTACCAGGTAGACCTGTTTGGTATAGCAGATTTAGCACATTTACTATTGTTCAAG
GAACACCTACAGGTCTTCTGGGATGGGTCTTCTGGAACCTTAGCCAAAATATTTCTGAG
CTAAAAGATGGTGAATTTGTGGAATAAATCTTTGTGCGGATTTCTGAATGCCAATGATGAG
GCCACAGTGTCTGTTCTTGGGGAGCTTGCAGCAGAAATGAATGGGGTTTTTGACACTACA
TTCCAAAGTCACTGAAACAAAGCCTTATGGAAGGTAGGGAAGTTAACTAGTCTTGGGGCT
TTGCTCTTTTCACTGAGCTAGGCAATCAAGTCTCACAGATGCTGCGCTCAGAGCAATGGTT
GTATTGTGGAACACTGAACTGTATGTGCTGTAATTTAATTTAGGACACATTTAGATGCA
CTACCATTTGCTGTCTACTTTTTTGGTACAGGTATATTTTGACGCTCACTGATATTTTTTAT
ACAGTGATATACTTACTCATGGCCTTGTCTAACTTTGTGAAGAACTATTTTATTCTAAA
CAGACTCATTAACAAATGGTTACCTTGTATTATTAACCAATTTGTCTCTACTTTTCCCTGTA
CTTTTCCCATTTGTAATTTGTAAATGTTCTCTTATGATCACCATGTATTTTGTAAATAA
TAAATAGTATCTGTTAAAAA

11/46

FIGURE 8

MAAVKKEGGALSEAMSLEGDEWELSKENVQPLRQGRIMSTLQALAQESACNNTLQQQKR
 AFEYEIRFYTGNDPLDVWDRIYSWTEQNYPOGGKESNMSTLLERAVEALQGEKRYYS DPR
 FLNLWLKLGRLCNEPLDMYSYLHNQIGVSLAQFYISWAEYEARENFRKADAFQEGIQ
 QKAEPLERLQSQHRQFQARVSRQTLLALEKEEEEEVFESSVPQRSTLAEKSKGKKTARA
 PIIRVGGALKAPSQNRGLQNPFPQMQNNSRITVFDENADEASTAELSKPTVQPWIAPPM
 PRAKENELQAGPWNTGRSLEHRPRGNTASLIAVPAVLPSFTPYVEETAQQPVMTPCKIEP
 SINHILSTRKPGKEEGDPLQRVQSHQQASEEKKEKMYCKEKIYAGVGEFSFEEIRAEVF
 RKKLKEQREAEELLTSAEKRAEMQKQIEEMEKKLKEIQTQQBERTGDQQEETMPTKETTKL
 QIASSESQKIPGMTLSSSVQVNCARETSLAENIWQEQPHSKGPSVPFSIFDEFLLSEKK
 NKSPPADPPRVLAQRRPLAVLKTSESITSNEDVSPDVCDEFTGIEPLSEDAIITGFRNVT
 ICPNPEDTCDFARAARFVSTPFHEIMSLKDLPSDPERLLPEEDLDVKTSEDQQTACGTIY
 SQTLSIKKLSPIIEDSREATHSSGFSGSSASVASTSSIKCLQIPEKLELTNETSENPTQS
 PWCSQYRRQLLKSLPELSASAELCIEDRPMPKLEIEKEIELGNEDYCIKREYLICEDYKL
 FWVAPRNSAELTVIKVSSQPVPWDFYINLKLKERLNEDFDHFCSCYQYQDGCIVWHQYIN
 CFTLQDLLQHSEYITHEITVLIYNNLTIVEMLHKAIEVHGDLSRCLILRNRIHDPYDC
 NKNNOALKIIVDFSYSDLRVQLDVFTLSGFRTVQILEGQKILANCSSPYQVDLFGIADLA
 HLLLFKEHLQVFDGSEFWKLSQNISELKDGELWNKFFVRILNANDEATVSVLGELAAMN
 GVFDTTFQSHLNKALWKVGLTSPGALLFQ

N-glycosylation site.

52-55
 97-100
 268-271
 598-601
 711-714
 944-947
 983-986

cAMP- and cGMP-dependent protein kinase phosphorylation site.

667-670

Tyrosine kinase phosphorylation site.

908-914

N-myristoylation site.

8-13
 92-97
 146-151
 148-153
 325-330
 491-496
 657-662
 687-692
 1021-1026

Amidation site.

233-236

12/46

FIGURE 9

GGAAGACTTGGGTCCTTGGGTCGCAGGTGGGAGCCGACGGGTGGGTAGACCGTGGGGGAT
ATCTCAGTGGCGGACGAGGACGGCGGGGACAAGGGGCGGCTGGTCGGAGTGGCGGAGCGT
CAAGTCCCCTGTCCGTTCCCTCCGTCCCTGAGTGTCTTGGCGCTGCCTTGTGCCCCGCCA
GCGCCTTTGCATCCGCTCCTGGGCACCGAGGCGCCCTGTAGGATACTGCTTGTACTTAT
TACAGCTAGAGGCATCATGGACCGATCTAAAGAAAACGCAATTCAGGACCTGTTAAGGC
TACAGCTCCAGTTGGAGGTCCAAAACGTGTTCTCGTGACTCAGCAAATTCCTTGTGAGAA
TCCATTACCTGTAAATAGTGGCCAGGCTCAGCGGGTCTTGTGTCTTCAAATTCCTCCCA
GCGCTTCCCTTTCAGCACAAAAGCTTGTCTCCAGTCACAAGCCGGTTCAGAATCAGAA
GCAGAAGCAATTCAGGCAACCAGTGACCTCATCCTGTCTCCAGGCCACTGAATAACAC
CCAAAAGAGCAAGCAGCCCCCTGCCATCGGCACCTGAAAATAATCCTGAGGAGGAAGTGGC
ATCAAAACAGAAAAATGAAGAATCAAAAAAGAGGCGAGTGGGCTTTGGGAAGACTTTGAAAT
TGGTCGCCCCCTCGGGTAAAGGAAAGTTTGGTAATGTTTATTTGGCAAGAGAAAAGCAAAG
CAAGTTTATTTCTGGCTCTTAAAGTGTTATTTAAAGCTCAGCTGGAGAAAAGCCGGAGTGGA
GCATCAGCTCAGAAGAGAAGTAGAAATACAGTCCCACCTTCGGCATCCTAATATTCTTAG
ACTGTATGGTTATTTCCATGATGCTACCAGAGTCTACCTAATTCGGAATATGCACCACT
TGGAACAGTTTATAGAGAACTTCAGAACTTTCAAAGTTTGATGAGCAGAGAACTGCTAC
TTATATAACAGAAATTCGCAATGCCCTGTCTTACTGTCTATTCGAAGAGAGTTATTATAG
AGACATTAAGCCAGAGAACTTACTTCTTGGATCAGCTGGAGAGCTTAAAATTGCAGATTT
TGGGTGGTCAGTACATGCTCCATCTTCAGGAGGACCACTCTCTGTGGCACCCCTGGACTA
CCTGCCCCCTGAAATGATTGAAGGTTCGGATGCATGATGAGAAGGTGGATCTCTGGAGCCT
TGGAGTTCTTTGCTATGAATTTTTAGTTGGGAAGCCTCCTTTTGAGGCAAACACATACCA
AGAGACCTACAAAAGAATATCACGGGTTGAATTCACATTCCTGACTTTGTAACAGAGGG
AGCCAGGGACCTCATTTCAAGACTGTTGAAGCATAATCCCAGCCAGAGGCCAATGCTCAG
AGAAGTACTTGAACACCCCTGGATCACAGCAAATTCATCAAAACCATCAAATTGCCAAAA
CAAAGAATCAGCTAGCAAACAGTCTTAGGAATCGTGAGGGGGAGAAATCCTTGAGCCAG
GGCTGCCATATAACCTGACAGGAACATGCTACTGAAGTTTATTTTACCATTGACTGCTGC
CCTCAATCTAGAACGCTACACAAGAAATATTTGTTTACTCAGCAGGTGTGCCTTAACCT
CCCTATTAGAAAAGCTCCACATCAATAAACATGACACTCTGAAGTGAAAGTAGCCACGAG
AATTGTGCTACTTATACTGGTTTCATAATCTGGAGGCAAGGTTGACTGCAGCCGCCCCGT
CAGCCTGTGTAGGCATGGTGTCTTCAAGGAGGCAAATCCAGAGCCTGGCTGTGGGGAA
AGTGACCACTCTGCCCTGACCCCGATCAGTTAAGGAGCTGTGCAATAACCTTCCTAGTAC
CTGAGTGAGTGTGTAACCTATTGGGTTGGCGAAGCCTGGTAAAGCTGTTGGAATGAGTAT
GTGATTCTTTTAAAGTATGAAAATAAAGATATATGTACAGACTTGTATTTTTTCTCTGGT
GGCATTCCTTTAGGAATGCTGTGTGTCTGTCCGGCACCCCGGTAGGCCTGATTGGGTTTC
TAGTCCCTCCTTAACCACTTATCTCCCATATGAGAGTGTGAAAAATAGGAACACGTGCTCT
ACCTCCATTTAGGGATTTGCTTGGGATACAGAAGAGGCCATGTGTCTCAGAGCTGTTAAG
GGCTATTTTTTTTAAACATTGGAGTCATAGCATGTGTGTAAACTTTAAATATGCAATA
AATAAGTATCTATGTCTAAAAA

13/46

FIGURE 10

MDRSKENCISGPVKATAPVGGPKRVLVTQQIPCONPLPVNSGQAQRVLCPSNSSQVRVPLQ
AQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPBEELASKQKN
EESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLR
EVEIQSHLRHPNILRLYGYPHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITEL
ANALSYCHSKRVIHRDIKPENLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEM
IEGRMHDEKVDLWSLGVLCEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLI
SRLKHNPSQRPMLREVLEHPWITANSSKPSNCONKESASKQS

N-glycosylation site.

52-55
93-96
386-389

cAMP- and cGMP-dependent protein kinase phosphorylation site.

285-288
339-342

Tyrosine kinase phosphorylation site.

326-334

Serine/Threonine protein kinases active-site signature.

252-264

Protein kinase domain
133-383

14/46

FIGURE 11

GGCCGGACAGTCCGCCGAGGTGCTCGGTGGAGTCATGGCAGTGCCCTTTGTGGAAGACTG
GGACTTGGTGCAAACCTGGGAGAAGGTGCCCTATGGAGAAGTTCAACTTGCTGTGAATAG
AGTAACTGAAGAAGCAGTCGCAGTGAAGATTGTAGATATGAAGCGTGCCGTAGACTGTCC
AGAAAAATATTAAGAAAGAGATCTGTATCAATAAAATGCTAAATCATGAAAATGTAGTAAA
ATTCTATGGTCAAGGAGAGAAGGCAATATCCAATATTTATTTCTGGAGTACTGTAGTGG
AGGAGAGCTTTTTGACAGAATAGAGCCAGACATAGGCATGCCTGAACCAGATGCTCAGAG
ATTCTTCCATCAACTCATGGCAGGGGTGGTTTATCTGCATGGTATTGGAATAACTCAGAG
GGATATTAACACAGAAAATCTTCTGTTGGATGAAAGGGATAACCTCAAAATCTCAGACTT
TGGCTTGGCAACAGTATTTCCGTATAATAATCGTGAGCGTTTGTGACAAGATGTGTGG
TACTTTACCATATGTTGCTCCAGAACTTCTGAAGAGAAGAGAATTTATGCAGAACCCAGT
TGATGTTTGGTCTGTGGAATAGTACTTACTGCAATGCTCGCTGGAGAATTGCCATGGGA
CCAACCCAGTGACAGCTGTCAGGAGTATTTCTGACTGGAAAGAAAAAAACATACCTCAA
CCCTTGGAAAAAAATCGATTCTGCTCCTCTAGCTCTGCTGCATAAAATCTTAGTTGAGAA
TCCATCAGCAAGAATTACCAATCCAGACATCAAAAAAGATAGATGGTACAACAAACCCCT
CAAGAAAGGGGCAAAAAGGCCCGAGTCACTTCAGGTGGTGTGTGAGAGTCTCCAGTGG
ATTTTCTAAGCACATTCAATCCAATTTGGACTTCTCTCCAGTAAACAGTGCTTCTAGTGA
AGAAAAATGTGAAGTACTCCAGTTCTCAGCCAGAACCCCGCACAGGTCTTTCCCTATGGGA
TACCAGCCCCCTACATATTGATAAAATGGTACAAGGGATCAGCTTTTCCAGCCACATG
TCCTGATCATATGCTTTTGAATAGTCAGTTACTTGGCACCCAGGATCCTCACAGAACCC
CTGGCAGCGGTTGGTCAAAAGAAATGACACGATTCTTTACCAAATTGGATGCAGACAAATC
TTATCAATGCCTGAAAGAGACTTGTGAGAAGTTGGGCTATCAATGGAAGAAAAGTTGTAT
GAATCAGGTTACTATATCAACAACTGATAGGAGAAAACAATAAACTCATTTTCAAAGTGAA
TTTGTTAGAAATGGATGATAAAATATTGGTTGACTTCCGGCTTTCTAAGGGTGATGGATT
GGAGTTCAAGAGACACTTCTGAAAGATTAAAGGGAAGCTGATTGATATTGTGAGCAGCCA
GAAGGTTTGGCTTCTGCCACATGATCGGACCATCGGCTCTGGGGAATCCTGGTGAATAT
AGTGCTGCTATGTTGACATTATTTCTTCTAGAGAAGATTATCCTGTCTGCAAACTGCAA
ATAGTAGTTTCTGAAGTGTTCACTTCCCTGTTTATCCAAACATCTTCCAATTTATTTGT
TTGTTCCGGCATACAAATAATACCTATATCTTAATTGTAAGCAAACTTTGGGGAAAGGAT
GAATAGAATTCATTTGATTATTTCTTCATGTGTGTTTAGTATCTGAATTTGAAACTCATC
TGGTGGAAACCAAGTTTCAGGGGACATGAGTTTTCCAGCTTTTATACACACGTATCTCAT
TTTTATCAAAACATTTTGT

15/46

FIGURE 12

MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEA VAVKIVDMKRAVDCPENIKKEICINK
MLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFHQLMAGVVY
LHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYVAPELLK
RREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLA
LLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGFSKHIQSNLDF
SPVNSASSEENVKYSSSQPEPRTGLSLWDTSPSYIDKL VQGIGSFSQPTCPDHMLLNSQLL
GTPGSSQNPWQRLVKRMTRFFTKLDADKSYQCLKETCEKLG YQWKSCMNQVTISTTDRR
NNKLIFKVNLLMDDKILVDFRLSKGDGLEFKRHLKIKGKLIDIVSSQKVWLPAT

CAMP- and cGMP-dependent protein kinase phosphorylation site.

375-378

Tyrosine kinase phosphorylation site.

383-390

394-402

N-myristoylation site.

123-128

195-200

341-346

361-366

Serine/Threonine protein kinases active-site signature.

126-138

Protein kinase domain

9-265

16/46

FIGURE 13

CCGCGGTTCCGGCTGCTCCGGCGAGGCGACCTTGGGTGCGGCGCTGCGGGCGAGGTGGGC
AGGTAGGTGGGCGGACGGCCGCGGTTCTCCGGCAAGCGCAGGCGGGCGGAGTCCCCACGG
CGCCCGAAGCGCCCCCGCACCCCGGCCCTCCAGCGTTGAGGCGGGGGAGTGAGGAGATG
CCGACCCAGAGGGACAGCAGCACCATTGTCCACACGTCGCGAGGCGGGCGGCAGCGGGGAC
CATTCCCACCAGGTCCGGGTGAAAGCCTACTACCGCGGGGATATCATGATAACACATTTT
GAACCTTCCATCTCCTTTGAGGGCCTTTGCAATGAGGTTCGAGACATGTGTTCTTTTGAC
AACGAACAGCTCTTCACCATGAAATGGATAGATGAGGAAGGAGACCCGTGTACAGTATCA
TCTCAGTTGGAGTTAGAAGAAGCCTTTAGACTTTATGAGCTAAACAAGGATTCTGAACTC
TTGATTATGTGTTCCCTTGTGTACCAGAACGTCCTGGGATGCCTTGTCCAGGAGAAGAT
AAATCCATCTACCGTAGAGGTGCACGCCGCTGGAGAAAGCTTTATTGTGCCAATGGCCAC
ACTTTCCAAGCCAAGCGTTTCAACAGGCGTGTCACTGTGCCATCTGCACAGACCGAATA
TGGGGACTTGGACGCCAAGGATATAAGTGCATCAACTGCAAACTCTTGGTTTCATAAGAAG
TGCCATAAACTCGTCACAATTGAATGTGGGCGGCATTCTTTGCCACAGGAACAGTGTATG
CCCATTGGATCAGTCATCCATGCATTCTGACCATGCACAGACAGTAATCCATATAATCCT
TCAAGTCATGAGAGTTTGGATCAAGTTGGTGAAGAAAAAGAGGCAATGAACACCAGGGAA
AGTGGCAAAGCTTCATCCAGTCTAGGTCTTCAGGATTTGATTTGCTCCGGGTAATAGGA
AGAGGAAGTTATGCCAAAGTACTGTTGGTTGATTTAAAAAAGAGATCGTATTTATGCA
ATGAAAGTTGTGAAAAAGAGCTTGTAAATGATGATGAGGATATTGATTGGGTACAGACA
GAGAAGCATGTGTTTGAGCAGGCATCCAATCATCCTTTCCTTGTGGGCTGCATTCTTGC
TTTCAGACAGAAAGCAGATTGTTCTTTGTTATAGAGTATGTAAATGGAGGAGACCTAATG
TTTCATATGCAGCGACAAAGAAAACCTTCTGAAGAACATGCCAGATTTTACTCTGCAGAA
ATCAGTCTAGCATTAAATTATCTTCATGAGCGAGGGATAATTTATAGAGATTTGAACTG
GACAAATGTATTACTGGACTCTGAAGGCCACATTAACTCACTGACTACGGCATGTGTAAG
GAAGGATTACGGCCAGGAGATACAACCAGCACTTTCTGTGGTACTCCTAATTACATTGCT
CCTGAAATTTTAAAGAGGAGAAGATTATGGTTTCAGTGTGACTGGTGGGCTCTTGGAGTG
CTCATGTTTGAGATGATGGCAGGAAGGTCTCCATTTGATATTGTTGGGAGCTCCGATAAC
CCTGACCAGAACACAGAGGATTATCTCTTCCAAGTTATTTTGGAAAAACAAATTTCGATA
CCACGTTCTCTGTCTGTAAAAGCTGCAAGTGTCTGAAGAGTTTCTTAATAAGGACCCT
AAGGAACGATTGGGTTGTCTCCTCAAACAGGATTTGCTGATATTCAGGGACACCCGTTT
TTCCGAAATGTTGATTGGGATATGATGGAGCAAAACAGGTGGTACCTCCCTTTAAACCA
AATATTTCTGGGGAATTTGGTTTGGACAACCTTTGATTCTCAGTTTACTAATGAACCTGTC
CAGCTCACTCCAGATGACGATGACATTGTGAGGAAGATTGATCAGTCTGAATTTGAAGGT
TTTGAGTATATCAATCCTCTTTTGATGTCTGCAGAAGAAATGTCTGATCCTCATTTTTTC
AACCATGTATTCTACTCATGTTGCCATTTAATGCATGGATAAACTTGCTGCAAGCCTGGA
TACAATTAACCATTTTATATTTGCCACCTACAAAAAACACCCAATATCTTCTCTGTAG
ACTATATGAATCAATTATTACATCTGTTTTACTATGAAAAAAAATTAATACTACTAGCT
TCCAGACAATCATGTCAAAATTTAGTTGAACTGGTTTTTTCAGTTTTTAAAGGCCTACAG
ATGAGTAATGAAGTTACCTTTTTTGTGTTAAAAAAG

17/46

FIGURE 14

MSHTVAGGGSGDHSQVRVKAYYRGDIMITHFEPSISFEGLCNEVRDMCSFDNEQLFTMK
 WIDEEGDPCTVSSQLELEEAFLYELNKDSELLIHVFPCVPERPGMPCPGEDKSIYRGA
 RRWRKLYCANGHTFOAKRFNRRAHCAICTDRIWGLGRQGYKCINCKLLVHKKCHKLVIE
 CGRHSLPQEPVMPMDQSSMHSDDHAQTVPYNPSSSHESLDQVGEEKEAMNTRESGKASSSL
 GLQDFDLLRVIGRGSYAKVLLVRLKKTDRYAMKVVKELVNDDDEDIDWVQTEKHVFEQA
 SNHPFLVGLHSCFQTESRLFFVIEYVNGGDLMFHMQRQRKLPEEHARFYSAEISLALNYL
 HERGIIYRDLKLDNVLLDSEGHIKLTDYGMCKEGLRPGDTTSTFCGTPNYIAPEILRGED
 YGFSVDWWALGVLMFEMMAGRSFPDIVGSSDNDQNTEDYLFQVILEKQIRIPRSLSVKA
 ASVLKSFLNKDPKERLGCHPQTGFADIQGHPPFRNVDWDMMEQKQVVPPFKPNISGEFGL
 DNFDSQFTNEPVQLTPDDDDIVRKIDQSEFEGFEYINPLLSAEECV

N-glycosylation site.

533-536

Tyrosine kinase phosphorylation site.

265-271

N-myristoylation site.

7-12
 308-313
 394-399

Cell attachment sequence.

24-26

Serine/Threonine protein kinases active-site signature.

365-377

Protein kinase domain
 245-513

Protein kinase C terminal domain
 514-580

Phorbol esters/diacylglycerol binding domain
 132-181

Octicosapeptide repeat
 56-85

FIGURE 15

GCGGCGGCGGCGGCGCAGTTTGCTCATACTTTGTGACTTGCGGTACAGTGGCATTGAGC
 TCCACACTTGGTAGAACACAGGCACGACAGCATAGAAACATCCTAAACAATCTTCATC
 GAGGCATCGAGGTCCATCCCAATAAAAATCAGGAGACCCTGGCTATCATAGACCTTAGTC
 TTCGCTGGTATACTCGCTGTCTGTCAACCAGCGGTTGACTTTTTTTAAGCCTTCTTTTTT
 CTCTTTTACCAGTTTCTGGAGCAAATTCAGTTTGCCTTCTGGATTGTAAATTGTAATG
 ACCTCAAACTTTAGCAGTTCTCCATCTGACTCAGGTTTGCTTCTCTGGCGGTCTTCAG
 AATCAACATCCACACTTCCGTGATTATCTGCGTGCATTTTGGACAAAGCTTCCAACCAGG
 ATACGGGAAGAAGAAATGGCTGGTGTATCTTTCAGCAGGTTTCTTCATGGAGGAACTTAAT
 ACATACCGTCAGAAGCAGGGAGTAGTACTTAAATATCAAGAAGTGCCTAATTCAGGACCT.
 CCACATGATAGGAGGTTTACATTTCAAGTTATAATAGATGGAAGAGAATTTCCAGAAGGT
 GAAGGTAGATCAAAGAAGGAAGCAAAAATGCCGACGCAAAATAGCTGTTGAGATACTT
 AATAAGGAAAAGAAGGCAGTTAGTCTTTATTATTGACAACAACGAATTTCTTCAGAAGGA
 TTATCCATGGGGAATTACATAGGCCTTATCAATAGAATTGCCAGAGAAAAGACTAAT
 GTAAATTATGAACAGTGTGCATCGGGGGTGCATGGGCGAGAAGGATTTATTATAAATGC
 AAAATGGGACAGAAAGAATATAGTATTGGTACAGGTTCTACTAAACAGGAAGCAAAACAA
 TTGGCCGCTAAACTTGCATATCTTCAGATATTATCAGAAGAAACCTCAGTGAAATCTGAC
 TACCTGTCTCTGGTTCTTTTGCTACTACGTGTGAGTCCCAAAGCAACTCTTTAGTGACC
 AGCACACTCGCTTCTGAATCATCATCTGAAGGTGACTTCTCAGCAGATACATCAGAGATA
 AATTCTAACAGTGACAGTTTAAACAGTTCTTCGTTGCTTATGAATGGTCTCAGAAATAAT
 CAAAGGAAGGCAAAAAGATCTTTGGCACCAGATTGACCTTCTGACATGAAAGAAACA
 AAGTATACTGTGGACAAGAGGTTTGGCATGGATTTTAAAGAAATAGAATTAATTGGCTCA
 GGTGGATTTGGCCAAAGTTTCAAAGCAAAACACAGAATTGACGGAAGACTTACGTTATT
 AAACGTGTTAAATATAATAACGAGAAGGCGGAGCGTGAAGTAAAGCATTGGCAAACTT
 GATCATGTAAATATTGTTCACTACAATGGCTGTTGGGATGGATTGATTATGATCCTGAG
 ACCAGTGATGATTCTCTTGAGAGCAGTGATTATGATCTGAGAACAGCAAAAATAGTTCA
 AGGTCAAAGACTAAGTGCCCTTTTCATCCAAATGGAATCTGTGATAAAGGGACCTTGGAA
 CAATGGATTGAAAAAAGAAGAGGCGAGAACTAGACAAAGTTTGGCTTTGGAACCTCTT
 GAACAAATAACAAAAGGGGTGGATTATATACATTCAAAAAAATTAATTCATAGAGATCTT
 AAGCCAAGTAATATATTCTTAGTAGATACAAAACAAGTAAAGATTGGAGACTTTGGACTT
 GTAACATCTCTGAAAAATGATGGAAAGCGAACAGGAGTAAGGGAACTTTGCGATACATG
 AGCCAGAACAGATTTCTTCGCAAGACTATGGAAAGGAAGTGGACCTCTACGCTTTGGGG
 CTAATCTTGCTGAACCTCTTCATGTATGTGACACTGCTTTTGAAACATCAAAGTTTTTC
 ACAGACCTACGGGATGGCATCATCTCAGATATATTTGATAAAAAAGAAAAACTCTTCTA
 CAGAAATTACTCTCAAAGAAACCTGAGGATCGACCTAACACATCTGAAATACTAAGGACC
 TTGACTGTGTGGAAGAAAAGCCAGAGAAAAATGAACGACACACATGTTAGAGCCCTTCT
 GAAAAAGTATCTGCTTCTGATATGCAGTTTTCTTAAATPATCTAAAATCTGCTAGGGA
 ATATCAATAGATATTTACCTTTTATTTTAAATGTTTCTTAAATTTTACTATTTTACT
 AATCTTTCTGCAGAAACAGAAAGGTTTTCTTCTTTTGGCTTCAAAAACATTCTTACATTT
 TACTTTTTCTGGCTCATCTCTTTATTCTTTTTTTTTTTTTTAAAGACAGAGTCTCGCTC
 TGTGCCCAGGCTGGAGTGCAATGACACAGTCTTGGCTCACTGCAACTTCTGCCTCTTGG
 GTTCAAGTGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGATTACAGGCATGTGCCACCC
 ACCCAACTAATTTTGTGTTTTTAATAAAGACAGGGTTTACCATGTTGGCCAGGCTGGT
 CTCAAACTCCTGACCTCAAGTAATCCACTGCCTCGGCCTCCCAAAGTGCTGGGATTACA
 GGGATGAGCCACCGCGCCAGCCTCATCTCTTGTCTTAAAGATGGAAAAACACCCCCA
 AATTTCTTTTATACTATTAATGAATCAATCAATTCATATCTATTTATTAAATTTCTAC
 CGCTTTTAGGCCAAAAAATGTAAGATCGTTCTCTGCCTCACATAGCTTACAAGCCAGCT
 GGAGAAATATGGTACTCATTAAAAAAGTGATGTACAACC

19/46

FIGURE 16

MAGDLSAGFFMEELNTYRQKQGVLKYQELPNSGPPHRRFTFQVIIDGREFPEGEGRSK
KEAKNAAAKLAVEILNKEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKRLTVNVEQ
CASGVHGPFGFHYKCKMGQKEYSIGTGSTKQEAQLAAYLQILSEETSVKSDYLSG
SFATTCEQSQNSLVTSTLASESSSEGDFASTSEINSNSDSLNSSSLLMNGLRNNQRKAK
RSLAPRFDLPDMKETKYTVDKRFGMDFKIELIGSGGFGQVFKAKHRIDGKTYVIKRVKY
NNEKAEREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLSSDYDPENSKNSSRSKTK
CLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALFLFEQITKGVDYIHSKLIHRDLKPSNI
FLVDTKQVKIGDFGLVTSKNDGKRTRSKGTLRYMSPEQISSQDYGKEVDLYALGLILAE
LLHVCDTAFETSKFFTDLRDGIISDIFDKKEKTLQKLLSKKPEDRPNTSEILRTLTVWK
KSPEKNERHTC

N-glycosylation site.

91-94
223-226
353-356
528-531

cAMP- and cGMP-dependent protein kinase phosphorylation site.

39-42
112-115

Tyrosine kinase phosphorylation site.

285-293

N-myristoylation site.

95-100
99-104
145-150
180-185
231-236
325-330
434-439
475-480

Amidation site.

442-445

Serine/Threonine protein kinases active-site signature.

410-422

Protein kinase domain

267-538

Double-stranded RNA binding motif

10-75
101-165

20/46

FIGURE 17

ATGTCFCGGGAGTCGGATGTTGAGGCTCAGCAGTCTCATGGCAGCAGTGCCTGTTACAG
CCCCATGGCAGCGTTACCCAGTCCCAAGGCTCCTCCTCACAGTCCCAGGGCATATCCAGC
TCCTCTACCAGCAGCATGCCAACTCCAGCCAGTCCCTCTCACTCCAGCTCTGGGACACTG
AGCTCCTTAGAGACAGTGTCCACTCAGGAACCTCTATTCTATTCTGAGGACCAAGAACCT
GAGGACCAAGAACCTGAGGAGCCTACCCCTGCCCCCTGGGCTCGATTATGGGCCCTTCAG
GATGGATTGCGCAATCTTGAATGTGTGAATGACAACCTACTGGTTTGGGAGGGACAAAAGC
TGTGAATATTGCTTTGATGAACCACTGCTGAAAAGAACAGATAAATACCGAACATACAGC
AAGAAACACTTTTCGGATTTTCAGGGAAGTGGGTCTTAAAACTCTTACATTGCATACATA
GAAGATCACAGTGGCAATGGAACCTTTGTAAATACAGAGCTTGTAGGGAAAGGAAAACGC
CGTCCCTTTGAATAACAATTCTGAAATTGCACTGTCACTAAGCAGAAATAAAGTTTTTGTG
TTTTTTGATCTGACTGTAGATGATCAGTCAGTTTATCCTAAGGCATTAAGAGATGAATAC
ATCATGTCAAAAACCTCTTGGAAGTGGTGCCTGTGGAGAGGTAAAGCTGGCTTTTCGAGAGG
AAAACATGTAAAGAAAGTAGCCATAAAGATCATCAGCAAAAGGAAGTTTGCTATTGGTTCA
GCAAGAGAGGGCAGACCCAGCTCTCAATGTTGAAACAGAAATAGAAATTTTGAAAAAGCTA
AATCATCCTTGCAATCATCAAGATTAAAACTTTTTTTGATGCAGAAGATTATTATATTGTT
TTGGAATTGATGGAAGGGGGAGAGCTGTTTGACAAAGTGGTGGGGAATAAACGCCTGAAA
GAAGCTACCTGCAAGCTCTATTTTTACCAGATGCTCTTGGCTGTGCAGTACCTTCATGAA
AACGGTATTATACACCGTGACTTAAAGCCAGAGAATGTTTTACTGTCTCATCTCAAGAAGAG
GACTGTCTTATAAAGATTACTGATTTTGGGCACTCCAAGATTTTGGGAGAGACCTCTCTC
ATGAGAACCTTATGTGGAACCCCCACCTACTTGGCGCTGAAGTTCTTGTCTGTGGG
ACTGCTGGGTATAACCGTGCTGTGGACTGCTGGAGTTTAGGAGTTATTCTTTTTATCTGC
CTTAGTGGGTATCCACCTTTCTCTGAGCATAGGACTCAAGTGTCACTGAAGGATCAGATC
ACCAAGTGGAAAAATACAACCTTCATTCTGAAGTCTGGGCAGAAAGTCTCAGAGAAAGCTCTG
GACCTTGTCAAGAAGTTGTTGGTAGTGGATCCAAAGGCACGTTTTACGACAGAAGAAGCC
TTAAGACACCCGTGGCTTCAGGATGAAGACATGAAGAGAAAGTTTCAAGATCTTCTGTCT
GAGGAAAATGAATCCACAGCTCTACCCAGGTTCTAGCCAGCCTTCTACTAGTCGAAAG
CGGCCCCGTGAAGGGGAAGCCGAGGGTGCCGAGACCACAAAGCGCCAGCTGTGTGTGCT
GCTGTGTGTGTAAGTCCGTGGTTTGAACACGAAAGAAATGTCTTCTTTCACTCTGCATC
TTTCTTTCTTTGAGTCGTTTTTTTATAGTTGGATTAAATTATGGAATAATGGTTT

21/46

FIGURE 18

MSRES DVEAQQSHGSSACSQPHGSVTQSQSSSSQSQGISSSSSTSTMPNSSQSSHSSSGTL
 SSLETVSTQELYSIPEDQEPEDQEPPEPTPAPWARLWALQDGFANLECVNDNYWFGDKS
 CEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTLVGKGKR
 RPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAER
 KTCKKVAIKIISKRFAGSAREADPALNVETEIEILKKLNHPCCI IKIKNFFDAEDYYIV
 LELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEE
 DCLIKITDFGHSKILGETSLMRTLCTPTYLAEVLVSVGTAGYNRAVDCWSLVILFIC
 LSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKLLVVDPKARFTTEEA
 LRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCA
 AVL

N-glycosylation site.

48-51
 166-169
 185-188
 503-506

Glycosaminoglycan attachment site.

164-167

Tyrosine kinase phosphorylation site.

289-297

N-myristoylation site.

14-19
 37-42
 58-63
 167-172
 227-232
 529-534

Amidation site.

177-180

Serine/Threonine protein kinases active-site signature.

343-355

Protein kinase domain

220-486

FHA domain

113-192

22/46

FIGURE 19

GGCACGAGTAGGGGTGGCGGGTCAGTGCTGCTCGGGGGCTTCTCCATCCAGGTCCCTGGA
GTTCTTGGTCCCTGGAGCTCCGCACCTGGCGCGCAACCTGCGTGAGGCAGCGCGACTCTG
GCGACTGGCCCGGCCATGCTTCCCGGGCTGAGGACTATGAAGTGTGTACACCATTTGGCA
CAGGCTCCTACGGCCGCTGCCAGAAGATCCGGAGGAAGAGTGATGGCAAGATATTAGTTT
GGAAAGAACTTGACTATGGCTCCATGACAGAAGCTGAGAAACAGATGCTTGTCTTCTGAAG
TGAATTTGCTTCGTGAACATGAAACATCCAAACATCGTTTCGTTACTATGATCGGATTATTG
ACCGGACCAATACAACACTGTACATTGTAATGGAATATTGTGAAGGAGGGGATCTGGCTA
GTGTAATTACAAAGGGAACCAAGGAAAGGCAATACTTAGATGAAGAGTTTGTCTTCGAG
TGATGACTCAGTTGACTCTGGCCCTGAAGGAATGCCACAGACGAAGTGATGGTGGTCATA
CCGTATTGCATCGGGATCTTAAACCAAGCAATGTTTTCCTGGATGGCAAGCAAAACGTCA
AGCTTGGAGACTTTGGGCTAGCTAGAATATTAAACCATGACACGAGTTTTCAGAAAAACAT
TTGTTGGCACACCTTATTACATGTCTCCTGAACAAATGAATCGCATGTCTACAATGAGA
AATCAGATATCTGGTCAATTGGGCTGCTTGTGTATGAGTTATGTGCATTAATGCCTCCAT
TTACAGCTTTTAGCCAGAAAGAACTCGCTGGGAAAATCAGAGAAGGCAAAATTCAGGCGAA
TTCCATACCGTTACTCTGATGAATTGAATGAAATTATTACGAGGATGTTAAACTTAAAGG
ATTACCATCGACCTTCTGTGAAGAAATCTTGAGAACCCTTTAATAGCAGATTTGGTTG
CAGACGAGCAAGAAGAAATCTTGAGAGAAGAGGGCGACAATTAGGAGAGCCAGAAAAAT
CGCAGGATTCCAGCCCTGTATTGAGTGAGCTGAAACTGAAGGAAATTCAGTTACAGGAGC
GAGAGCGAGCTCTCAAAGCAAGAGAAGAAAGATTGGAGCAGAAAGAACAGGAGCTTTGTG
TTCGTGAGAGACTAGCAGAGGACAAACTGGCTAGAGCAGAAAATCTGTTGAAGAACTACA
GCTTGCTAAAGGAACCGGAAGTTCTCTGTCTCTGGCAAGTAATCCAGAATCTCTTAATCTTC
CATCCTCAGTAATTAAGAAGAAAGTTTCAATTTAGTGGGAAAGTAAAGAGAACATCATGA
GGAGTGAGAATTTTGAGAGTCAGCTCACATCTAAGTCCAAGTGCAAGGACCTGAAGAAAA
GGCTTCACGCTGCCCAGCTGCGGGCTCAAGCCCTGTCAGATATTGAGAAAAATTACCAAC
TGAAAAGCAGACAGATCCTGGGCATGCGCTAGCCAGGTAGAGAGACACAGAGCTGTGTAC
AGGATGTAATATTACCAACCTTTAAAGACTGATATTCAAATGCTGTAGTGTGAATACTT
GGCCCATGAGCCATGCCTTTCTGTATAGTACACATGATATTTGGAATTGGTTTTACTG
TTCTTCAGCAACTATTGTACAAAATGTTACATTTAATTTTTCTTCTTTTAAAGAAC
ATATTATAAAAAGATACTTTCTTGGTTGGGCTTTTAAATCCTGTGTGTGATTACTAGTAG
GAACATGAGATGTGACATTTAAATCTTGGGAGAAAAATAATATTAGGAAAAAAATATT
TATGCAGGAAGAGTAGCACTCACTGAATAGTTTTAAATGACTGAGTGGTATGCTTACAAT
TGTCATGCTTAGATTTAAATTTTAAGTCTGAGATTTTAAATGTTTTTGAGCTTAGAAAAAC
CCAGTTAGATGCAATTTGGTCATTAATACCATGACATCTTGCTTATAAATATTCCATTGC
TCTGTAGTTCAAATCTGTAGCTTTGTGAAAATTCATCACTGTGATGTTTGTATTCTTTT
TTTTTTCTGTTTAAACAGAAATATGAGCTGTCTGTCAATTTACCTACTTCTTTCCCACTAAA
TAAAGAATTTCTCAGTTA

23/46

FIGURE 20

MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTAEKQMLVSEVNLLR
ELKHFNIVRYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQL
TLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKTFVGT
YYMSPEQMNRMSYNEKSDIWSLGCCLLYELCALMPPFTAFSOKELAGKIREGKFRRIPYR
SDELNEIITRMLNLKDYHRPSVEEILENPLIADLVADEQRRNLERRGRQLGEPEKSQDSS
PVLSELKLKEIQLQERERALKAREERLEQKEQELCVRRERLAEDKLARAENLLKNYSLLKE
RKFLSLASNPPELLNLPSSVIKKKVHFSGESKENIMRSENSESQLTSSKSKCKDLKKRIHAA
QLRAQALSDIEKNYQLKSRQILGMR

N-glycosylation site.

79-82
354-357

cAMP- and cGMP-dependent protein kinase phosphorylation site.

26-29

Tyrosine kinase phosphorylation site.

100-107

N-myristoylation site.

91-96

Leucine zipper pattern.

306-327
313-334

Serine/Threonine protein kinases active-site signature.

137-149

Protein kinase domain

8-271

24/46

FIGURE 21

TTGGCGGGCGGAAGCGGCCACAACCCGGCGATCGAAAAGATTCTTAGGAACGCCGTACCA
 GCCGCGTCTCTCAGGACAGCAGGCCCTGTCTTCTGTGCGGGCGCCGCTCAGCCGTGCCC
 TCCGCCCCCTCAGGTTCTTTTTCTAATTCCAAATAAACTTGCAAGAGGACTATGAAAGATT
 ATGATGAACCTTCTCAAATATTATGAATTACATGAACTATTGGGACAGGTGGCTTTGCAA
 AGGTCAAACCTTGCTGCCATATCCTTACTGGAGAGATGGTAGCTATAAAAATCATGGATA
 AAAACACACTAGGGAGTGATTGCCCCGGATCAAAACGGAGATTGAGGCCTTGAAGAACC
 TGAGACATCAGCATATATGTCAACTCTACCATGTGCTAGAGACAGCCAACAAAATATTCA
 TGGTTCTTGAGTACTGCCCTGGAGGAGAGCTGTTTGACTATATAATTTCCCAGGATCGCC
 TGTGAGAAGAGGAGACCCGGGTTGTCTTCCGTGAGATAGTATCTGCTGTTGCTTATGTGC
 ACAGCCAGGGCTATGCTCACAGGGACCTCAAGCCAGAAAATTTGCTGTTTGATGAATATC
 ATAAATTAAGCTGATTGACTTTGGTCTCTGTGCAAAACCAAGGGTAACAAGGATTACC
 ATCTACAGACATGCTGTGGGAGTCTGGCTTATGCAGCACCTGAGTTAATACAAGGCAAAT
 CATATCTTGGATCAGAGGCAGATGTTTGGAGCATGGGCATACTGTTATATGTTCTTATGT
 GTGGATTTCTACCATTTGATGATGATAATGTAATGGCTTTATACAAGAAGATTATGAGAG
 GAAAATATGATGTTCCCAAGTGGCTCTCTCCAGTAGCATTCTGCTTCTTCAACAAATGC
 TGCAAGTGGACCCAAAGAAACGGATTCTATGAAAAATCTATTGAACCATCCCTGGATCA
 TGCAAGATTACAACATCTCTGTTGAGTGGCAAAGCAAGAATCCTTTTATTCACCTCGATG
 ATGATTGCGTAACAGAACTTTCTGTACATCACAGAAACAACAGGCAAACAATGGAGGATT
 TAATTTCACTGTGGCAGTATGATCACCTCACGGCTACCTATCTTCTGCTTCTAGCCAAGA
 AGGCTCGGGGAAAACAGTTCTGTTTAAAGGCTTTCTTCTTCTCCTGTGGACAAGCCAGTG
 CTACCCCATTCACAGACATCAAGTCAAATAATTGGAGTCTGGAAGATGTGACCGCAAGTG
 ATAAAATTATGTGGCGGGATTAAATAGACTATGATTGGTGTGAAGATGATTTATCAACAG
 GTGCTGCTACTCCCCGAACATCACAGTTTACCAAGTACTGGACAGAATCAAATGGGGTGG
 AATCTAAATCATTAACCTCCAGCCTTATGCAGAACACCTGCAATAAATTAAAGAACAAAG
 AAAATGTATATACTCCTAAGTCTGCTGTAAAGAATGAAGAGTACTTTATGTTTCTTGAGC
 CAAAGACTCCAGTTAATAAGAACCAGCATAGAGAGAAATACTCACTACGCCAAATCGTT
 ACACTACACCCCTCAAAGCTAGAAAACAGTGCCTGAAAGAAACTCCAATTAAAATACCAG
 TAAATTC AACAGGAACAGACAAGTTAATGACAGGTGTCTATTAGCCCTGAGAGGCGGTGCC
 GCTCAGTGGAATTGGATCTCAACCAAGCACATATGGAGGAGACTCCAAAAGAAAGGGAG
 CCAAAGTGTGTTGGGAGCCTTGAAAGGGGGTTGGATAAGGTTATCACTGTGCTCACCAGGA
 GCAAAAAGGAAGGGTTCTGCCAGAGACGGGCCAGAGAAGACTAAAGCTTCACTATAATGTGA
 CTACAACCTAGATTAGTGAATCCAGATCAACTGTTGAATGAAATAATGTCTATTCTTCAA
 AGAAGCATGTTGACTTTGTACAAAAGGGTTATACACTGAAGTGTCAAACACAGTCAGATT
 TTGGGAAAGTGACAATGCAATTTGAATTAGAAGTGTGCCAGCTTCAAAAACCCGATGTGG
 TGGGTATCAGGAGGCAGCGGCTTAAGGGCGATGCCTGGGTTTACAAAAGATTAGTGGAAG
 ACATCCTATCTAGCTGCAAGGTATAATTGATGGATTCTTCCATCCTGCCGGATGAGTGTG
 GGTGTGATACAGCCTACATAAAGACTGTTATGATCGCTTTGATTTTAAAGTTTATTGGAA
 CTACCAACTTGTTTCTAAAGAGCTATCTTAAGACCAATATCTCTTTGTTTAAACAAAA
 GATATTATTTTGTGTATGAATCTAAATCAAGCCCATCTGTCAATTATGTTACTGTCTTTT
 TAATCATGTGGTTTTGTATATTAATAATTGTTGACTTTCTTAGATTCACTTCCATATGTG
 AATGTAAGCTCTTAACATATGTCTCTTGTAAATGTGTAATTTCTTCTGAAATAAAACCAT
 TTGTGAATAT

25/46

FIGURE 22

MKDYDELLKYYELHETIGTGGFAKVKLACHILTGMVAIKIMDKNTLGSDLPRIKTEIEA
LKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEETRNVFRQIVSAV
AYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCGSLAYAAPELI
QGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPPSSILL
QQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFILHDDDCVTELSVHHRNNRQT
MEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFCGQASATPFTDIKSNNWSLEDV
TASDKNYVAGLIDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTLTPANKL
KNKENVYTPKSAVKNEEYFMFPEPKTPVNKNQHKREILTPNRYTTPSKARNQCLKETPI
KIPVNSTGTDKLMGTGVI SPERRCRSVELDLNQAHEETPKRKGAKVFGSLERGLDKVITV
LTRSKRKGSA RDGPRLKLHYNVTTRLVNPDLNNEIMSILPKKHVDFVQKGYTLKCQT
QSDFGKVTMQFELEVCQLQKPDVVGIRRQLKGDWVYKRLVEDILSSCKV

N-glycosylation site.

354-357
485-488
562-565

cAMP- and cGMP-dependent protein kinase phosphorylation site.

250-253
546-549

Tyrosine kinase phosphorylation site.

2-10
421-427
630-638

N-myristoylation site.

340-345

Microbodies C-terminal targeting signal.

649-652

Leucine zipper pattern.

165-186

Serine/Threonine protein kinases active-site signature.

128-140

Protein kinase domain

11-263

Kinase associated domain 1

602-651

26/46

FIGURE 23

GTCTTTATTTTCAGTCCCGGATCCGCGGGCGCAGGCCAGCTCAGGCCCCAGGGATGGAC
GTCGTGGACCCGTGACATTTTCAATAGAGACCCCGGGACCACTATGACCTGCTACAGCGG
CTGGGTGGCGGCACGTATGGGGGAAGTCTTTAAGGCTCGAGACAAGGTGTGAGGGGACCTG
GTGGCACTGAAGATGGTGAAGATGGAGCCTGATGATGATGTCTCCACCCTTCAGAAGGAA
ATCCTCATATTGAAAACCTTCCCGGCACGCCAACATCGTGGCCTACCATGGGAGTTATCTC
TGGTTGTCAGAAAACCTGGATCTGCATGGAATTCTGTGGGGCTGGTTCTCTCCAGGACATC
TACCAAGTGACAGGCTCCCTGTGAGAGCTCCAGATTAGCTATGTCTGCCGGGAAGTGCTC
CAGGGACTGGCCTATTTGCACTCACAGAAGAAGATACACAGGGACATCAAGGGAGCTAAC
ATCCTCATCAATGATGCTGGGGAGGTGAGATTGGCTGACTTTGGCATCTCGGCCAGATT
GGGGCTACACTGGCCAGACGCCCTCTTTTCATTGGGACACCCTACTGGATGGCTCCGGAA
GTGGCAGCTGTGGCCCTGAAGGGAGGATACAATGAGCTGTGTGACATCTGGTCCCTGGGC
ATCAGCGCCATCGAACTGGCCGAGCTACAGCCACCGCTCTTTGATGTGACCCCTCTCAGA
GTTCTCTTCCCTCATGACCAAGAGTGGCTACCAGCCTCCCCGACTGAAGGAAAAAGGCAA
TGGTCGGCTGCCCTTCCACAACCTCATCAAAGTCACTCTGACTAAGAGTCCAAGAAACGA
CCCAGCGCCACCAAGATGCTCAGTCATCAACTGGTATCCAGCCTGGGCTGAATCGAGGC
CTGATCCTGGATCTTCTTGACAACTGAAGAATCCCGGGAAGGACCCCTCCATTGGGGAC
ATTGAGGATGAGGAGCCCGAGCTACCCCTGCTATCCCTCGGCGGATCAGATCCACCCAC
CGCTCCAGCTCTTGGGGATCCAGATGCAGACTGCTGTGCGCGGCACATGGAGTTCAGG
AAGCTCCGAGGAATGGAGACCCAGACCCCGAGCCAAACACCGCTCGCCTACAGCCTCCTCGA
GACCTCAGGAGCAGCAGCCCCAGGAAGCAACTGTGAGAGTCGTCTGACGATGACTATGAC
GACGTGGACATCCCCACCCCTGCAGAGGACACACCTCCTCCACTTCCCCCAAGCCCAAG
TTCGTTCTCTCATGACGAGGGTCTTGGGAGCATGGGGGATGATGGGCAGCTGAGCCCC
GGGGTGTGCTCCGGTGTGCGAGTGGGCGCCCCACCAACAGCCCCCGTCTGGGCGCTCCC
CCATCCACCAGCAGCCCCACCTCACCGCCCATTCAGAACCCCTCACTCTGGAACCCACCC
TCCCGGGAGCTTGACAAGCCCCCACTTCTGCCCCCAAGAAGGAAAAGATGAAGAGAAAG
GGATGTGCCCTTCTCGTAAAGTTGTTCAATGGCTGCCCCCTCCGGATCCACAGCACGGCC
GCCTGGACACATCCCTCCACCAAGGACCAAGCACCTGCTCCTGGGGGCAGAGGAAGGCATC
TTCATCCTGAACCGGAATGACCAGGAGGCCACGCTGGAAATGCTCTTTCTAGCCGGACT
ACGTGGGTGTACTCCATCAACAACGTTCTCATGTCTCTCTCAGGAAAGACCCCCACCTG
TATTCTCATAGCATCCTTGGCCTGCTGGAACGGAAGAGACCAGAGCAGGAAACCCCATC
GCTCACATTAGCCCCACCGCCTACTGGCAAGGAAGAACATGGTTTCCACCAAGATCCAG
GACACCAAAGGCTGCCGGGCGTGTGTGTGGCGGAGGGTGGAGCTCTGGGGGCGCGTTC
CTGTGCGGTGCATTGGAGACGTCCGTTGTCTGCTTCAGTGGTACCAGCCCATGAACAAA
TTCCTGCTTGTCCGGCAGGTGCTGTTCCTCACTGCCGACGCTCTGTCCGTGTTCCGCTG
CTGACCGGGCCAGGCTCTGAGCTGCCCGCTGTGTGCATCGGCGTGAGCCCGGGCGCGCG
GGGAAGTCGGTGCTCTTCCACACGGTGCGCTTTGGCGCGCTCTCTGTGCTGGCTGGGCGAG
ATGAGCACCGAGCACAGGGGACCCGTGCAGGTGACCCAGGTAGAGGAAGATATGGTGATG
GTGTTGATGGATGGCTCTGTGAAGCTGGTGACCCCGGAGGGGTCCCAGTCCGGGGACTT
CGCACACCTGAGATCCCATGACCGAAGCGGTGGAGGCCGTGGCTATGGTTGGAGGTGAG
CTTCAGGCCTTCTGGAAGCATGGAGTGCAGGTGTGGGCTCTAGGCTCGGATCAGCTGCTA
CAGGAGCTGAGAGACCTACCTCACTTCCGTCTGCTTGGCTCCCCAGGCTGGAGTGC
AGTGGCAGCATCTGCCTCACTGCAACCTCCTCCTCCAGGTTCAAGCAATTCTCCTGCC
TCAGCCTCCCGAGTAGCTGGGATTACAGGCCTGTAGTGGTGGAGACACGCCAGTGGATG
ATCCTACTGCTCCAGCAACCTCTACATCCAGGAATGAGTCCCTAGGGGGGTGTGAGGAA
CTAGTCTTGCACCCCTCCCCATAGACACACTAGTGGTTCATGGCATGTCTCATCTCC
CAATAAACATGACTTTAGCCTCTGCAAAAAA

27/46

FIGURE 24

MDVVDPDIFNRDPRDHYDLLQRLGGGTYGEVFKARDKVSGLVALKMKMEPDDDVSTLQ
 KEILILKTCRHANIVAYHGSYLWLQKLWICMEFCGAGSLQDIYQVTGSLSELQISYVCRE
 VLQGLAYLHSQKKIHRDIKGANILINDAGEVRLADFGISAQIGATLARRLSPIGTPYWMA
 PEVAAVALKGGYNELCDIWSLGITAIELAELOPPLFDVHPLRVLFMTKSGYQPPRLKEK
 GKWSAAFHNFIKVTLTSPKPSATKMLSHQVLSQPLNRLGLLDLLDKLKNPGKGPSI
 GDIEDEEPPELPPAIPRRIRSTHRSSSLGIPDADCCRRHMEFRKLGRMETRPPANTARLQP
 PRDLRSSSPRKQLSESSDDDDYDDVDIPTPAEDTPPPLPPKPKFRSPSDEGPSSMGDDGQL
 SPGVLVRCASGPPPNSPRPGPPFSTSSPHLTAHSEPSLWNPPSRELDKPPLLPPKKEKMK
 RKGCALLVKLFNGCPLRIHSTAATHPSTKDQHLLLGAREGIFILNRNDQEATLEMLFPS
 RTTWVYSINNVLMSLSGKTPHLYSHSILGLLERKETRAGNPIAHISPHRLLARKNMVSTK
 IQDTKGCRACCVAEGASSGGPFLCGALETSSVLLQWYQPMNKFLLVRQVLFPLPTPLSVF
 ALLTGPGSELPAVCIGVSPGRPGKSVLFHTVRFGLSCWLGMSTEHARGPVQVTQVEEDM
 VMVLMDGSVKLVTPGSPVRGLRTPEIPMTEAVEAVAMVGGQLQAFWKHGVQVWALGSDQ
 LLQELRDPTLTFRLLGSPRLCSTISPHCNLLLPSSNSPASASRVAGITGL

cAMP- and cGMP-dependent protein kinase phosphorylation site.

168-171
 261-264
 573-576

N-myristoylation site.

25-30
 163-168
 278-283
 328-333
 517-522
 579-584
 606-611
 615-620
 625-630
 676-681
 694-699
 761-766

CNH domain
 500-805

Protein kinase domain

17-274

28/46

FIGURE 25

GAATTCGGCACGAAGGAGAGTAGCAGTGCCTTGGACCCCAGCTCTCCTCCCCCTTTCTCT
CTAAGGATGGCCCGAGAGGAGAACTCCTACCCCTGGCCCTACGGCCGACAGACGGCTCCA
TCTGGCCTGAGCACCCCTGCCCCAGCGAGTCTCCGGAAAGAGCCTGTCACCCCATCTGCA
CTTGTCCTCATGAGCCGCTCCAATGTCCAGCCCACAGCTGCCCTGGCCAGAAGGTGATG
GAGAATAGCAGTGGGACACCCGACATCTTAACGCGGCACTTCACAATTGATGACTTTGAG
ATTGGGCGTCTCTGGGCAAAGGCAAGTTTGGAAACGTGTACTTGGCTCGGGAGAAGAAA
AGCCATTTTCATCGTGGCGCTCAAGGTCTTCAAGTCCCAGATAGAGAAGGAGGGCGTG
GAGCATCAGCTGCGCAGAGAGATCGAAATCCAGGCCACCTGCACCATCCCAACATCCTG
CGTCTCTACAACTATTTTTATGACCGGAGGAGGATCTACTTGATTCTAGAGTATGCCCC
CGCGGGGAGCTCTACAAGGAGCTGCAGAAGAGCTGCACATTTGACGAGCAGCGAACAGCC
ACGATCATGGAGGAGTTGGCAGATGCTCTAATGTACTGCCATGGGAAGAAGGTGATTCAC
AGAGACATAAAGCCAGAAAATCTGCTCTTAGGGCTCAAGGGAGAGCTGAAGATTGCTGAC
TTCGGCTGGTCTGTCCATGCGACCTCCCTGAGGAGGAAGACAATGTGTGGCACCCCTGGAC
TACCTGCCCCCAGAGATGATTGAGGGGCGCATCGACAATGAGAAGGTGGATCTGTGGTGC
ATTGGAGTGCTTTGCTATGAGCTGCTGGTGGGGAACCCATTTGAGAGTGTCATCACACAAC
GAGACCTATCGCCGCATCGTCAAGGTGGACCTAAAGTTCCCCGCTTCTGTGCCACGGGA
GCCCAGGACCTCATCTCCAACTGCTCAGGCATAACCCCTCGGAACGGCTGCCCCCTGGCC
CAGGTCTCAGCCCACCTTGGGTCCGGGCCAACTCTCGGAGGGTGTGCCTCCCTCTGCC
CTTCAATCTGTGCGCTGATGGTCCCTGTCAATCACTCGGGTGCGTGTGTTGTATGTCTG
TGTATGTATAGGGGAAGAAGGGATCC

29/46

FIGURE 26

MAQKENSYPWPYGRQTAPSGSLSTLPQVRLEKPVTPSALVLMRSRNVQPTAAPGQKVMEN
SSGTPDILTRHFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEH
QLRREIEIQAHLHHPNILRLYNYFYDRRRIYLLILEYAPRGELYKELOKSCTFDEQRTATI
MEELADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFGWSVHATSLRRKTMCGTLDYL
PPEMIEGRIDNEKVDLWCIGVLCYELLVGNPFESASHNETYRRIVKVDLKFPASVPTGAQ
DLISKLLRHNPSERLPLAQVSAHPWVRANSRRVLPPSALQSVA

N-glycosylation site.

60-63
278-281

cAMP- and cGMP-dependent protein kinase phosphorylation site.

229-232

Amidation site.

192-195

Serine/Threonine protein kinases active-site signature.

196-208

Protein kinase domain

77-326

30/46

FIGURE 27A

GGAATTCCTTTTTTTTTTTTTTTTGGAGATGGAGTTTCACTCTTGGTTGGCCAGGCTGGAGTG
 CAATGGCACAATCTCAGCTTACTGCAACCTCCGCTCCCGGGTTCAAGCGATTCTCCTGC
 CTCAGCCTCTCAAGTAGCTGGGATTACAGGCATGTGCCACCACCCCTGGCTAACTAATTT
 CTTTTCTATTTAGTAGAGATGGGGTTTACCCTGTTGGTCAGGCTGGTCTTGAACCTCTG
 ACCTCAGGTGATCCACTTGCCTTGGCTCCCAAAGTGCTAGGATTACAGCCGTGAACTG
 TGCCCTGGCTGATCTTTTTTTTTTGGTTGGATTTTTGAAACAGGGTCTCCCTTGGTCGCCC
 AGGCTGGAGTGACGTGGTGGCATCTTGGCTCACTATAACCTCCACCTCCTGGTTTCAAGT
 GATCCTCCCACTTTAGCCTCCTGAGTAGCTGTGATTACAGGCGTGACCACCACACCCGG
 CTAATTTTTGTATTTTTATTAGAGACAGGGTTTACCCTGTTGGCCAGGCTGTTCTCAA
 CTCCTGGACTCAAGGGATCCGCTGCCTCCACTTCCCAAAGTCCCGAGATTACAGGTGTG
 AGTCACCATGCTGACCTTATAATTCTTAAGTCATTTTTCTGGTCCATTTCTTCCTTAG
 GGTCTCACAACAAATCTGCATTAGGCGGTACAATAATCCTTAACCTTCATGATTACAAAA
 AGGAAGATGAAGTGATTGATGTTAGAAAGGGGAAGTAGTAAGCCCACTGCACACTCCT
 GGATGATGATCCTAAATCCAGATACAGTAAAAATGGGGTATGGGAAGGTAGAATACAAAA
 TTTGGTTTAAATTAATTTATCTAAATATCTAAAAACATTTTTGGATACATTGTTGATGTGA
 ATGTAAGACTGTACAGACTTCTAGAAAAACAGTTTGGGTCCATCTTTTTCATTTCCCCAG
 TGCAGTTTTCTGTAGAAATGGAATCCGAGGATTAAAGTGGCAGAGAATTGACAATTGATT
 CCATAATGAACAAAGTGAGAGACATTAATAATAAGTTTAAAAATGAAGACCTTACTGATG
 AACTAAGCTTGAATAAAAAATTTCTGCTGATACTACAGATAAATCGGGAACTGTTAACCAAA
 TTATGATGATGGCAAAACAACCCAGAGGACTGGTTGAGTTTGTGCTCAAACTAGAGAAAA
 ACAGTGTTCGCTAAGTGATGCTCTTTTAAATAAATGATTGGTTCGTTACAGTCAAGCAA
 TTGAAGCGCTTCCCCCAGATAAATATGGCCAAAATGAGAGTTTTGCTAGAATTCAAGTGA
 GATTGCTGTAATTAAGCTATTCAAGAGCCAGATGATGCACGTGACTACTTTCAATGG
 CCAGAGCAAACCTGCAAGAAATTTGCTTTTGTTCATATATCTTTGCACAATTTGAAGTGT
 CACAAGGTAATGTCAAAAAAGTAAACAACCTTCTTCAAAAAGCTGTAGAAGCTGGAGCAG
 TACCAGTAGAAATGCTGGAAATTTGCCCTGCGGAATTTAAACCTCCAAAAAAGCAGCTGC
 TTTCCAGAGGAGAAAGCAAGAAATTTATCAGCATCTACGCTATTAACTCGCCCAAGAATCAT
 TTTCCGGTTCACTTGGGCATTTACAGAATAGGAACAACAGTTGTGATTCCAGAGGACAGA
 CTACTAAAGCCAGGTTTTTATATGGAGAGAATGCCACCACAAGATGCAGAAATAGGTT
 ACCGGAATTCATTGAGACAACTAACAAAATAACAGTCATGCCCATTTGGAAGAGTCC
 CAGTTAACCTTCTAAATAGCCAGATTGTGATGTGAAGACAGATGATTCAAGTTGTACCTT
 GTTTTATGAAAAGACAAACCTCTAGATCAGAATGCCGAGATTTGGTTGTGCCTGGATCTA
 AACCAAGTGGAAATGATTCTGTGAATTAAGAAATTTAAAGTCTGTTCAAAAATAGTCATT
 TCAAGGAACCTCTGGTGTGATGAAAAGAGTTCTGAACCTATTATTACTGATTCAATAA
 CCCTGAAGAAATAAACCGAATCAAGTCTTCTAGCTAAATTAGAAGAACTAAAGAGTATC
 AAGAACAGAGGTTCCAGAGAGTAACCAAGAACAGTGGCAAGCTAAGAGAAAGTCAGAGT
 GTATTAACCAGAATCCTGCTGCATCTTCAAATCACTGGCAGATTCCGGAGTTAGCCCGAA
 AAGTTAATACAGAGCAGAAACATACCACTTTTGGCAACCTGTCTTTTTCAGTTTCAAAAC
 AGTCACCAACCAATATCAACATCTAAATGGTTTGACCCAAAATCTATTGTGAAGACACCAA
 GCAGCAATACCTTGGATGATTACATGAGCTGTTTTAGAACTCCAGTTGTAAAGAATGACT
 TTCCACCTGCTTGTGAGTTGTCAACACCTTATGGCCAACCTGCCTGTTTCCAGCAGCAAC
 AGCATCAATACTTGCCACTCCACTTCAAAATTTACAGGTTTATAGCATCTTCTTACGAA
 ATGAATGCATTTCCGTTAAAGGAAGAATTTATTCCATATTAAAGCAGATAGGAAGTGGAG
 GTTCAAGCAAGGTATTTTCCAGGTGTTAAATGAAAAGAAACAGATATATGCTATAAAATATG
 TGAACCTAGAAGAAGCAGATAACCAAACTCTTGATAGTTACCGGAACGAAATAGCTTATT
 TGAATAAACTACAACAACACAGTGATAAGATCATCCGACTTTATGATTATGAAATCACGG
 ACCAGTACATCTACATGGTAAATGGAGTGTGGAAATATTGATCTTAATAGTTGGCTTAAAA
 AGAAAAATCCATTGATCCATGGGAACGCAAGAGTTACTGGAAAAATATGTTAGAGGCAG
 TTCACACAATCCATCAACATGGCATTGTTACAGTGATCTTAAACCAGCTAACTTTCTGA
 TAGTTGATGGAATGCTAAAGCTAATTGATTTTGGGATTGCAAACCAAATGCAACCAGATA
 CAACAAGTGTGTTAAAGATTCTCAGGTTGGCACAGTTAATTATATGCCACCAGAAGCAA
 TCAAAGATATGTCTTCTCCAGAGAGAATGGGAATCTAAGTCAAGATAAGCCCCAAAA
 GTGATGTTGGTCTTGGATGTTTGTACTATATGACTTACGGGAAAAACACCATTTTC
 AGCAGATAATTAATCAGATTTCTAAATTACATGCCATAATTGATCCTTAATCATGAAATTG
 AATTTCCCGATATTCCAGAGAAAGATCTTCAAGATGTGTTAAAGTGTGTTTAAAAAGGG
 ACCCAAAACAGAGGATATCCATTCCCTGAGCTCCTGGCTCATCCATATGTTCAAATTCAAA
 CTCATCCAGTTAAACCAATGGCCAAGGGAACCACTGAAGAAATGAAATATGTTCTGGGCC
 AACTTGTGGTCTGAATCTCCTAACTCCATTTTGAAGCTGCTAAAACTTTATATGAAC
 ACTATAGTGGTGGTGAAAGTCATAATCTTTCATCCTCCAAGACTTTTGAAGAAAAAGGG
 GAAAAAATGATTTGAGTTATTTCGTAATGTCAGATAGGAGGTATAAAATATATTGGACT
 GTTATACTCTTGAATCCCTGTGGAAATCTACATTTGAAGACAACATCACTCTGAAGTGT
 ATCAGCAAAAAAATTCAGTGAGATTATCTTAAAGAAAACTGTAAAAATAGCAACCAC

31/46

FIGURE 27A

TTATGGCACTGTATATATTGTAGACTTGTTTTCTCTGTTTTATGCTCTTGTGTAATCTAC
TTGACATCATTCTTACTCTTGGAAATAGTGGGTGGATAGCAAGTATATTCTAAAAAAGTTTG
TAAATAAAGTTTTGTGGCTAAAAATGA

32/46

FIGURE 28

MNKVRDIKNKPKNEDLTDELSLNKISADTTDNSGTVNQIMMMANNPEDWLSLLLKLEKNS
 VPLSDALLNKLIGRYSQAIEALPPDKYGQNESFARIQVRFAELKAIQEPDDARDYFQMAR
 ANCKKFAFVHISFAQFELSQGNVKKSKQLLOKAVERGAVPLEMLEIALRNLNLQKKQLLS
 EEEKNLSASTVLTAQESFSGSLGHLQNRNNSCDSRGQTTKARFLYGENMPPQDAEIGYR
 NSLRQTNKTKQSCPFGRVPVNLNNSPDCDVKTDDSVVPCFMKRQTSRSECRDLVVPGSKP
 SGNDSCELRNLKSVQNSHFKEPLVSEKSSSELIITDSITLKNKTESSLLAKLEETKEYQE
 PEVPESNQKQWQAKRKSECINQNPAASSNHWQIPELARKVNTBQKHTTTEQPVFSVSKQS
 PPSTSKWFDPKSICKTPSSNTLDDYMSCFRTPVVKNDFFPACQLSTPYGQPACFQQQQH
 QILATPLQNLQVLASSANECISVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVN
 LEEADNQTLDSYRNEIAYLNKLQOHSDKIIRLYDYEITDQYIYMVMCEGNI DLNSWLKKK
 KSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMOPDTT
 SVVKDSQVGTVNYPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYMTYGTTPFQQ
 IINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCLKRDPKQRISIPELLAHPYVQIQTH
 PVNQMAKGTTEEMKYVLGQLVGLNSPNSILKAAKTLYEHYSGGESHNSSSSKTFEKKRGK
 K

N-glycosylation site.

90-93
 186-189
 210-213
 247-250
 303-306
 342-345
 546-549
 827-830

CAMP- and cGMP-dependent protein kinase phosphorylation site.

282-285
 374-377
 599-602

Tyrosine kinase phosphorylation site.

351-358
 787-796

N-myristoylation site.

88-93
 297-302
 302-307
 470-475
 516-521
 626-631
 798-803

Amidation site.

838-841

Serine/Threonine protein kinases active-site signature.

627-639

Protein kinase domain

509-775

FIGURE 29

GAATTCGCGCGCCGCGTCGACGATCTCTTGGAGACGGCGACCCAGGCATCTGGGGAGCCAC
AGAAGTCGTACTCCCTTAAACCCTGCTTTGCTCCCCCTGTGGATGTAACCCCTTAGCTGG
CATTTTGCATCTCAATTGGCTTGTGATGGAGGCGCTTTTGGGGATTGAGATGGATGAGCC
AATGGCTTTTCTCCCCAGCGTGACCGGTTTCAGGCTGAAGGCTCTTTAAAAAAAACGA
GCAGAATTTTAAACTTGCAGGTGTTAAAAAAGATATTGAGAAGCTTTATGAAGCTGTACC
ACAGCTTAGTAATGTGTTTAAAGATTGAGGACAAAATTGGAGAAGGCACTTTAGCTCTGT
TTATTTGGCCACAGCACAGTTACAAGTAGGACCTGAAGAGAAAATTGCTCTAAAACACTT
GATTCCAACAGTCATCCTATAAGAATTGCAGCTGAACCTCAGTGCCCTAACAGTGGCTGG
GGGGCAAGATAATGTCATGGGAGTTAAATACTGCTTTAGGAAGAATGATCATGTAGTTAT
TGCTATGCCATATCTGGAGCATGAGTCGTTTTTGGACATCTGAATTCTCTTCTCTTCA
AGAAGTACGGGAATATATGCTTAATCTGTTCAAAGCTTTGAAACGCATTTCATCAGTTTGG
TATTGTTACCGTGATGTTAAGCCAGCAATTTTATATAATAGGCGCCTGAAAAAGTA
TGCCTTGGTAGACTTTGGTTTGGCCCAAGGAACCCATGATACGAAAATAGAGCTTCTTAA
ATTTGTCAGTCTGAAGCTCAGCAGGAAGGTGTTTCAAAAAACAATCCACATAATCAC
AGGAACAAGATTCCACTGAGTGGCCAGTACCTAAGGAGCTGGATCAGCAGTCCACCAC
AAAAGCTTCTGTTAAAAAGACCCCTACACAAATGCACAAATTCAGATTAAACAAGGAAAAGA
CGGAAGGAGGGATCTGTAGGCCTTTCTGTCCAGCGCTCTGTTTTTGGAGAAAGAAATTT
CAATATACACAGCTCCATTTTACATGAGAGCCCTGCAGTGAAACTCATGAAGCAGTCAAA
GACTGTGGATGTACTGTCTAGAAAGTTAGCAACAAAAAAGAGGCTATTTCTACGAAAGT
TATGAATAGTGTGTGATGAGGAAAACCTGCCAGTTCTTGCCAGCTAGCCTGACCTGTGA
CTGCTATGCAACAGATAAAGTTTGTAGTATTTGCCCTTTCAAGGCGTCAGCAGGTTGCCCC
TAGGGCAGGTACACCAGGATTCAGAGCACCAGAGGTCTTGACAAAGTGCCCAATCAAC
TACAGCAATTGACATGTGGTCTGCAGGTGTCATATTTCTTTCTTTGCTTAGTGGACGATA
TCCATTTTATAAAGCAAGTGATGATTTAACTGCTTTGGCCCAAATTATGACAATTAGGGG
ATCCAGAGAACTATCCAAGCTGCTAAAACTTTTGGGAAATCAATATTATGTAGCAAAGA
AGTTCCAGCAAGACTTGAGAAAACCTGTGTGAGAGACTCAGGGGTATGGATTCTAGCAC
TCCCAAGTTAAACAAGTGATATACAAGGGCATGCTTCTCATCAACCAGCTATTTAGAGAA
GACTGACCATAAAGCTTCTTGCCCTCGTTCAAACACCTCCAGGACAATACTCAGGGAATTC
ATTTAAAAAGGGGGATAGTAATAGCTGTGAGCATTTGTTTTGATGAGTATAATACCAATTT
AGAAGCTGGAATGAGGTACCTGATGAAGCTTATGACCTGCTTGATAAACTTCTAGATCT
AAATCCAGCTTCAAGAATAACAGCAGAAGAAGCTTTGTTGCATCCATTTTAAAGATAT
GAGCTTGTGATAATGGATCTTCATTTAATGTTTACTGTTATGAGGTAGAATAAAAAAGAA
TACTTTGTAATAGCCACAAGTTCTTGTTTAGAGACCAGAGCAGGATTAATAATTTATTTT
AACATTTTAGTGTTTGGTGGCACATTCTAAAATATAGATTAAAGAACTTAAATGSCCTG
GGATAGTTCTTGGGACTAACAACATGATCTTCTTTGAGTTAAACCTACCTAAGTAGATTT
TAGGTGGGTTCCCTATTAGGTCAGATTTTTAGCTTCCCTAATTACCTTTCACTGACATACA
GAAAAAGGAGCAGTTTATGTTTTAATTAATTAAATTAACAGATGTGATGAGGATTAAAT
GAATCAAAAGACTTAATTTGTAGATTCTTTTAGAGTTATGAGCTAGGTATAGTTTGGGA
AACTCAACCTGGTGCTGGTGCTCTTAACAATTTTGTAAATAAAGAAGATAATTTCTTTT
CTAGAGGTACATATTAGGCCTTTTATGAACACTAAAACAATGAGGAAATGTTGGTCTAGG
GGCAAAGTATCACTTAAATTTGAATTCATCCATTTTAAAAAACACTTCATGAAAGCATT
CTGGTGTGAATTGCCATTTTTTTCTTACTGGCTTCTCAATTTTCTTCTCTGCCCCCT
ACCTAAAACATTTCTCCTCGGAAATTACATGGTGCTGACCACAAAGTTTCTGGATGTTTTA
TTAAATATTGTACGTGTTTACAGTTGGGAATTTAAATAATACATACACTGGTTGATAAA
GGGAAGCTGCAGGACCAAGGTGAAGATTGATAGTCCAAATGCTTTTCTTTTTTGTAGTTGT
ATATTTTTTACACCATCTTAGATATAATTAGGTAGCTGCTGAAAGGAAAAGTGAATACA
GAATTGACGGTATTATTGGAGATTTTTCTCTGCGTAGAGCCATCCAGATCTCTGTATCC
TGTTTTGACTAAGTCTTAGGTGGGTTGGGAAGACAGATAATGAAGTAGGCAAGAGAAAA
GGACCCAAGATAGAGGTTTATATTAGAAATGGTATATATCAATGACAGCATATCAAAC
TCCTATGGGAAAAAGTCTGGTGGGTGGTCAGCTGACAGATTTCCCATTTAGTAGTCATAG
AATACAGAAATAGTTTAGGGACATGTATTCAATTTGTTATTTTGGACATTGATAGGTCAG
TATATCTACCTAATCTGTTTGGTAAGTATAGGATATATAAACCAATTACCATTTGATCTGTC
TTATGCCATAATCTTAAAAAAAATTGAATGCTCTTGAATTTGTATATTCAATAAAGTTA
TCCTTTTATAAAAAAAGTCGACGCGGCCGC

- 34/46

FIGURE 30

MEASLGIQMDEPMAFSPQRDRFQAEGSLKKNEQNFKLAGVKKDIEKLYEAVPQLSNVFKI
EDKIGEGTFSSVYLATAQLQVGPEEKIALKHLIPTSHPIRIAELQCLTVAGGQDNVMGV
KYCFRKNDFHVVAMPYLEHESFLDILNSLSFQEVREYMLNLFKALKRIHQFGIVHRDVKP
SNFLYNRRLLKXYALVDFGLAQGTHDTKIELLKQVQSEAQQERCSONKSHIITGNKIPLSG
PVPKELDQQSTTKASVKRPYTNAQIQIKQKDGKEGSGVGLSVQSVFGERNFNIHSSISH
ESPAVKLMKQSKTVDVLSRKLATKKKAISTKVMNSAVMRKTASSCPASLTCDCYATDKVC
SICLSRRQQVAPRAGTPGFRAPEVLTKCPNQTTAIDMWSAGVIFLSLLSGRYPFYKASDD
LTALAQIMTIRGSRETIQAAKTFGKSILCSKEVPAQDLRLKLCERLRGMDSSSTPKLTSDIQ
GHASHQPAISEKTDHKASCLVQTPPGQYSGNSFKKGDNSNCEHCFDEYNTNLEGWNEVPD
EAYDLLDKLLDLNFPASRITAEALLHPFFKXMSL

N-glycosylation site.

226-229
390-393

Tyrosine kinase phosphorylation site.

41-48

N-myristoylation site.

67-72
112-117
119-124
198-203
202-207
432-437
467-472
506-511

ATP/GTP-binding site motif A (P-loop).

439-446

Serine/Threonine protein kinases active-site signature.

173-185

Protein kinase domain

58-569

35/46

FIGURE 31

CCGAGTTACGAGTCGGCGAAAGCGGCGGGAAGTTCTGTAAGGCGAGACGCGACGGGTCT
GCGGCTTAGGTGAAAATGCCTCGTGTAAAAGCAGCTCAAGCTGGAAGACAGAGCTCTGCA
AAGAGACATCTTGCAGAACAAATTTGCAGTTGGAGAGATAATAACTGACATGGCAAAAAG
GAATGGAAAGTAGGATTACCCATTGGCCAAGGAGGCTTTGGCTGTATATATCTTGCTGAT
ATGAATCTTCAGAGTCAGTTGGCAGTGATGCACCTTGTGTTGTAAAAGTGAACCCAGT
GACAAATGGACCTCTTTTTACTGAATTTAAAGTTCTACCAACGAGCTGCAAAACCAGAGCAA
ATTCAGAAATGGATTTCGTACCCGTAAGCTGAAGTACCTGGGTGTTCTTAAGTATTGGGGG
TCTGGTCTACATGACAAAAATGGAAAAAGTTACAGGTTTATGATAATGGATCGCTTTGGG
AGTGACCTTCAGAAAAATATATGAAGCAAATGCCAAAAGGTTTTCTCGGAAAACGTCTTG
CAGCTAAGCTTAAGAATTCTGGATATTCTGGAATATATTCACGAGCATGAGTATGTGCAT
GGAGATATCAAGGCCTCAAATCTTCTTCTGAACCTACAAGAATCCTGACCAGGTGTACTTG
GTAGATTATGGCCTTGCTTATCGGTACTGCCAGAAAGGAGTTTCATAAAGAATACAAAGAA
GACCCCAAAGATGTACGATGGCCTATTGAATTCACGAGCATCGATGCACACAATGGT
GTGGCCCATCAAGACGTGGTGATTTGGAAATACTTGGTTATTGCATGATCCAATGGCTT
ACTGGCCATCTTCTTGGGAGGATAATTTGAAAGATCCTAAATATGTTAGAGATTCCAAA
ATTAGATACAGAGAAAATATTGCAAGTTTGATGGACAAATGTTTTCTGAGAAAAACAAA
CCAGGTGAAATTGCCAAATACATGGAAACAGTGAAATTAAGACTACACTGAAAAACCT
CTTTATGAAAATTTACGTGACATTCCTTTGCAAGGACTAAAAGCTATAGGAAGTAAGGAT
GATGGCAAATTTGGACCTCAGTGTGTGGAGAAATGGAGGTTTGAAAGCAAAAACAATAACA
AAGAAGCGAAAGAAAGAAATGAAGAAAGCAAGGAACCTGGTGTGAAGATACGGAATGG
TCAACACACAGACAGAGGAGGCCATACAGACCCGTTCAAGAACCAGAAAGAGAGTCCAG
AAGTAATTCAGATGCTGTGAACCAGATTTCTTTCTTTGTTTTCTTTGACTTTTTTCT
CCTTTTCTGTAGAACTGTTTTATTTTCTTGTGAGTCTTGCGAGGTGGAATTAATGATTA
AATACTCATGTGTTTCAAAAAACATAAACTTTTTTTTATAAAAAATATTTGTACAATTCATT
AAAGGCTAATTTATGAAATTTGAAATCTTCAGGTTATACTCCTTAAGTTATCCCAAAGC
CGTGTGTTTGTGATGTTTTGGAGTACATATATATGAAAATTATTATGACACGCACCTTTTC
TAATCATTTGTACATTTCTCAGAGTGGATAAAAAATGTTTGACAAAGTCCTCACTTTTAAGG
AAATGCAAAGCTTAAATAAAACTCTCTTTTGTGTTGATGCAG

36/46

FIGURE 32

MPRVKAAQAGRQSSAKRHLAEQFAVGEIITDMAKKEWKVGLPIGQGGFGCIYLADMNSSE
 SVGSDAPCVVKVEPSDNGPLFTELKFYQRAAKPEQIQKWIRTRKLKYLGVPKYWGSGLHD
 KNGKSYRFMIMDRFGSDLQKIYEANAKRFSRKTIVLQLSLRILDILEYIHEHEYVHGDICA
 SNLLLNKYNPDQVYLVDYGLAYRYCPEGVHKEYKEDPKRCHDGTIEFTSIDAHNGVAPSR
 RGDLEILGYCMIQWLTGHLPWEDNLKDPKYVRDSKIRYRENIASLMDKCFPEKNKPGEIA
 KYMETVKLLDYTEKPLYENLRDILLQGLKAIGSKDDGKLDLSVVENGGLKAKTITKKRKK
 EIESKEPGVEDTEWSNTQTEEAIQTRSRTRKRQK

N-glycosylation site.

57-60

cAMP- and cGMP-dependent protein kinase phosphorylation site.

147-150

Tyrosine kinase phosphorylation site.

160-167

188-194

241-249

295-302

N-myristoylation site.

40-45

46-51

235-240

347-352

369-374

Cell attachment sequence.

241-243

Serine/Threonine protein kinases active-site signature.

173-185

Protein kinase domain

37-325

37/46

FIGURE 33

AGTTGGCGGGAATGGCTGCTCGCGGAGGGGCGAGTGACGCGGGGCCGCTGTAGGCTGTCC
AGCGATGGATCCCACCGCGGAAGCAAGAAGGAGCCTGGAGGAGGCGCGGCGACTGAGGA
GGGCGTGAATAGGATCGCAGTGCCAAAGCCGCCCTCCATTGAGGAATTCAGCATAGTGAA
GCCCATTAGCCGGGGCGCCTTCGGGAAAGTGTATCTGGGGCAGAAAGGCGGCAAAATTGTA
TGCAGTAAAGGTTGTTAAAAAGCAGACATGATCAACAAAAATATGACTCATCAGGTCCA
AGCTGAGAGAGATGCACTGGCACTAAGCAAAAGCCATTCAATTGTCCATTGTATTATTC
ACTGCAGTCTGCAACCAATGTCTACTTGGTAATGGAATATCTTATTGGGGGAGATGTCAA
GTCTCTCCTACATATATATGGTTATTTTGTATGAAGAGATGGCTGTGAAATATATTTCTGA
AGTAGCACTGGCTCTAGACTACCTTCACAGACATGGAATCATCCACAGGGACTTGAAACC
GGACAATATGCTTATTTCTAATGAGGGTCATATTAACCTGACGGATTTTGGCCTTTCAAA
AGTTACTTTGAATAGAGATATTAATATGATGGATATCCTTACAACACCATCAATGGCAAA
ACCTAGACAAGATTATTCAGAACCCAGGACAAGTGTATCGCTTATCAGCTCGTTGGG
ATTTAACACACCAATTGCAGAAAAAATCAAGACCCTGCAACATCCTTTCAGCCTGTCT
GTCTGAAACATCACAGCTTCTCAAGGACTCGTATGCCCTATGTCTGTAGATCAAAAGGA
CACTACGCTTATTTCTAGCAAAATTACTAAATCATGTCTTGAACAGTTGCCTTCCAACCC
AGGAATGCCCTGTGAAGTGTCTAATCTTAATTTACTCCAGTCTAGGAAAAGGCTGGCCAC
ATCCAGTGCCAGTAGTCAATCCCACACCTTCATATCCAGTGTGGAATCAGAATGCCACAG
CAGTCCCAATGGGAAAAAGATTGCCAGGAAAGTGTGAAGCAATTGGGCCCCAACAATGAT
GAGTTGGAATGCAGTTGAAAAGTTATGCGCAAAATCTGCAATGCCATTGAGACGAAAGG
TTTCAATAAAAAGGATCTGGAGTTAGCTCTTTCTCCATTCAACAGCAGTGCCCTTCC
CACCCTGGACGCTCTTGTGTAAACCTTGCTAAAAAATGCTTCTCTGGGGAGTTTCTTG
GGAAGCAGTAGAATGGATGTAAATAATATAAATATGGACACTGACACAAGTCAGTTAGG
TTTCCATCAGTCAAATCAGTGGGCTGTGGATTCTGGTGGGATATCTGAAGAGCACCTTGG
GAAAAGAGATTTTAAAAAGAAAATTTTGAAGTTGGTTGACTCCAGTCTTGTAAAAAATAT
ACAGAATAAAAAAATTTGTGTAGAGTATAAGCATAACGAAATGACAAATTGTTATACAAA
TCAAAATACAGGCTTAACAGTTGAAGTGCAGGACCTTAAGCTATCAGTGCACAAAAGTCA
ACAAAATGACTGTGCTAATAAGGAGAACATTTGTCAATTCTTTTACTGATAAACACAAAC
ACCAGAAAAAATTACCTATACCAATGATAGCAAAAAACCTTATGTGTGAACCTCGATGAAGA
CTGTGAAAAGAATAGTAAGAGGGACTACTTAAGTTCTAGTTTTCTATGTTCTGATGATGA
TAGAGCTTCTAAAAATATTTCTATGAACCTCGATTTCATCTTTTCTGGAATTTCTATAAT
GGAAAGTCCATTAGAAAGTCAGCCCTTAGATTTCAGATAGAAGCATTAAAGAATCCTCTTT
TGAAGAATCAAATATTGAAGATCCACTTATTTGTAACACAGATTGGCAAGAAAAGACCTC
ACCAAAAGGTGTGAGAACCTTGCTGTACAAGAGAGTAACCAAAAAATGTTAGGTCCTCC
TTTGGAGGTGCTGAAAACGTTAGCCTCTAAAAGAAATGCTGTTGCTTTTCGAAGTTTAA
CAGTCATATTAATGCATCCAATACTCAGAACCATCCAGAATGAACATGACTTCTTTAGA
TGCAATGGATATTTTCGCGTGCCTACAGTGGTTTCATATCCCATGGCTATAACCCCTACTCA
AAAAAGAAGATCCTGTATGCCACATCAGACCCCAATCAGATCAAGTCGGGAACCTCCATA
CCGAACCTCCGAAGAGTGTGAGAAGAGGGGTGGCCCCCGTTGATGATGGGCGAATTCTAGG
AACCCAGACTACCTTGACCTGAGCTGTTACTAGGCAGGGCCCATGGTCTCGCGGTAGA
CTGGTGGGCACTTGGAGTTTGCTTGTGAAATTTCTAACAGGAATTTCCCTTTCAATGA
TGAAACACCACAACAAGTATTCAGAATATTCTGAAAAGAGATATCCCTTGGCCAGAAGG
TGAAGAAAAGTTATCTGATAATGCTCAAAGTGCAGTAGAAATACTTTTAACCATTGATGA
TACAAAGAGAGCTGGAATGAAAGAGCTAAAACGTCATCCTCTCTTCAGTGATGTGGACTG
GGAAAATCTGCAGCATCAGACTATGCCCTTTCATCCCCCAGCCAGATGATGAAACAGATAC
CTCCTATTTTGAACACAGGAATACTGCTCAGCACCTGACCGTATCTGGATTTAGTCTGTA
GCACAAAAATTTTCTTTTAGTCTAGCCTCGTGTATAGAATGAACTTGCATAATTATAT
ACTCCTTAATACTAGATTGATCTAAGGGGGAAGATCATTATTTAACCTAGTTCAATGTG
CTTTTAATGTACGTTACAGCTTTCACAGAGTTAAAAGGCTGAAAGGAATATAGTCAGTAA
TTTATCTTAACCTCAAACTGTATATAAATCTTCAAAGCTTTTTCATCTATTTATTTG
TTTATTGCACTTTATGAAAACGTGAAGCATCAATAAAATAGAGGACACTATTGAGAGTGA
GCCACTAGCTTGATTTTCTTTCTCCTCTGATTTCAGTTCAGTTTCACTTTAGCATTA
ATAATAAAATAATCATACAGTTCC

38/46

FIGURE 34

MDPTAGSKKBPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVYLQKGGKLYA
 VKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSLSQANNVYLVMEYLIGGDVKS
 LLHIYGYFDEEMAVKYI SEVALALDYLHRHGI IHRDLKPDNMLISNEGHIKLTDFGLSKV
 TLNRDINMMDILTTPSMAKPRQDYSRTPGQVLSLISSLGFNTPIAEKNQDPANILSACLS
 ETSQLSQGLVCPMSVDQKDTTPYSSKLLKSCLETVASNPGMPVKCLTSNLLQSRKRLATS
 SASSQSHTFISSVESECHSSPKWEKDCQESDEALGPTMMSWNAVEKLCAKSANAIETKGF
 NKKDLELALSPIHNSSALPTTGRSCVNLAKKCFSGEVSWEAVELDVNNINMDTDTSQLGF
 HQSNQWAVDSSGGISEEHLGKRSLKRNFEVDSSPCKKIIQNKKTCVEYKHNEMTNCTNQ
 NTGLTVEVQDLKLSVHKSQQNDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELEDC
 EKNSKRDLSSSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQPLSDRSIKESSFE
 ESNIEDPLIVTPDCQEKTSKPGVENPAVQESNQKMLGPPLEVLKTLASKRNAVAFRSFNS
 HINASNNSEPSRMNMTSLDAMDISRAYSGSYPMAITPTQKRRSCMPHOTPNQIKSGTPYR
 TPKSVRRGVAPVDDGRILGTPDYLAPELLLGRAHGPAVDWWALGVCLFEFLTGI PPFNDE
 TPQQVFQNILKRDI PWPEGEEKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWE
 NLQHQTMPFIPQPDDETDTSYFETRNTAQHLTVSGFSL

N-glycosylation site.

73-76
 374-377
 564-567
 663-666
 666-669
 674 -677

cAMP- and cGMP-dependent protein kinase phosphorylation site.

700-703

N-myristoylation site.

12-17
 13-18
 52-57
 209-214

Amidation site.

438-441

Serine/Threonine protein kinases active-site signature.

152-164

Protein kinase domain

35-834

39/46

FIGURE 35

CAAGAGCCCTTCCTGCAGGGAACCTCAGGCTTCAGAGAGCCGAAAAGTTGGGAGGCGTAA
CCACTTACAGGCCGGAAGTGTCCGGGGTGGACGCATTCCGGGTAGCCGAAGAAGTCCCAGG
ATTGCCGAAGAAGTCCCAGGATTTCCGAAGCGAGCCGAAGCATCGCGACAGTTTTTCAGAG
ACAGCTGATCGGTTGGAGCTGTTGCGCCGAGCAGTCATGGCGGCGGCCAGAGCTACTACG
CCGGCCGATGGCGAGGAGCCCGCCCGGAGGCTGAGGCTCTGGCCGAGCCCGGGAACGG
AGCAGCCGCTTCTTGAGCGGCCTGGAGCTGGTGAAGCAGGGTGCCGAGGCGCGCTGTTC
CGTGGCCGCTTCCAGGGCCGCGCGGCGGTGATCAAGCACCGCTTCCCCAAGGGCTACCGG
CACCCGGCGCTGGAGGCGCGGCTTGGCAGACGGCGGACGGTGCAAGGAGGCCCCGGGCGCTC
CTCCGCTGTCCCGCGCTGGAATATCTGCCCCAGTTGTCTTTTTTGTGGACTATGCTTCC
AACTGCTTATATATGGAAGAAATTGAAGGCTCAGTGACTGTTTCGAGATTATATTCAGTCC
ACTATGGAGACTGAAAAAACTCCCCAGGGTCTCTCCAACCTAGCCAAGACAATTGGGCAG
GTTTTGGCTCGAATGCACGATGAAGACCTCATTTCATGGTGATCTCACCACCTCCAACATG
CTCCTGAAACCCCCCTGGAACAGCTGAACATTGTGCTCATAGACTTTGGGCTGAGTTTC
ATTTAGCACCTTCCAGAGGATAAGGGAGTAGACCTCTATGTCCTGGAGAAGGCCTTCCTC
AGTACCCATCCCAACACTGAAACTGTGTTTGAAGCCTTTCTGAAGAGCTACTCCACCTCC
TCCAAAAGGCCAGGCCAGTGCTAAAAAAATTAGATGAAGTGCCTGAGAGGAAGAAAG
AGGTCCATGGTTGGGTAGAAGAATGTGTATGACAACCACACACAGTGAAGCTCTTTTTTC
AAAGTAAATTTGAAGAAATGCTACAAGTATGAGATGAGATCTAAGTAAAGGTGTTAAGAT
ATTAAAAA

40/46

FIGURE 36

MAAARATTPADGEEPAPAEALAAARERSRFLSGLELVKQGAEARVFRGRFQGRAAVIK
HRFPKGYRHPALEARLGRRRTVQEARALLRCRRAGISAPVVFFVDYASNCLYMEEIEGSV
TVRDYIQSTMETKTPQGSLNLAKTIGQVLARMHDEDLIHGDLTTSNMLLKPPLEQLNIV
LIDFGLSFISALPEDKGVLDLYVLEKAFLSTHPNTETVFEAFLKSYSTSSKKARPVLKKLD
EVRLRGRKRSMVG

CAMP- and cGMP-dependent protein kinase phosphorylation site.

78-81
247-250

N-myristoylation site.

147-152

Amidation site.

76-79
245-248

Tyrosine protein kinases specific active-site signature.

158-170

Protein kinase domain

33-252

FIGURE 37

AGCGCGCGACTTTTTGAAAGCCAGGAGGGTTTCAATTGCAACGGCAGCTGCCGGGCGTAT
GTGTTGGTGTCTAGAGGCAGCTGCAGGGTCTCGCTGGGGGCCGCTCGGGACCAATTTTGAA
GAGGTACTTGGCCACGACTTATTTTCACCTCCGACCTTTCCTTCCAGGCGGTGAGACTCT
GGACTGAGAGTGGCTTTCACAATGGAAGGGATCAGTAATTTCAAGACACCAAGCAAATTA
TCAGAAAAAAGAAATCTGTATTATGTTCAACTCCAATAAATATCCCGGCCTCTCCG
TTTATGCAGAAGCTTGGCTTGGTACTGGGGTAAATGTGTACCTAATGAAAAGATCTCCA
AGAGGTTTGTCTCATCTCTCTTGGGCTGTAAAAAAGATTAATCCTATATGTAATGATCAT
TATCGAAGTGTGTATCAAAAGAGACTAATGGATGAAGCTAAGATTTTGAAAAGCCTTCAT
CATCCAAACATTGTTGGTTATCGTGCTTTTACTGAAGCCAATGATGGCAGTCTGTGTCTT
GCTATGGAATATGGAGGTGAAAAGTCTCTAAATGACTTAATAGAAGAACGATATAAAGCC
AGCCAAGATCCTTTTCCAGCAGCCATAATTTTAAAAGTTGCTTTGAATATGGCAAGAGGG
TTAAAGTATCTGCACCAAGAAAAGAACTGCTTCATGGAGACATAAAGTCTTCAAATGTT
GTAATTAAGGCGATTTTGAAACAATTAAAATCTGTGATGTAGGAGTCTCTCTACCACTG
GATGAAAATATGACTGTGACTGACCTGAGGCTTGTACATTGGCACAGAGCCATGGAAA
CCCAAAGAAGCTGTGGAGGAGAATGGTGTATTACTGACAAGGCAGACATATTTGCCTTT
GGCCTTACTTTGTGGGAAATGATGACTTTATCGATTCCACACATTAATCTTTCAAATGAT
GATGATGATGAAGATAAACTTTTGATGAAAGTGATTTTGATGATGAAGCATACTATGCA
GCGTTGGGAAGTGGCCACCTATTAAATATGGAAGAAGTGGATGAATCATACCAGAAAGTA
ATTGAACCTCTCTCTGTATGCATAATGAAGACCTTAAAGATCGTCTTCTGCTGCACAC
ATTGTTGAAGCTCTGGAAACAGATGTCTAGTGATCATCTCAGCTGAAGTGTGGCTTGGCT
AAATAACTGTTTATTTCCAAAATATTTACATAGTTACTATCAGTAGTTATTAGACTCTAAA
ATTGGCATATTTGAGGACCATAGTTTCTTGTAAACATATGGATAACTATTTCTAATATGA
AATATGCTTATATTGGCTATAAGCACTTGGAAATGTACTGGGTTTTCTGTAAAGTTTTAG
AAACTAGCTACATAAGTACTTTGATACTGCTCATGCTGACTTAAAACACTAGCAGTAAAA
CGCTGTAAACTGTAAACATTAAATTTGAATGACCATTACTTTTATTAATGATCTTTCTTAAA
TATTCTATATTTTAAATGGATCTACTGACATTAGCACTTTGTACAGTACAAAATAAAGTCT
ACATTTGTTTAAAACACTGAACCTTTTGCTGATGTGTTTATCAAATGATAACTGGAAGCT
GAGGAGAATATGCCTCAAAAAGAGTAGCTCCTTGGATACTTCAGACTCTGGTTACAGATT
GTCTTGATCTCTTGGATCTCCTCAGATCTTTGGTTTTTGCTTTAATTTATTAAATGTATT
TTCCATACTGAGTTTAAAATTTATTAATTTGTACCTTAAGCATTTCCAGCTGTGTAAAA
ACAATAAAACTCAAATAGGATGATAAAGAATAAAGGACACTTTGGGTACCAGAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

42/46

FIGURE 38

MEGISNFKTPSKLSEKKKSVLCSTPTINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSP
WAVKKINPICNDHYRSVYQKRLMDEAKILKSLHHPNIVGYRAFTEANDGSLCLAMEYGGGE
KSLNDLIEERYKASQDPFPAAIILKVALNMARGLKYLHQEKLLHGDIKSSNVVIKGDFF
TIKICDVGVSPLDENMTVTDPEACYIGTEPWKPKEAVEENGVI TDKADIFAFGLTLWEM
MTLSIPHINLSNDDDDDEDKTFDESDFDDEAYYAALGTRPPINMEELDESYQKVIELFSVC
TNEDPKDRPSAAHIVEALETDV

N-glycosylation site.

196-199
249-252

cAMP- and cGMP-dependent protein kinase phosphorylation site.

16-19

N-myristoylation site.

41-46
118-123

Serine/Threonine protein kinases active-site signature.

163-175

Protein kinase domain
32-320

FIGURE 39

GTGCGATCCCGGGCCCGAGGGCATCAGACGGCGGGCTGATTAGCTCCGGTTTGCATCACCC
GGACCGGGGGATTAGCTCCGGTTTGCATCACCCGGACCGGGGGCCGGGCGCGCACGAGAC
TCGCAGCGGAAGTGAGGGCGGCTCCGCGCGCGTCCGCTGCTAGGACCCGGGCGAGGCTGG
AGCTGGGCTGGGATCCCGAGCTCGGCAGCAGCGCAGCGGGCCGGCCACCTGCTGGTGCC
CTGGAGGCTCTGAGCCCCGGCGGCGCCGGGCCACGCGGAACGACGGGGCGAGATGCGA
GCCACCCCTCTAGCTGCTCCTGCGGGTTCCCTGTCCAGGAAGAAGCGTTGGAGTTGGAT
GACAACTTAGATACCGAGCGTCCCGTCCAGAAACGAGCTCGAAGTGGGCCCCAGCCCAGA
CTGCCCCCTGCTGTTGCCCCCTGAGCCACCTACTGCTCCAGATCGTGCAACTGCTGTG
GCCACTGCCCTCCCGTCTTGGGCCCTATGTCCTCCTGGAGCCCGAGGAGGGCGGGCGGGCC
TACCAGGCCCTGCACTGCCCTACAGGCACTGAGTATACCTGCAAGGTGTACCCCGTCCAG
GAAGCCCCGGCGGTGCTGGAGCCCTATGCGCGGCTGCCCCCGCACAAGCATGTGGCTCGG
CCCACTGAGGTCTTGGCTGGTACCCAGCTCCTCTACGCCCTTTTCACTCGGACCCATGGG
GACATGCACAGCCTGCTGCGAAGCCGCCACCGTATCCCTGAGCCTGAGGCTGCCGTGCTC
TTCGCCAGATGGCCACCGCCCTGGCGCACTGTCAACAGCACGGTCTGGTCTGCGTGTAT
CTCAAGCTGTGTGCTTTGTCTTCTGCTGACCGTGAGAGGAAGAAGCTGGTGTGAGAGAAC
CTGGAGGACTCTGCGTGTGACTGGGCCAGATGATTCCCTGTGGGACAAGCACGCGTGC
CCAGCCTACGTGGGACCTGAGATACTCAGCTCACGGGCCCTCACTACTCGGGCAAGGCAGCC
GATGTCTGGAGCCTGGGCGTGGCGCTCTTCAACATGCTGGCCGGCCACTACCCCTTCCAG
GACTCGGAGCCTGTCTGCTCTTGGCAAGATCCGCCGCGGGGCTACGCCCTTGCCTGCA
GGCCTCTCGGCCCTGCCCCGCTGTCTGGTTCTGCTGCCCTCCTTCTGTCGGGAGCCAGCTGAA
CGGCTCACAGCCACAGGCATCCTCCTGCACCCCTGGCTGCCACAGGACCCGATGCCCTTA
GCCCCAACCCGATCCCATCTCTGGGAGGCTGCCAGGTGGTCCCTGATGGTCTGGGGCTG
GACGAAGCCAGGGAAGAGGAGGGAGACAGAGAAGTGGTTCTGTATGGCTAGGACCACCT
ACTACACGCTCAGCTGCCAACAGTGGATTGAGTTTGGGGGTAGCTCCAAGCCTTCTCCTG
CCTCTGAAGTGAAGCAACCTTCACTGCTTCCAGAAAGGAGAAAGGCAGAAAGCCTGTGT
GGAGTGTGCTGTGTACACATCTGCTTTGTTCCACACACATGCAGTTCTTGCTTGGGTGCT
TATCAGGTGCCAAGCCCTGTTCTCGGTGCTGGGAGTACAGCAGTGAGCAAAGGAGACAAT
ATTCCTGCTCACAGAGATGACAACTGGCATCCTTGAGCTGACAAACACTTTTCCATGAC
CATAGGTCACTGTCTACACTGGGTACACTTTGTACCAGTGTGCGCCTCCACTGATGCTGG
TGCTCAGGCACCTCTGTCCAAGGACAATCCCTTTCACAAACAAACCAGCTGCCTTTGTAT
CTTGTAACCTTTTCAGAGAAAGGGAGGTATCCCTGTGCCAAAGGCTCCAGGCCTCTCCCT
GCAACTCAGGACCCAGCCAGCTCACTCTGGGAACGTGTGTTCCAGCATCTCTGTCTCTC
TTGATTAAGAGATTCTCCTTCCAGGCCTAAGCCTGGGATTGGGGCCAGAGATAAGAATCC
AAACTATGAGGCTAGTTCTTGTCTAACTCAAGACTGTTCTGGAATGAGGGTCCAGGCCTG
TCAACCATGGGGCTTCTGACCTGAGCACCAGGTGAGGGACAGGATTAGGCAGGGTCTG
TCCTGTGGCCACCTGGAAAGTCCAGGTGGGACTCTTCTGGGGACACTTGGGGTCCACAA
TCCAGGTCCATACTCTAGGTTTTGGATACCATGAGTATGTATGTTTACCTGTGCCTAAT
AAAGGAGAATTATGAAATAAAAAAAAAAAAAAAAAA

44/46

FIGURE 40

MRATPLAAPAGSLSRKKRLEDDNLDTERPVQKRARSGPQPRLPCLLPLSPPTAPDRAT
 AVATASRLGPYVLLPEEGGRAYQALHCPTGTETCTKVYPVQEAPAVLEPYARLPCHKV
 ARPTEVLAGTQLLYAFFTRTHGDMHSLVRSRHRIPEPEAAVLFRQMATALAHCHQHGLVL
 RDLKLCRFVFADRERKKLVLENLEDSCVLTGPDDSLWDKHACPAYVGPEILSSRASYSKG
 AADVWSLGVALFTMLAGHYPFQDSEPVLLFGKIRRGAYALPAGLSAPARCLVRCLLRREP
 AERLTATGILLHPWLRQDPMPLAPTRSHLWEAAQVVPDGLGLDEAREEEGDREVVLYG

N-myristoylation site.

91-96
 341-346

Protein kinase domain

71-315

45/46

FIGURE 41

GAAGTTTCTCACTAGGGTCTTCTCTGGCCCAGCCTTTGACTGAAGCTGGTCTGGAGACAG
GGGCATTAGAGAAGTGACTCATAGATGGCCTAAAGAAGCGGGGCCACTCAAGGACCCAGG
ACAGAGGGAAGAGGGCCAACCCAGCTGGACCACAGGCAAACCCATTGCCTTTGAGAGAA
AGAAGAGGACCCGGTGAACATGCTGCTGCTGAAGAAACACACGGAGGACATCAGCAGCG
TCTACGAGATCCGCGAGAGGCTCGGCTCGGGTGCTTCTCCGAGGTGGTGTGGCCCAGG
AGCGGGGCTCCGCACACCTCGTGGCCCTCAAGTGCATCCCCAAGAAGGCCCTCCGGGGCA
AGGAGGCCCTGGTGGAGAACGAGATCGCAGTGCTCCGTAGGATCAGTCACCCCAACATCG
TCGCTCTGGAGGATGTCCACGAGAGCCCTTCCACCTCTACCTGGCCATGGAAGTGGTGA
CGGGTGGCGAGCTGTTTGACCGCATCATGGAGCGCGGCTCCTACACAGAGAAGGATGCCA
GCCATCTGGTGGGTGAGGTCTTGGCGCCGTCTCCTACCTGCACAGCCTGGGGATCGTGC
ACCGGGACCTCAAGCCCCGAAAACCTCCTGTATGCCACGCCCTTTGAGGACTCGAAGATCA
TGGTCTCTGACTTTGGACTCTCCAAAATCCAGGCTGGGAACATGCTAGGCACCGCCTGTG
GGACCCCTGGATATGTGGCCCCAGAGCTCTTGGAGCAGAAACCTACGGGAAGGCCGTAG
ATGTGTGGGCCCTGGGCGTCATCTCCTACATCCTGCTGTGTGGGTACCCCCCTTCTACG
ACGAGAGCGACCCCTGAGCTCTTCAGCCAGATCCTGAGGGCCAGCTATGAGTTTGACTXTC
CTTCTGGGATGACATCTCAGAATCAGGCAAAGACTTTATTGGGCACCTTCTGGAGCGAG
ACCTTCAGAAGAGGTTTACCTGCCAACAGGCCTTGGCGGACCTTTGGATCTTTGGGACA
CAGGCTTTGGCAGGGACATCTTAGGGTTTGTCACTGAGCAGATCCGGAAGAACTTTGCTT
GGACACACTGGAAGCGAGCCTTCAATGCCACCTTGTTCCTGCGCCACATCCGGAAGCTGG
GGCAGATCCCAGAGGGCGAGGGGGCTCTGAGCAGGGCATGGSCCGXCACAGCCACTXAG
GCCTTCGTGCTGGCCAGCCCCCAAGTGGTATGCCCAGGXAGATGCCGAGGCCAAGTGG
AXTGAXCCCCAGATTTXCTTXC

46/46

FIGURE 42

MLLLKKHTEDISSVYEIRERLGSGAFSEVVLAQERGAHLVALKCIPKKALRGKEALVEN
EIAVLRRISHENIVALEDVHESPSHLYLAMELVTGGELFDRIMERGSYTEKDASHLVGQV
LGAVSYLHSLGIVHRDLKPENLLYATPFEDSKIMVSDFGLSKIAGNMLGTACGTPGYVA
PELLEQKPYGKAVDVWALGVISYILLCGYPPFYDESDPELFSQILRASYEFDXPFWDDIS
ESGKDFIRHLLERDLQKRFTCQQALRDLWIFWDTGFGRDILGFVSEQIRKNFAWTHWKRA
FNATLFLRHIRKLGIPEGEGASEQGMXRHSHXGLRAGQPPKW

N-glycosylation site.

302-305

cAMP- and cGMP-dependent protein kinase phosphorylation site.

5-8

66-69

257-260

Tyrosine kinase phosphorylation site.

101-108

N-myristoylation site.

118-123

166-171

170-175

334-339

Serine/Threonine protein kinases active-site signature.

132-144

Protein kinase domain

15-270